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Glycosylation is the most abundant post-translational modification of proteins and has 
the ability to change the physical properties of the protein and its cell biology. The 
cellular prion protein (PrP
C
) is a membrane bound host glycoprotein present in a 
number of isoforms in vivo due to variable occupancy of the two N-linked glycosylation 
sites. The function of PrP
C
 is still unclear but it is essential for disease in transmissible 
spongiform encephalopathies (TSEs). The significance of the PrP glycoforms in the 
physiological function is unknown. Gene targeted mice have been created with point 
mutations that selectively abolish the glycosylation sites of PrP
C
. These GlycoD 
mutants have been used to study the effect of glycosylation at the different sites on the 




This study showed that both glycosylation sites played a role in the cell biology of PrP
C
. 
Removal of a single or both glycosylation sites significantly reduced total PrP
C
 protein. 
The relative amount of the truncated protein produced through proteolytic cleaving was 
slightly reduced in the GlycoD mutants; however the proportion of truncated to full 
length PrP was increased, further reducing full length protein. The maintenance of 
truncated protein levels indicates a potential importance of the fragment in PrP
C
 
function. Wild type PrP is predominantly diglycosylated and localised to the cell 
surface. In this study it was shown that all GlycoD mutants had reduced amounts of cell 
surface PrP
C
 and an increased proportion of PrP
C
 associated with the secretory pathway. 
Removal of either the first or the second glycosylation site produced changes in cell 
biology that were almost indistinguishable from each other whilst disruption of both 
glycosylation sites produces a more extreme phenotype than removal of a single site. 
 
Previous studies have shown an altered susceptibility for TSE disease GlycoD mice. An 
in vitro conversion assay was used to investigate the ability of the glycoforms to initiate 
conversion from PrP
C
 to the disease associated PrP
Sc
. Mice which had only the second 
site abolished were much more efficient at seeding conversion than all other 
glycoforms. This may reflect the difference in susceptibility between the two 
v 
 
monoglycosylated PrPs but does not explain the increased resistance compared to wild 
type mice. All other GlycoD mutants had similar seeding times to wild type mice 
despite having increased TSE resistance. The differences observed in the cell biology of 
PrP
C
 of the GlycoD mutants may go some way to explaining the differences in TSE 





Asn  Asparagine (amino acid) 
APP  Amyloid precursor protein 
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The transmissible spongiform encephalopathies (TSEs) are a group of rare, fatal 
neurodegenerative diseases which affect a variety of hosts, such as Creutzfeldt-Jakob 
disease (CJD) in humans, scrapie in sheep and bovine spongiform encephalopathy 
(BSE) in cattle. Disease is characterised by long incubation periods before a clinical 
phase with neurological symptoms such as ataxia, dementia, hallucinations, depression, 
anxiety and insomnia. There are currently no cures or treatments for TSEs. 
 
The central event in TSE disease is the conversion of the host cellular prion protein 
(PrP
C
) into a disease associated conformer, PrP
Sc
. Several different strains of TSE can 
exist within the same host species, which is thought to be due to different conformations 
of PrP
Sc
. Mice are not natural hosts for TSEs but have been used as models to 






 contain two glycosylation sites which can be variably occupied to 
produce four glycoforms in vivo. The glycosylation has been shown to influence TSE 
disease susceptibility and pathology in transgenic mice that have the glycosylation sites 
of PrP
C
 abolished. Most research has focused on PrP
Sc
 thus very little is known about 
the function and biological relevance of the cellular protein. The influence of the 
glycosylation on the normal cell biology of PrP
C
 may indicate whether the glycoforms 
have different functions and may give an insight into the altered TSE disease phenotype 
observed when glycosylation is disrupted.  
 




 was first identified in 1985 during the search for the infectious agent of the TSEs 
(Oesch et al., 1985). The scrapie agent was purified and the N-terminal sequence 
obtained (Prusiner et al., 1984). It was found that the sequence of PrP
C
 and the scrapie 
agent, PrP
Sc 
did not differ indicating that the differences between the cellular protein 
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The cellular prion protein (PrP
C
) is encoded by a small, single copy gene, Prnp. The PrP 
open reading frame (ORF) is encoded within a single exon although the gene itself 
comprises two to three exons depending upon the species (Basler et al., 1986, Gabriel et 
al., 1992). Other exons contain the 5’ untranslated region including the GC rich 
promoter. PrP
C
 belongs to the prion protein family which also includes the paralogues 
Prnd which produces doppel and Sprn which produces shadoo. PrP is highly conserved 
between species. Orthologs of Prnp have been identified in many species and their loci 
mapped (Ryou, 2007). 
 
In mice Prnp is located on chromosome 2 (Oesch et al., 1985, Siracusa et al., 1990), 
spans 16kb and is made up of 3 exons (Lee et al., 1998). Mice have three distinct alleles 
of Prnp, a, b and c which differ at two codons (108 and 189) (Westaway et al., 1987, 
Brown et al., 2000, Lloyd et al., 2004).  
 
Prnp mRNA is developmentally regulated and increases in response to neuronal 
differentiation (Lazarini et al., 1994). In situ hybridisation shows mRNA can be 
detected in the murine brain as early as embryonic day 9 (E9) (Miele et al., 2003). 
Levels of mRNA are low at birth and rise steadily to increase by four fold at postnatal 
day 20 (P20) to a level maintained in adult mice (Lazarini et al., 1991). Increased 
expression correlates with brain development and neuronal differentiation but not 
astroglial differentiation. During development mRNA expression is detected in brain 
areas with highly active cell proliferation, such as the ventricular zones containing 
multipotent neural stem cells and the marginal zone of the superficial cortical plate. By 
E16.5 mRNA can also be detected in non-neuronal tissues (Benvegnu et al., 2010). 
 
In adult mice Prnp mRNA is constitutively expressed and highly expressed in the 
central nervous system (CNS) (Manson et al., 1992, Miele et al., 2003). Several 
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effectors cause a change in mRNA expression but there is very little understanding of 
the mechanisms and pathways involved in the cell responses that lead to changes in 
Prnp mRNA. Cellular stresses have been shown to upregulate Prnp mRNA although the 
mechanisms are unknown. Heat shock in neuroblastoma cells increased Hsp-70 and 
Prnp mRNA. Hyperbaric oxygen, hypoglycaemia and chronic copper overload also 
upregulate PrP
C 
by interacting with the heat shock element of the Prnp promoter (Shyu 
et al., 2005, Shyu et al., 2004, Armendariz et al., 2004). Upregulation of Prnp mRNA in 
response to different cytokines in vitro is neuronal cell-type specific (Lazarini et al., 
1994). 
 




 is a glycosylated, glycosylphospatidylinositol (GPI) anchored protein 
found in lipid-rich membrane rafts on the extracellular side of the plasma membrane 
(Naslavsky et al., 1997, Taylor and Hooper, 2006).  
 
Murine Prnp mRNA encodes a 254 amino acid protein containing two signal peptides. 
Upon entering the endoplasmic reticulum the 22 amino acid N-terminal signal peptide is 
cleaved off. Once translated a C-terminal signal peptide (22 amino acids) is cleaved off 
and a GPI anchor is attached to the terminal serine of the protein to leave a 210 amino 
acid protein attached to the membrane.  
 
The protein can be separated into two distinct domains; the globular C-terminal domain 
(amino acids 127-231) and the flexible N-terminal domain (amino acids 23-124) (Figure 
1.1). The structure of the globular domain is identical in mammals, as expected for the 
high degree of sequence similarity (Lysek et al., 2005). The structure of PrP in non-
mammalian species is surprisingly well preserved despite the low sequence identity 





Figure 1.1 Structure of murine cellular prion protein 
(A) Cartoon depicting the regions of PrP
C. 
A GPI anchor tethers the protein to the membrane. 
There
 
are 2 distinct regions to the protein; the flexible N-terminal and the globular C-terminal. 
The N-terminal of the protein (23-124) is highly flexible and lacks any identifiable structure in the 
absence of Cu
2+
. There are 5 octarepeats (PH/QGGGWGQ) that bind copper ions and a toxic 
domain that is important during TSE disease. The C-terminal domain is highly structured and 
consists of 2 short antiparallel β-strands (aa 128-131 and 161-164) and 3 longer α-helices 
(aa144-154, 173-194 and 200-228). There are two N-linked glycosylation sites (aa 180 and 196) 
and a disulphide bridge is formed between C179 and C214. (B) Computer generated model of 
the structure of the C-terminal domain with two glycans. Helices are shown in red and yellow 
and β-sheets in blue. Produced by A. Gill, The Roslin Institute. 
 
The N-terminal domain of the protein is highly flexible and lacks any identifiable 
structure in the absence of Cu
2+
 (Donne et al., 1997, Whittal et al., 2000). There are 5 
octarepeats (PH/QGGGWGQ) in this domain that bind metal ions, with a high affinity 
for copper ions (Aronoff-Spencer et al., 2000). The N-terminal also contains a 
neurotoxic domain, which is important during TSE disease (Forloni et al., 1993, Chen et 
al., 1995, Solomon et al., 2011).   
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The C-terminal domain is highly structured and highly conserved in mammals due to 
the sequence similarities. It consists of two short antiparallel β-strands (128-131 and 
161-164) forming a β sheet and three α-helices (144-154, 173-194 and 200-228) 
(Linden et al., 2008, Riek et al., 1996). The C-terminal is selectively glycosylated at 
residues Asn-180 and Asn-196 and a single disulphide bond is formed between cysteine 
residues 179 and 214 (Jackson et al., 1999).  
 
The GPI anchor and interactions with the membrane lipids may play a role in the 




 interacts with acidic lipid containing 
membranes under acidic conditions and showed a consistent shift in circular dichroism 
(CD) spectrum. The C-terminal domain becomes destabilised and the N-terminal shows 
significant ordering (Morillas et al., 1999). However bacterially expressed recombinant 
bovine PrP, which lacks glycosylation and the GPI anchor shows an indistinguishable 
CD spectra to PrP
C
 isolated from calf brain, suggesting that the GPI anchor alone does 
not necessarily affect tertiary structure (Hornemann et al., 2004).  
 




 protein can be detected in all adult tissues with the exception of liver and kidney 
(Miele et al., 2003). The highest levels of PrP
C
 are found in the brain (Miele et al., 
2003). Within the brain there are various different cell types, both neuronal and glial, 
which show varying levels of PrP
C
. Levels of mRNA do not always correlate with 
levels of protein suggesting a high degree of post-translational control (Manson et al., 
1992, Ford et al., 2002a). Astrocytes and oligodendrocytes have detectable levels of 
Prnp mRNA yet little or no detectable PrP
C
 is detected in glia (Ford et al., 2002a, Moser 
et al., 1995). Neuronal subtypes have varying levels of PrP
C
; GABAergic neurons 
display high levels of PrP
C
, cholinergic neurons have low levels of PrP
C
 and 
dopaminergic neurons little detectable protein (Ford et al., 2002a). 
 
It has previously been shown that there are differing levels of PrP
C
 in different brain 
regions in hamsters and mice (Ford et al., 2002a). High PrP
C
 levels were detected in the 
hippocampus and the thalamolimbic system (Benvegnu et al., 2010). This likely reflects 
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the differing amounts of PrP
C
 produced by the different neuronal subpopulations found 
in each region. Most cells in grey matter areas contain PrP
C
 whereas myelinated fibre 
tracts in white matter areas show little evidence of PrP
C
 (Ford et al., 2002a). Within 
grey matter regions, basket and stellate cells were intensely positive for PrP
C
. In the 
deep cerebellar nuclei all cells expressed high levels of PrP
C
 (Ford et al., 2002a). In the 
white matter of the cerebellum the majority of axons were PrP
C
 negative but a minor 






 has been reported to have a physiological role at the synapse and is localised 
primarily to synapses (Fournier et al., 1995, Moya et al., 2000). This is reflected in the 
hippocampus, with synaptic layers expressing high levels of PrP
C
 and no detectable 
PrP
C
 in the cell bodies (Beringue et al., 2003, Moya et al., 2000).    
 




 is a cell surface protein synthesised and modified through the secretory pathway 
and trafficked to the plasma membrane. The N-terminal of PrP
C
 contains a signal 
peptide, which causes translocation to the endoplasmic reticulum (ER) to be further 
translated. Upon entry into the ER lumen the signal peptide is cleaved off. PrP
C
 can be 
found in 3 different topologies. The majority of protein produced (>90%) is GPI 
anchored to the plasma membrane. A small minority (<10%) is either an N-terminal 
(
Ntm
PrP) or C-terminal (
Ctm
PrP) transmembrane form due to a hydrophobic pocket 




 undergoes several post-translational modifications whilst in the ER. High 
mannose, endoglycosidase H (Endo H) sensitive N-linked oligosaccharides are added 
co-translationally. A single disulphide bond is also created between C179 and C214. 
The GPI anchor is added after removal of a C-terminal signal peptide upon translation, 
which causes association with the lipid rafts, low-density, detergent insoluble regions of 
the membrane rich in cholesterol and sphingolipids (Taylor and Hooper, 2006). The 
glycans are further modified in the Golgi by adding sialic acid to create mature PrP
C
 




Once it has reached the plasma membrane PrP
C
 is constitutively cycled between the 
membrane and endosomal compartments, with >95% of endocytosed protein returned to 
the membrane (Shyng et al., 1993). PrP
C
 is rapidly cycled between the cell surface and 
internal membranes. Once internalised the majority of the PrP
C
 is recycled to the 
surface, however some protein is degraded by lysosomes and some is secreted into the 
extracellular medium with exosomes (Vetrugno et al., 2005, Porto-Carreiro et al., 2005, 




 lacks a transmembrane domain and therefore relies on binding partners to interact 
with cytosolic proteins required for internalisation. Endocytosis occurs either by 
caveolae-like domains (Prado et al., 2004) or via clathrin coated pits (Shyng et al., 
1994). GPI anchored proteins are typically endocytosed via caveosomes formed from 
lipid rafts however disruption of clathrin dependent endocytosis reduced PrP 
internalisation. Blocking clathrin dependent endocytosis does not completely prevent 
endocytosis suggesting a combination of methods are employed, depending upon the 
cell type and the binding partner initiating internalisation. For clathrin dependant 
endocytosis PrP
C
 has to move out of lipid raft domains and into non-raft membranes by 
binding ligands. Deletion of the N-terminal portion of PrP
C
 reduces internalisation and 
turnover, suggesting an important role of the highly conserved N-terminal in trafficking 
of the protein (Nunziante et al., 2003). The N-terminal domain has been proposed as the 
ligand binding domain for partners such as LRP1 (Parkyn et al., 2008) and NCAM 
(Schmitt-Ulms et al., 2001). Ligands that bind to PrP
C
 may also activate signalling 
pathways leading to neuronal survival or neuritic outgrowth (Pantera et al., 2009, 









 can undergo several different cleavage events in vivo to produce both membrane 
attached and soluble fragments. There are three main cleavage events described in 





 cleavage sites 
PrP
C
 can be cleaved at 3 different cleavage sites. PrP is shed by removal of the GPI anchor and 
releasing soluble full length PrP from the membrane. Proteolytic cleavage can occur at two sites 
in the N-terminal region. Alpha cleavage cuts at 110/111, producing C1 and N1 fragments and 
beta cleavage cuts at 90/91, producing C2 and N2 fragments. Both C1 and C2 fragments are 
membrane bound, GPI anchored and glycosylated. The N1 and N2 fragments are released from 
the cell surface.  
 
1.1.5.1 Alpha cleavage 
 
Alpha cleavage occurs between residues 110/111 to produce a 17 kDa C1 fragment and 
a 9 kDa N1 fragment (Mange et al., 2004). C1 remains GPI anchored to the membrane 
and retains both glycans whilst N1 is most likely secreted from the cell. C1 has been 
reported for different species, such as human, sheep and mice (Chen et al., 1995, 
Nieznanski et al., 2005b, Laffont-Proust et al., 2006, Kuczius et al., 2007a, Kuczius et 
al., 2007b). 
 
Defining the location of alpha cleavage has been challenging due to the constant 
recycling of the protein. It has been suggested that cleavage occurs in the late Golgi 
before PrP
C
 reaches the cell surface (Walmsley et al., 2009). This study showed that 
disruption of exit from the secretory pathway increased C1 levels whilst retention in the 
9 
 
ER lowered C1 levels. There is also evidence that cleavage could occur in endocytic 
vesicles, once PrP
C
 has been internalised (Shyng et al., 1993). Alpha cleavage was 
reduced by lysosomal protease inhibitors and raising the pH of endocytic compartments 
suggesting cleavage in an acidic endocytic vesicle after internalisation from the cell 
surface.  
 
Very little is known about the cleavage event and there is conflicting evidence in the 
literature regarding the enzymes responsible. Several metalloproteases from the ADAM 
family (A Disintegrin And Metalloproteinase) have been suggested as candidate 
enzymes which carry out alpha cleavage, including ADAM 9, 10 and 17. It has been 
shown that the presence of active ADAM10 was associated with high C1 levels in 
human brain and inhibition of metalloproteases ADAM 10 and 17 reduced N1 
formation in vitro (Laffont-Proust et al., 2005, Vincent et al., 2001). However, Taylor et 
al. (2009) showed that ADAM10 was responsible for shedding of the protein rather than 
alpha cleavage and ADAM10 knockdown in neurons did not reduce C1 (Altmeppen et 
al., 2011). The ADAMs may indirectly modulate cleavage by regulating an unidentified 
protease responsible for alpha cleavage. It has been shown that purified plasminogen 
can interact with recombinant PrP
C
 in vitro and cleave it to produce a C1 like fragment 
(Kornblatt et al., 2003). This was accelerated by the presence of plasmin. N1 could 
potentially augment PrP
C
 alpha cleavage through enhanced plasminogen activation to 
produce more N1 (Praus et al., 2003). However, plasminogen-deficient mice showed no 
alteration in cleavage patterns, suggesting that plasmin has no role in cleavage in vivo 
(Barnewitz et al., 2006). Protein kinase C upregulated alpha cleavage (Vincent et al., 
2000, Alfa Cisse et al., 2007). 
 
Alpha cleavage of PrP
C
 is believed to be important in the physiological functions. A 
series of mutants with portions of the N-terminal have been created (Shmerling et al., 
1998, Li et al., 2007) (Figure 1.4). Some mutants, but not all, showed spontaneous 
neurodegeneration with the absence of accumulated misfolded protein. There was a 
strong correlation between the absence of alpha cleavage and neurotoxicity caused by 
the truncated PrP [reviewed in (Yusa et al., 2012)]. Mutants that showed C1 did not 
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develop spontaneous neurological disease whilst mutants that had at least residues 105-
125 deleted lacked detectable C1 and developed disease.   
 
 
Figure 1.3 PrP deletion mutants and their neurodegenerative phenotype 
Wild type PrP with the domains (shown in figure 1.1) is shown at the top. Deleted domains are 
shown with a solid line and the deleted amino acids indicated to the right (Del). The presence of 
C1 is indicated for each mutant to demonstrate whether it is able to undergo cleavage. NDG 
shows whether the mutants show spontaneous neurodegeneration. Data from (Yusa et al., 
2012)  
 
Both C1 and N1 have also been shown to be biologically active fragments both in vitro 
and in vivo. It has been suggested that C1 acts as a pro-apoptotic signal, pushing a cell 
towards apoptosis. Cells overexpressing C1 had an enhanced apoptotic effect when 
treated with staurosporine through positively regulating caspase-3 activation in a p53-
depedent mechanism (Sunyach et al., 2007). However, transgenic mice expressing only 
C1 did not display neurological changes showing that C1 is not neurotoxic (Westergard 
et al., 2011). In contrast it is believed that N1 exerts a neuroprotective effect on the cell, 
preventing cell death (Guillot-Sestier et al., 2009). Alpha cleavage may be linked to 
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signal transduction. Increased alpha cleavage in response to membrane perturbation 
increased signal transduction through MAPK intermediates (Haigh et al., 2009). 
  
1.1.5.2 Beta cleavage 
 
Beta cleavage of PrP
C
 occurs upstream of the alpha cleavage site at the end of the 
octarepeat region (around aa 90) to produce a membrane bound 20 kDa fragment (C2) 
and a 9 kDa secreted fragment (N2). Cleavage occurs at the cell surface in response to 
reactive oxygen species (ROS) and is dependent upon the octarepeat region (McMahon 
et al., 2001, Watt et al., 2005). Copper binds to the octarepeat region and can promote 
formation of a hydroxyl radical from H2O2 resulting in peptide bond cleavage. Cleavage 
is prevented by hydroxyl radical trapping by dimethyl sulphoxide and by removal of the 
octarepeat region (Watt et al., 2005).   
 
In contract to C1, the C2 fragment has not been demonstrated to have a biological 
function (Sunyach et al., 2007). Beta cleavage has been proposed to be a mechanism for 
the protective role of PrP
C
 against oxidative stress. PrP
C
 may act as an external sensor 
for external ROS and cleavage is the first response in a cascade of cellular events 
against increased oxidative stress. Failure to undergo beta cleavage correlated with an 
increased sensitivity of cells to oxidative stress (Watt et al., 2005).  
 
Beta cleavage of PrP
C
 occurs at low levels and C2 is rarely observed in healthy mice. 





 is cleaved by calpain to produce a protease resistant C2-like fragment.  
 
1.1.5.3 Extreme C-terminal shedding 
 
Soluble full length PrP lacking the GPI anchor has been identified both in vitro and in 
vivo (Zhao et al., 2006). A small proportion of PrP
C
 is shed into the medium by cultured 
cells (Borchelt et al., 1993) and soluble PrP
C
 has been identified in human cerebrospinal 





 was recognised by antibodies to the extreme C-terminal and did not 
change molecular weight when treated with hydrofluoric acid to remove the GPI 
anchor, indicating that the protein was full length but lacked the entire GPI anchor 
(Borchelt et al., 1993). Naturally shed PrP
C
 has been shown to be cleaved between Gly 
228/Arg 229, close to the GPI anchor by a zinc metalloproteinase (Parkin et al., 2004, 
Taylor et al., 2009). Disruption of the lipid rafts with filipin and methyl-β-cyclodextrin 
stimulates cleavage within the GPI anchor possibly by a phospholipase (Parkin et al., 
2004).  
 
1.1.6 Functions of PrPC in the CNS  
 
Several different null mice were created on different mouse backgrounds in order to 
elucidate the function of PrP
C
 (Bueler et al., 1992, Manson et al., 1994a, Sakaguchi et 
al., 1996, Moore et al., 1999, Rossi et al., 2001). Initial screening of PrP null mice 
showed no overt phenotype, no gross anatomical abnormalities, fully functioning 
immune systems and no impairment of learning when tested with several complex 
behavioural tests (Bueler et al., 1992, Manson et al., 1994a). Later knockouts showed 
normal development but developed ataxia and Purkinje cell degeneration with age, 
however this was due to overexpression of doppel caused by the deletion of Prnp 
(Moore et al., 1999, Sakaguchi et al., 1996, Rossi et al., 2001). The lack of phenotype 
hindered identifying the function and suggests that PrP
C
 is not essential for development 




However, later studies with PrP null mice have shown subtle changes. Null mice had a 
slight increase in locomotor activity (Roesler et al., 1999) and a decrease in anxiety 
during acute stress (Nico et al., 2005). Electrophysiology studies found subtle changes 
in circadian rhythm and sleep (Tobler et al., 1996), weakened GABA-A (gamma-
aminobutyric acid type A) receptor-mediated fast inhibition and impaired long-term 
potentiation (Collinge et al., 1994, Coitinho et al., 2003).  
 
Another method of elucidating the function of PrP
C
 has been to identify the proteins and 
molecules with which PrP
C
 interacts. Identifying binding partners allows potential 
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physiological pathways of PrP
C
 to be identified. Several binding partners have been 
identified through yeast two hybrid systems, co-immunoprecipitation (Co-IP) and cross 
linking. PrP binds many different molecules in vitro and some of these are localised to 
the cytoplasm so would not be able to interact directly with PrP
C
 in vivo, bringing into 
question the validity of some of the binding partners (Table 1.1). Some of the binding 




 has been proposed to be involved in neuroprotection by an anti-apoptotic activity. 
PrP
C
 protects cells against apoptosis induced by serum deprivation, TNF-α, doppel and 
Bax-mediated apoptosis (Bounhar et al., 2001, Kuwahara et al., 1999, Diarra-Mehrpour 
et al., 2004, Drisaldi et al., 2004, Qin et al., 2006). PrP
C
 also protects against Bax-
mediated apoptosis in yeast systems (Li and Harris, 2005, Bounhar et al., 2006). The N1 
fragment produced by proteolytic cleavage has been shown to have neuroprotective 
properties both in vitro and in vivo (Guillot-Sestier et al., 2009). Mice which lack a 
portion of the N-terminal, encompassing at least residues 105-125 develop 
neurodegeneration which is rescued by introduction of full length PrP. This deletion 
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 may also protect against oxidative stress. Mice lacking PrP
C
 are more susceptible 
to oxidative stress and brain lesions induced by hypoxia or ischemia are larger than in 
wild type mice (McLennan et al., 2004, Spudich et al., 2005). Cultured PrP null neurons 
are more susceptible to treatments that induce oxidative stress (Brown et al., 2002). The 
protective mechanism of PrP
C
 is not known, but PrP
C
 may activate signalling pathways 
or upregulate other proteins that detoxify ROS. It has been proposed that PrP
C
 monitors 
the levels of oxidative stress and initiates protective signal cascades under conditions of 




 has the ability to bind copper and other metal ions to the octarepeat region in the N 
terminal of the protein. PrP
C
 has also been implicated in copper homeostasis at the 
synaptic cleft. PrP
C
 binds copper at the cell surface which promotes endocytosis to 
allow maintenance of copper in the pre-synaptic cytosol and buffering against toxic 




 is localised to lipid raft regions of the membrane, which have been demonstrated 
to act as membrane scaffold for signal transduction (Tsui-Pierchala et al., 2002, Taylor 
and Hooper, 2006). Treatment of cells with recombinant PrP
C
 enhanced neurite 
outgrowth and neuronal survival through activation of fyn, PKC, PKA, PI-3 kinase/Akt 
and ERK (Kanaani et al., 2005, Chen et al., 2003). PrP
C
 is on the outer membrane of the 
cell and does not contain any transmembrane domains and therefore must interact with 
proteins with a transmembrane domain to be able to initiate signal transduction. Several 
signalling proteins have been identified as binding partners for PrP
C
 (Spielhaupter and 
Schatzl, 2001). Antibody-mediated cross linking of PrP
C
 stimulated the non-receptor 
tyrosine kinase, fyn in vitro and caused downstream stimulation of NADPH oxidase and 
extracellular regulated kinases (ERKs) (Mouillet-Richard et al., 2000, Schneider et al., 
2003). STI-1 is a co-chaperone for heat shock proteins and binds to PrP
C
 to stimulate 
neurite outgrowth through the MAPK pathway and neuroprotection through the 
activation of the PKA pathway (Lopes et al., 2005). Interactions of PrP
C
 with N-CAM 







 interacts with several proteins involved in cell adhesion, such as the laminin 
receptor and N-CAM. Laminin has a significant role in neurite outgrowth and aids cell 
migration (Graner et al., 2000a). Removal of cell surface PrP causes disruption of 
laminin-induced differentiation and retraction of neurites (Graner et al., 2000b).  
 
The localisation of PrP
C
 at the synapses has led to the proposal of the involvement of 
PrP
C
 in neuronal communication. PrP
C
 promotes neurite outgrowth and increases the 
number of synaptic contacts suggesting it could regulate synapse formation (Kanaani et 
al., 2005). The synaptic role of PrP
C
 is supported by the electrophysiological changes 




 has also been shown to have functions in the peripheral nervous system (PNS) that 
are separate from the CNS functions. PrP
C
 has also been shown to have a role in 
peripheral myelin maintenance which is dependent upon the cleavage of PrP
C
 to 
produce C1/N1 fragments (Bremer et al., 2010).    
 
1.2 N-linked glycosylation of proteins 
 
Glycosylation of proteins occurs in both prokaryotes and eukaryotes and has a huge 
biological and functional significance. It is the most common post-translational 
modification; over half of all human proteins are glycosylated. Proteins can possess 
more than one glycosylation site and a mixture of N-linked or O-linked glycosylation 
sites, which may be occupied with an array of complex and heterogeneous glycan 
structures. Only N-linked glycosylation in eukaryotes will be discussed in this thesis.  
 
The addition of glycans is usually in the secretory pathway in eukaryotes and has three 
conserved steps. 
 
1. A core of sugars are synthesised on the cytoplasmic membrane and transferred 
to the ER lumen. Glycans are assembled from nucleotide-activated building 
blocks on a lipid carrier anchored to the membrane through stepwise 
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incorporation of oligosaccharides by glycosyl-transferases. The core is then re-
oriented into the luminal side and may be further extended 
2. Proteins are translated in the ER with an N-linked glycosylation sites, usually 
encoded by Asn-X-Ser/Thr (where X is any amino acid except proline). This 
consensus acts as an acceptor for glycosylation. 
3. The conserved oligosaccharide core (Glc3-Man9-GlcNAc2) is added to the 
asparagine side chain by the oligosaccharyl transferase complex (OST). 
 
The glycans are then processed by a series of trimming and elongation reactions in the 
ER and Golgi by glycoenzymes to produce mature glycans, which can be either high 
mannose, complex or hybrid, depending upon the sugar composition (Marino et al., 
2010). There are nine monosaccharides which are used in the process of glycosylation 
in mammals. Due to the number of OH groups available on each monosaccharide many 
glycosidic links can potentially be formed producing diverse branching with different 
types of linkage. The diversity of the glycans is determined by the enzymes present in 
the cell; glycosyltransferases and glycosylhydrolases recognise the different linkages 
and work together to modify basic glycan structures. This allows for species-specific 
and cell-type specific glycosylation. The availability of these enzymes can change 
depending upon cellular conditions, such as in aging or in disease (Ohtsubo and Marth, 
2006) to produce differences in glycosylation and subsequently the properties of the 
glycoproteins. The structure of the protein backbone and the position of the 
glycosylation site will also limit and regulate glycosylation, allowing a protein to direct 
its own pattern of glycosylation. Each glycosylation site may accommodate different 
glycans, producing a subset of glycoforms. The properties of a protein can be altered by 
the heterogeneous oligosaccharides attached to a glycosylation site, which allows extra 
diversity not encoded by the genome. 
 
1.2.1 Functions of glycosylation 
 
Glycosylation can influence many aspects of a protein; the properties, localisation, 
function, stability and activity can be altered by the presence or absence of glycans 
(Table 1.2). Glycosylation many alter just one of these aspects or may affect more than 
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one, depending upon the protein. Most glycans attached are large, flexible and cover 
large areas of proteins. 
 
Table 1.2 Influences of glycans on proteins 
Type Function 
Physico-chemical 






Protection against proteolysis 




Change half-life of protein 
Modulate activity of enzymes 
Act as cell surface receptors 
Assist with cell-cell interactions 
 
Not all glycosylation consensus sites are occupied; a site may never be glycosylated or 
sometimes it may be selectively glycosylated, leading to a number of different 
glycoforms existing in vivo. Although different glycoforms can exist the significance of 
having multiple glycoforms is poorly understood for most proteins. 
 
Most glycoproteins studied have a high level of site occupancy and under-glycosylation 
is associated with disease, such as cancer and congenital disorders of glycosylation 
(CDG) (Table 1.3). The level of site occupancy correlates with the severity of the 
disease (Hulsmeier et al., 2007). Glycophorin A, CD52 and CD45 are all fully 
glycosylated on the extracellular regions of the protein (Tomita et al., 1978, Treumann 
et al., 1995). Transferrin and α1-antitrypsin have a normal physiological range of 99-
100% glycan site occupancy and a reduction in site occupancy is associated with CGD. 
Thy-1 is a GPI anchored protein with three N-glycosylation sites. GPI anchored 
partially glycosylated Thy-1 is not detected on the cell surface and is believed to be 
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retained in the ER and degraded. When the GPI anchor is removed all sites are variable 
occupied and a range of glycoforms are detected (Devasahayam et al., 1999).  
 
Site occupancy is influenced by several factors; both from the protein itself and from the 
local environment. The sequence around the glycosylation site can prevent 
glycosylation. The presence of a proline flanking or in the middle of the glycosylation 
site prevents glycan attachment. The peptide sequence can prevent efficient 
glycosylation due to folding occurring so rapidly that glycosylation sites become 
inaccessible to the dolichol-linked precursor or glycosylation enzymes (Go et al., 2008, 
Fujii et al., 1990). A disulphide bridge near the glycosylation site can hinder 
glycosylation as seen with interleukin-6 (IL-6) (Hasegawa et al., 1992). Glycosylation 
sites close to the amino or carboxy terminals are less efficiently glycosylated (Livi et al., 
1991) potentially due to accessibility of the glycosylation enzymes. The availability of 
the dolichol-linked precursor and oligosaccharyl transferases also influences the levels 




Table 1.3 Effect of altered N-linked glycosylation of glycoproteins 
Glycoprotein Function Effect of lack or alteration of glycosylation 
Most lysosomal enzymes 
Enzyme 
Loss of targeting signal for lysosomes 
β-glucosidase Loss of enzymatic activity 
Lipoprotein lipase 
Core glycosylation important for secretion and 
activity 
Hepatic lipase Reduced secretion 
Propain Loss of transport and secretion 
α-antitypsin Altered CD and spectrum leading to aggregation 
Pancreatic ribonuclease Increased susceptibility to proteases 
Granulocyte/macrophage 
colony stimulating factor Growth 
factor 
Increased activity and binding but increased 
antigenicity and clearance 
Vascular endothelial 
growth factor 
Decreased rate and efficiency of secretion 
Erythropoietin Hormone 
Loss of secretion and decreased stability and 
activity 
Interleukin-4 Cytokine Increased activity 
Immunoglobulins  
Complex effects dependent upon Ig. Altered 
secretion and enhanced antigen binding if 









Increased susceptibility to proteases 
Low density lipoprotein 
receptor Membrane 
receptor 
Redistribution of intracellular and surface 
protein. Decrease in ligand binding capacity 





1.2.1.1 Protein folding and degradation 
 
N-linked glycosylation is important for quality control of protein folding in the 
secretory pathway. Glycosylation occurs concomitantly with translocation into the ER 
lumen before the protein is fully synthesised or folded. Some subunits of the OST 
interact with the translocon and ribosome and are thought to modulate or prevent 
protein folding, allowing glycosylation of the nascent polypeptides before potential 
glycosylation sites become buried (Wilson et al., 2005, Chavan et al., 2005).  
 
Terminal glucoses and mannoses in combination with lectin receptors assist in protein 
folding and can direct misfolded proteins towards degradation. Removal of two 
glucoses by glucosidase II from the core glycan allows recognition by ER chaperones 
which prevent misfolding and aggregation (Aebi et al., 2010). Calnexin and calreticulin 
bind and recruit the lectin-associated oxidoreductase ERp57, which catalyses the 
formation of native disulfide bonds. If the protein is misfolded it is detected and rebinds 
the chaperones until it is either refolded correctly or targeted for ER associated 
degradation (ERAD). Abnormally folded proteins can still sometimes be secreted, but 
usually have impaired biological function and the effect is dependent upon the location 
of the glycosylation site.  
 
1.2.1.2 Physico-chemical functions 
 
The N-linked triose core added cotranslationally can improve both kinetics and 
thermodynamics of a protein. Glycosylation can increase the thermodynamic stability 
by reducing the disorder of the unfolded protein (Imperiali and O'Connor, 1999).  
Glycans form hydrogen bonds with the protein, giving it a more rigid structure (Hanson 
et al., 2009). A mutation resulting in an under-glycosylated tyrosinase observed in 
mouse melanocytes has been shown to be  active but at the same time to be more heat 




The addition of glycans can change the overall charge of the protein, with the negative 
charges of sialic acids and sulphate groups increasing solubility (Sola and Griebenow, 
2009).  
 
Most glycans are large and have a degree of rotational flexibility, allowing large areas 
of the protein to be shielded by the glycans. The core oligosaccharides are close to the 
surface of the protein and are responsible for structural functions of the glycans, 
whereas the distal oligosaccharides are responsible for interactions with lectins and 
receptors (Drickamer and Taylor, 1998). It does not matter which core oligosaccharides 
are attached, as long as they are present, to help shield the protein. Glycan shielding is 
more commonly employed by pathogens, particularly viruses to subvert the host 
immune system and prevent recognition of the surface proteins (Kobayashi and Suzuki, 
2012). 
 
Different glycosylation sites on the same protein may impart different features and 
influence other glycosylation sites. Human protein C has four potential glycosylation 
sites which each impart different features. Glycosylation at Asn97 is critical for 
secretion of the protein but also influences the level of core glycosylation at Asn329. 
Glycosylation at Asn248 affects the intra-molecular cleavage of the peptide required for 
activation and a lack of glycosylation at Asn313 enhances the peptides binding affinity, 
increasing its catalytic ability (Grinnell et al., 1991).   
 
1.2.1.3 Biological functions 
 
Glycosylation can determine the trafficking of a protein, which in turn influences the 
localisation and degradation. Glycans can act as an ER export signal for assisting 
proteins to move through the ER and into the Golgi. Glycosylation of the potassium ion 
channel kv1.4 is essential for the efficient cell surface expression of the protein 




On the cell surface glycans are able to interact with other molecules which can change 
the localisation and sorting of the proteins. Glycosylation of a protein generates binding 
sites for galactose-specific lectins (galectins). Galectins cross-link glycoproteins 
forming dynamic microdomains or lattices that regulate various mediators of cell 
adhesion, migration, proliferation, survival and differentiation. The interactions of 
glycoproteins and galectins at the cell surface are dynamic and allow the cell to adapt 
and respond to cellular conditions.  
 
Glycans allow proteins to interact with other molecules to carry out functions. 
Glycoproteins provide a scaffold for cell adhesion. In addition to interacting with 
galectins the glycans can also prevent interactions with other glycoproteins on the cell 
surface. The size and rotational flexibility of the glycans can shield areas of the 
polypeptide. A mutation in the epidermal growth factor receptor (EGFR) deletes a 
domain and four glycosylation sites and increases ligand independent homodimerisation 
(Fernandes et al., 2001, Tsuda et al., 2000). The glycans appear to insulate against 
dimerisation by restricting the approaches between monomeric EGFR. The glycans of 
ErbB3 play a role in negative regulation of receptor dimerisation and activation 
(Takahashi et al., 2008).   
 
Separate functions for individual glycoforms have not been reported for variable 
glycosylated proteins although a change in the ability to carry out a function has been 
observed. Plasma cholesteryl ester transfer protein (CETP) has multiple glycosylation 
sites but is found as two glycoforms in vivo depending upon site occupancy at Asn341. 
CETP lacking the glycan has a higher activity than the protein with a glycan at this site, 
possibly due to charge alteration or a decrease in steric hindrance in proximity to the 
active site (Stevenson et al., 1993). Glycosylation of tissue plasminogen activator (t-PA) 
is variably glycosylated at Asn184. Glycosylation decreases the activity of the enzyme, 
possibly by steric hindrance of the active site in the kringle domain (Berg et al., 1993). 
Plasminogen is found naturally in two different forms, type I and II, which differ in the 
presence of N-linked glycosylation in the kringle 3 domain and have different functional 




1.2.2 Glycosylation of PrPC in health 
 
In wild type mice diglycosylated PrP is the predominant form and other glycoforms are 
minor forms. The oligosaccharides added to PrP are large and heterogeneous, with over 
50 different carbohydrate species found on hamster PrP (Rudd et al., 2001). Comparison 
of the glycans for the different sites in wild type mice show differing populations of 
glycans at each site (Stimson et al., 1999). The major oligosaccharides are present at 
both sites and many sialylated bi- and triantennary structures are common to both sites 
but some of the larger tetraantennary glycans were not detected at the first site. The 
majority of glycans at the first glycosylation site have a mass between 1660-2340 Da 
whilst glycans at the second site have a mass of 2000-3020 Da (Stimson et al., 1999). 
 
The role of the glycans remains elusive. The N-glycans do not appear to impart 
structural features on PrP
C
. Recombinant PrP, which lacks post-translational 
modifications, shows the same structure as native, glycosylated PrP
C
 using CD and 
nuclear magnetic resonance (NMR) spectroscopy (Hornemann et al., 2004, DeMarco 
and Daggett, 2009).  
 
Several ligands have been demonstrated to bind to PrP and initiate signalling cascades 
to promote neuritogenesis and neuronal survival (Santuccione et al., 2005, Martins et 
al., 2001). The N-glycosidic link is flexible, allowing large areas of PrP to be shielded, 
possibly to protect from proteases and to prevent non-specific protein-protein 
interactions (Rudd et al., 2001, Ermonval et al., 2003). The oligosaccharides interact 
with the environment so may also play a role in trafficking and ligand binding (Varki, 
1993).  
 
It is not known whether the different glycoforms of PrP
C 
have different functions but the 
diverse functions proposed for PrP
C
 and the multiple isoforms may indicate separate 
functions for different isoforms. Methods used to investigate PrP
C
 captures PrP in all 
stages of its life cycle therefore it cannot be ruled out that incompletely glycosylated 
PrP represents immature PrP which will become diglycosylated before being trafficked 
to the surface, rather than an isoform with a distinct function. Several physiological 
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functions have been suggested for PrP
C
 from modulating synaptic plasticity, a role in 
cell differentiation and protection against oxidative stress. Neurons with high levels of 
PrP
C
 are less susceptible to oxidative stress than those that have little PrP
C
 (Ford et al., 
2002a).  
 
Unglycosylated proteins have been reported to have a different localisation and to 
aggregate more readily (Powell and Pain, 1992, Kayser et al., 2011), potentially causing 
a toxic species. Cytoplasmic PrP
C
 has been shown to be toxic in vitro (Wang et al., 
2009, Norstrom et al., 2007) and unglycosylated PrP provokes apoptosis in vitro (Yang 
et al., 2009). However, studies with  a mouse model producing only unglycosylated 
PrP
C
 show an altered localisation of PrP
C
 but no spontaneous disease or overt phenotype 
(Cancellotti et al., 2005).  
 
1.3 PrP Glycosylation deficient mouse models 
 
1.3.1 Gene targeted mouse models 
 
Gene-targeted transgenic mouse lines were developed to investigate the influence of PrP 
glycosylation on host susceptibility and TSE disease susceptibility. GlycoD mice have a 
Prnp gene replacement containing point mutations at codons 180 (G1), 196 (G2) or 
both (G3) that replace asparagine (N) with threonine (T) thereby abolishing N-linked 
glycosylation (Cancellotti et al., 2005).  
 
The endogenous murine Prnp gene is replaced by homologous recombination with the 
gene containing the point mutation. The altered PrP allele is in the correct genomic 
location and under control of the endogenous promoter and transcriptional controls. PrP 
mRNA is expressed in the same tissues and at the same levels as wild type mice. All 3 
lines of gene targeted mice are on an inbred 129/Ola line, allowing any alteration in host 
susceptibility or TSE disease process to be attributed to the mutation of the PrP gene or 
altered glycosylation status of the host. It also allows a direct comparison between the 
different GlycoD mice.  
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Western blot analysis has shown that G1 and G2 mice only express mono- and 
unglycosylated PrP, while G3 mice express only unglycosylated PrP
C
 (Figure 1.4). 
Deglycosylation with N-Glycosidase F (PNGase F), which removes all carbohydrates 
from glycosylated asparagine residues, showed all transgenic mice with a single 
unglycosylated product. This demonstrated that the isoforms with heavier molecular 
weight are due to the addition of glycans and that the point mutations are preventing 
glycosylation.  
 
The GlycoD mice showed no overt phenotype due to a lack of PrP glycosylation. Mice 
were fertile and aged normally. G3 mice aged to 850 days did not show any signs of 
neurodegeneration, vacuolation or gliosis (Cancellotti et al., 2005). 
 
 
Figure 1.4 PrP isoforms present in each PrP glycosylation deficient mouse line 
Normally glycosylated wild type mice express un, mono or diglycosylated PrP. Treatment with 
PNGase F to remove N linked glycans leaving only the unglycosylated band, showing that the 
different isoforms are due to attachment of carbohydrates. The PrP glycosylation deficient mice 
demonstrate that mutation at one or both of the glycosylation sites prevents glycosylation as the 
diglycosylated isoforms are not present in any of the mutants. Taken from (Cancellotti et al., 
2005) 
 




 may influence localisation of the protein in vivo (Cancellotti et 
al., 2007). A study performed using fixed brain tissues from the GlycoD mice have 
shown that PrP from G1 and G2 mice localised on the cell surface in a pattern 
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indistinguishable from wild type mice. Unglycosylated PrP from the G3 mice appeared 
to be intracellular (Figure 1.5). 
 
 
Figure 1.5 Localisation of PrP
C
 glycotypes in brain sections 
Immunofluorescence on brain sections (A) wild type, (B) G1, (C) G2, (D) G3 and (E) PrP null. 
G1 and G2 PrP have similar cell surface localisation as wt PrP. G3 PrP appears to be mainly 





Co-localisation with ER (ErP60) and Golgi (23C β–cop) markers showed that G1 and 
G2 mice had a high cell surface localisation but an increased proportion of intracellular 
PrP compared to wild type mice (Cancellotti et al., 2005). PrP
C
 in the GlycoD mutants 
did not co-localise with the ER marker, showing that glycosylation did not prevent PrP 
from exiting the ER. The Golgi marker surrounded a significant portion of the 
intracellular PrP in all genotypes, suggesting presence in the Golgi (Cancellotti et al., 
2005).  
 
In other studies it has been observed that accumulation of intracellular PrP causes 
severe toxicity in cultured cells and leads to ataxia, neurodegeneration and gliosis in 
mice (Ma et al., 2002), however G3 mice develop normally despite relocation of PrP
C
 
(Cancellotti et al., 2005). 
 
1.3.3 Effect of amino acid substitution in GlycoD mutants  
 
There is a potential that any changes in cell biology seen in the GlycoD mice are due 
not to the glycosylation state of PrP but to the amino acid substitution. In order to 
abolish the glycosylation in the GlycoD mutants the Asn of the glycosylation site is 
substituted with a Thr. This amino acid change has the potential to change the physical 
properties of the protein, such as stability or solubility, which can in turn affect the cell 
biology.   
 
Glycosylation has been abolished in an epithelial cell line expressing ovine PrP
C
 by 
substitution of asparagine at either site with 5 different amino acids, including threonine 
(Salamat et al., 2011). Immunoblots show the same expected profiles and there is no 
reported difference between the different amino acid substitutions. Although PrP
C
 was 
not quantified there appears to be a reduced expression of PrP for all of the different 
substitutions. This suggests that the replacement of Asn with Thr does not have an 





1.4 Transmissible spongiform encephalopathies 
 
The cellular prion protein plays a central role in the transmissible spongiform 
encephalopathies (TSEs), a group of infectious fatal neurodegenerative diseases that 
affect a variety of mammals (Table 1.4). These include Creutzfeldt-Jakob disease (CJD) 




Table 1.4 TSE diseases and their hosts 




Jakob disease (sCJD) 
Human Idiopathic 1920 
Familial Creutzfeldt-
Jakob disease 




Medical exposure to infected human 
tissues (Dura mater graft, corneal 
transplant and human growth hormone) 
1974 
Variant CJD (vCJD) Human 
Consumption of BSE contaminated beef 






Human Familial mutations in PRNP 1938 
















Infectious, Unknown 1750 
Atypical Scrapie Sheep Unknown 2003 
Bovine Spongiform 
Encephalopathy (BSE) 
Cattle Consumption of BSE contaminated feed 1985 
Atypical BSE 
(L and H type) 
Cattle Unknown 2004 
Chronic Wasting 
Disease (CWD) 
Deer, elk and 
moose 




Consumption of contaminated feed, 












Consumption of BSE contaminated feed 1986 
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1.4.1 Clinical signs 
 
Clinical signs are limited to the CNS and reflect the areas of the brain damaged due to 
vacuolation and PrP
Sc
 deposition (Brown et al., 1994, Santuccione et al., 2005). TSEs 
are characterised by a long incubation period, typically months for rodents and years for 
larger species, such as sheep and cattle. Clinical signs are usually only evident in older 
animals due to the long incubation times. A short clinical phase of progressive 
neurological deterioration leads invariably to death.  
 
Clinical signs are heterogeneous and vary between TSEs. The differences in clinical 
signs are used to differentiate the strain of TSE, alongside molecular typing of PrP
Sc
, the 
misfolded form of PrP
C
, and genotyping of the PrP encoding gene. 
 
Classic CJD is a heterogeneous group of diseases due to their sporadic, familial or 
iatrogenic nature (Table 1.5). There are different disease associated mutations which 
can give rise to different clinical signs, ages of onset and duration times. Clinical 
presentation is influenced by the 129 codon of the PRNP gene and the PrP
Sc
 subtype of 
the patient (type 1 or 2 depending upon the size of the PK resistant core when run on an 
immunoblot).  
 
Variant CJD presents with earlier symptoms consisting of psychiatric disturbances, such 
as depression, anxiety and insomnia, peripheral sensory disturbances and cerebellar 
ataxia. Neurological symptoms appear much later in the disease. The average duration is 
also much longer than classic CJD, at 14 months. The median illness duration was 14 
months (range, 8-38 months) and the median age at death was 29 years (range, 18-53 





















Early signs include cognitive 
impairment such as memory loss and 
confusion. Cognitive impairment, 
ataxia, myoclonus and pyramidal 
signs become very common in more 









Presentation is characterised by 
fronto-temporal dementia. Myoclonus 
and pyramidal signs eventually appear 








Presentation is dominated by 
cognitive impairment followed by 
aphasia. As disease progresses 
myoclonus and pyramidal signs also 
become common, and Parkinsonism, 
apraxia and seizures are present in 








Ataxia is the most common presenting 
sign, with cognitive and mental signs 
also present. As disease progresses 
myoclonus and pyramidal signs are 







Ataxia is the most common presenting 
sign. As disease progresses 
dementia, myoclonus and pyramidal 
signs are seen in most patients 
Data from (Gambetti et al., 2003) 
 
Clinical symptoms of scrapie vary depending upon the strain and the genotype of the 
infected animal (Williams, 2003). The most common symptom is intense pruritis 
leading to rubbing, scraping and wool loss. Behavioural changes, blindness and tremors 
may also occur. In atypical scrapie pruritis is uncommon and instead the dominant 
symptoms are ataxia and incoordination.  
 
The clinical signs of BSE include tremors, hind limb ataxia, aggressive behaviour and 
hyper-reactivity to stimuli. The most common sign of CWD is the chronic weight loss 
of the affected animal along with a deterioration of the coat condition and patchy 
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retention of the winter coat in summer (Williams, 2003). Animals also show ataxia, 
excessive salivation and regurgitation of ruminal fluid. Behavioural changes also occur, 
such as loss of fear of humans and repetitive walking.  
 
1.4.2 Pathological features 
 
As with clinical signs, pathological features are heterogeneous and vary with strain of 
TSE. Broad pathological features include spongiform change, characterised by diffuse 
or focally clustered vacuoles in the neuropil of the deep cortical layers, cerebellar cortex 
or subcortical grey matter (Budka et al., 1995), neuronal death, gliosis and PrP
Sc
 
deposition in the brain (Manson et al., 2006, Caughey and Baron, 2006).  
 
Deposition of the abnormally folded, disease associated PrP
Sc
 is an early event and 
precedes vacuolation. PrP
Sc
 is most commonly deposited as diffuse aggregates on or 
within the neurons but in some strains, such as GSS, PrP
Sc
 is associated with amyloid 
plaque deposits (DeArmond and Prusiner, 2003). The pattern and type of PrP
Sc
 
deposition is influenced by both host PrP
C
 and TSE strain in a characteristic pattern and 
is commonly used to distinguish between strains.  
 
Vacuolation is a defining characteristic of TSEs and causes the spongiform appearance 
in the brain (Brownlee, 1940). In some models vacuolation is closely associated with 
PrP deposition whilst in others there is a clear dissociation between vacuolation and 
deposition. In some models there are high levels of vacuolation with little or no 
detectable PrP
Sc
 (Barron et al., 2007) whilst other models have PrP
Sc
 deposition with 
little vacuolation observed. 
 
Neuronal dysfunction and neurodegeneration are very poorly understood in TSEs. 
Synaptic loss and dendritic abnormalities in the CNS are early disease events and can 
precede PrP
Sc
 deposition (Jamieson et al., 2001). Gamma-aminobutyric acid 
(GABAergic) neurons are particularly susceptible to TSEs and changes in these are 
often the first detectable neuropathological change. At terminal stages of disease there is 





 (Bouzamondo-Bernstein et al., 2004).  PrP null mice show 
weakened GABA receptor-mediated fast inhibitions and impaired long-term 
potentiation (Collinge et al., 1994) which indicates a loss of function of PrP
C
 may be 
responsible for some of the clinical phenotypes.   
 
A glial response is seen very early on in disease and is characteristic for all TSE strains; 
however hosts fail to mount an inflammatory response to the abnormal protein and anti-
prion antibodies are not detected during the disease (Aguzzi and Heikenwalder, 2005). 
As with other protein misfolding diseases, it is uncertain of the exact role of the glia in 
disease; whether it is protective or detrimental. Microglia express low levels of anti-
inflammatory cytokines prior to neuronal loss but in association with synaptic loss 
(Cunningham et al., 2003). The profile of the microglia appears to be benign but 
primed. They can become abnormally activated with systemic inflammation, which is a 
common occurrence in clinical disease, where they switch to an aggressive 
inflammatory phenotype and can exacerbate disease symptoms (Ransohoff and Perry, 
2009). It has been postulated that microglia undergo a switch in an attempt to 
phagocytose or degrade the PrP deposits.  
 
Although a clinical disease of the CNS, PrP
Sc
 can often be found in the lymphoreticular 
system, particularly spleen before neural invasion (Kimberlin and Walker, 1979, 
Farquhar et al., 1994) depending upon the strain and route of infection. There is 
prominent and uniform PrP
Sc
 deposition in lymphoid tissue, particularly in the tonsils of 
patients with vCJD, whilst PrP
Sc
 is very rarely found in lymphoid tissues of patients 
with sCJD and at very low levels (Peden and Ironside, 2004). Despite accumulation of 
PrP
Sc
 there is a lack of phenotype in peripheral tissues. 
 
1.4.3 Nature of the infectious agent 
 
The infectious agent has not been formally defined and several theories have been 
proposed over the years. Initially it was believed that TSEs were caused by a slow virus, 
due to the long incubation periods; however the infectious agent was difficult to identify 
because it was resistant to formaldehyde, ethanol, nucleases, UV and ionising radiation, 
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unlike any other known pathogens (Alper et al., 1967, Latarjet et al., 1970). It is 
however sensitive to phenol, proteases and urea (Hunter and Millson, 1967, Hunter et 
al., 1969). These properties led to the notion that the infectious agent may not have a 
nucleic-acid genome (Griffith, 1967).  
 
The lack of evidence for genetic material led to the proposal of the ‘protein only’ 
hypothesis by Alper (Alper et al., 1967) and Gibbons (Gibbons and Hunter, 1967), 
which was developed by Prusiner, who coined the term prion (Prusiner, 1982, Prusiner, 
1998), which is now the most widely accepted theory. The prion hypothesis suggested 
that the transmissible agent was composed entirely of a modified host protein, the prion 
protein (PrP), which was partially resistant to proteolytic degradation, with no nucleic 
acid component (Prusiner, 1982). During disease host prion protein (PrP
C
) is converted 
to the abnormal isoform PrP
Sc
 in an autocatalytic manner leading to neurodegeneration. 
Some have suggested that nucleic acid or unknown co-factors are required but these 
have not yet been identified (Chesebro, 1998). 
 
One feature of prion diseases is the existence of several different TSE strains within the 
same species (Pattison and Millson, 1961, Beringue et al., 2006). Each strain has 
distinct phenotypic properties which are reproducible when transmitted to another 
animal of the same species. Strains are characterised by the incubation time, 
neuropathology and physicochemical properties such as susceptibility to proteinase K 
(PK), electrophoretic mobility after PK digestion and the ratio of the glycoforms 
(glycotype) (Kuczius and Groschup, 1999, Collinge et al., 1996, Telling et al., 1996). 
As only a single PrP
C
 sequence is shared by all strains the different strains are believed 
to arise from different conformations of aggregated PrP
Sc
. Two strains that have been 
used in this thesis are 79A and ME7, which are mouse-adapted scrapie strains from two 
different isolates of natural scrapie (Zlotnik and Rennie, 1963, Kimberlin et al., 1989).  
 
It is unclear whether or not the prion protein is the infectious agent but the cellular prion 
protein (PrP
C
) is essential for disease (Weissmann et al., 1994, Manson et al., 1994b) 
and the aberrant folding is present in all TSE diseases. The amount of PrP
C
 influences 
the incubation period of disease but not the pathology at terminal disease (Manson et 
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al., 1994b). Heterozygous mice carrying a single wild type PrP allele (Prnp 
+/-
) had 50% 
Prnp mRNA, significantly reduced PrP
C
 and longer incubation times. Overexpression 
of PrP in mice also showed an inverse correlation between incubation period and steady 
state PrP
C
 levels (Scott et al., 1989, Westaway et al., 1991) (Vilotte et al., 2001).  
 
1.4.4 Transmissibility of TSEs 
 
Transmissible spongiform encephalopathies are unusual for protein misfolding diseases 
in that they can be acquired from external sources and are transmissible between 
animals. They can also be inherited although the majority of human cases are sporadic, 
with the cause of disease unknown. 
 
Approximately 10-15% of all human TSEs are caused by an inherited autosomal 
dominant mutation in the PRNP gene (Wadsworth and Collinge, 2007, Weissmann, 
2002, Mead, 2006). Mutations are thought to destabilise PrP
C
, allowing a more ready 
conversion to PrP
Sc
 without an external source of PrP
Sc
. Mutations can introduce a 
premature stop codon, insert additional octapeptide repeats or cause a point mutation 
leading to a single amino acid change (van der Kamp and Daggett, 2011). Amino acid 
changes are found at 28 different locations and effect protein stability, cell processing 
and function (van der Kamp and Daggett, 2009).  
 
Although no familial TSEs or disease causing mutations have been identified for any 
species other than humans, polymorphisms in the PrP gene play a role in disease 
progression and susceptibility, such as in sheep and goats. 
 
1.4.5 Conversion of PrPC to PrPSc 
  
The central event in disease is the conversion of host PrP
C





 undergoes post-translational modification and conformational change to 
become the pathogenic PrP
Sc
, which shares the same amino acid sequence as PrP
C
 but is 






 is composed of 40% beta-sheets and only ~30% is alpha-helical, compared to the 
40% alpha-helical and 3% beta-sheet structure of PrP
C
 (Baldwin et al., 1994, Pan et al., 
1993). The high beta-sheet content increases propensity to aggregate and form amyloid 
fibrils. The altered structure also makes it more detergent insoluble and resistant to the 
activity of proteases.  
 











40% alpha helical 30% alpha helical 
3% beta sheet 40% beta sheet 
GPI anchor Yes Yes 
PI-PLC sensitive Yes No 
Solubility Detergent soluble Detergent insoluble 
Protease sensitivity Sensitive Resistant 
 
1.4.5.1 Interaction of PrPC with PrPSc 
 





 substrate to drive the formation of nascent infectious prions (Prusiner, 
1998, Horiuchi and Caughey, 1999). The C-terminal (residues 90-231) of PrP
Sc
 contains 
beta-sheets which form hydrogen bonds with beta-sheets from other PrP
Sc
 molecules to 
form a cross-β core (Chiti and Dobson, 2006, Collinge, 2001).  
 
Originally it was proposed that the propagation of PrP
Sc





 monomers (Prusiner, 1991). The conversion was 
proposed to act in a two stage process; firstly PrP
C
 binds to PrP
Sc
 and then PrP
C
 
undergoes a conformational change into PrP
Sc
. However, there is no evidence of a stable 
PrP
Sc
 monomer and conversion is associated with PrP
Sc
 aggregation and seeding with 
PrP
Sc
 aggregates making it unlikely that conversion is by a heterodimeric interaction. 
An alternative theory, the nucleated polymerisation mechanism states that 
conformational change to PrP
Sc
 only occurs when there is an oligomer large enough to 
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act as a stable nucleus (Jarrett and Lansbury, 1993, Harper and Lansbury, 1997, Come 
et al., 1993). This also supports the maintenance of prion strains as monomeric proteins 
are unlikely to adopt different stable conformations however aggregates can stably form 
many different conformations (Faber and Matthews, 1990).  
  
Helix 2 and 3 are important regions for amyloid formation and are believed to be the 




 transition (Yamaguchi et al., 2008, Chen and Thirumalai, 
2013). The first glycosylation site lies within helix 2 and presence of the glycan has 
been shown to reduce the rate of fibril formation by stabilising the intermolecular 
disulphide bond formation (Bosques and Imperiali, 2003) therefore unglycosylated PrP
C
 




The N-terminal undergoes conformational change (Peretz et al., 1997) however the 
entire N-terminal is not required for conversion. Deletions of the N-terminal do not 
prevent conversion to PrP
Sc
 but prevent efficient conversion and change pathology 
(Flechsig et al., 2000, Fischer et al., 1996). Peptides of residues 109-122 have been 
shown to exhibit high beta-sheet structure and form amyloid (Gasset et al., 1992). 
Conversion is also dependent upon the central domain of the prion protein. Deletions of 
residues 114-121, 95-107 or 108-121 prevent conversion to PrP
Sc
 in cultured cells and 
transgenic mice (Holscher et al., 1998, Muramoto et al., 1997).  
 




 is important for conversion and 
may contribute to the interspecies barrier observed with some TSEs (Kocisko et al., 
1995). Homogenous seeding is more effective than heterogeneous seeding, thus seeding 
mouse PrP
C
 with mouse PrP
Sc
 gives more efficient conversion than seeding hamster 
PrP
C
 with mouse PrP
Sc
 (Kocisko et al., 1995). The effect of glycosylation homogeneity 
is significant but is secondary to PrP sequence in determining compatibility for 
conversion (Priola and Lawson, 2001). The ratios of the glycoforms have also been 
shown to affect the efficiency of conversion in vitro in a species and/or strain specific 




Conversion has different efficiencies with different isoforms of PrP
C
 and the 
interactions between isoforms may also influence conversion. Truncated C1 is not able 
to convert to PrP
Sc
 in vivo but acts as a dominant negative inhibitor for early stages of 
conversion (Westergard et al., 2011).  
 






 conversion site has not been defined. It has been proposed that 
PrP
C
 undergoes conversion either on the cell surface or following endocytosis of PrP
C
 
(Borchelt et al., 1992, Beranger et al., 2002, Veith et al., 2009). The site of conversion 
may occur at multiple sites and may be strain dependent.  
 
Localisation to the cell membrane is important for conversion. The plasma membrane is 
believed to be the primary site of conversion. Fluorescent epitope tagging has 
demonstrated rapid conversion of PrP
C
 after one minute of exposure to PrP
Sc
 at the cell 
surface (Goold et al., 2011). Infectivity is reduced on exposure to anti-PrP antibodies or 
if PrP is released from the cell surface by removal of the GPI anchor (Borchelt et al., 
1992, Campana et al., 2005) or if trafficking to the cell surface is altered (Gilch et al., 
2001) suggesting that PrP
C
 must go to the cell membrane before conversion can occur.  
 
In addition to conversion at the cell surface PrP
C
 may act as a receptor allowing 
internalisation of PrP
Sc
 and intracellular conversion. Studies have shown that conversion 
may occur in endosomal compartments. In cell culture, exosomes are infectious and 
PrP
Sc
 can be secreted into the media to infect other cells (Fevrier et al., 2004). Dominant 
negative peptides that disrupt trafficking have shown that in more than one cell line 
early and late endosomes do not take part in conversion but endosomal recycling 
compartments do (Marijanovic et al., 2009). Blocking endocytosis by lowering the 
temperature inhibits PrP
Sc
 formation (Borchelt et al., 1992).  
PrP
Sc
 can undergo retrograde transport to the Golgi apparatus or ER, where it can form 
new PrP
Sc
 from newly synthesised immature PrP
C
 (Campana et al., 2005). Stimulation 
of retrograde transport and intracellular accumulation by the small GTPase Rab6a 
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showed an increase in PrP
Sc
 in infected cells (Beranger et al., 2002). Immature PrP
C
 
may be a better substrate for conversion than mature PrP
C
 because it is easier to misfold 
(Campana et al., 2005). The ER is thought to play a key role in conversion of PrP
C
 
mutants in familial TSEs. Studies have shown that PrP
C
 containing some familial 
mutations convert spontaneously to PrP
Sc
 soon after synthesis and are much slower to 
leave the ER, suggesting accumulation in the ER rather than the cytoplasm is important 
in this set of familial TSEs (Harris, 2003, Gu et al., 2003).   
 
Efficient conversion of PrP is dependent upon membrane tethered PrP
C
. Cell cultures 
that expressed only GPI anchorless PrP were resistant to TSEs (McNally et al., 2009). 
Mice that express PrP lacking the GPI anchor do not have PrP
C
 on the cell surface 
(Chesebro et al., 2005). The anchorless PrP is processed through the secretory pathway 
but remains mostly unglycosylated and is secreted from the cell surface. These mice are 
still susceptible to TSEs; however they show PrP
Sc
 positive amyloid plaques rather than 
diffuse deposition and live a normal lifespan. Transmission of TSEs to GPI anchorless 
animals was much more inefficient than in mice with GPI anchored PrP (Chesebro et 
al., 2005).  
 
1.4.5.3 In vitro conversion assays 
 
In order to understand the prion hypothesis several in vitro conversion assays have been 
developed to amplify PrP
Sc
. These assays can aid in identifying the infectious agent and 
are being developed as a sensitive diagnostic test for natural TSE diseases. These assays 
use a small seed from infectious material as a template to induce refolding and 
fibrillisation of PrP
C
 under different biophysical conditions. The conversion product is 
PK resistant but not necessarily the same as PrP
Sc
 generated in disease as it does not 
always cause disease when inoculated into mice.  
 
The first assay developed was the cell free conversion (CFC) assay. Radiolabelled PrP
C
 
is incubated with brain derived PrP
Sc
 in the presence of guanidine to induce conversion 
to a similarly protease resistant protein (Kocisko et al., 1994). Cell free conversion is 
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highly specific, correlating with species transmission and strains (Raymond et al., 2000, 
Kocisko et al., 1995, Bossers et al., 1997). Very little PrP
Sc
 is generated from this single 
round conversion; therefore assays with repeated rounds of conversion were developed 
to improve sensitivity.  
 
Two other in vitro conversion assays were developed to amplify small amounts of PrP
Sc
 
in an excess of PrP
C
 substrate using alternating cycles of incubation to allow PrP
Sc
 
aggregates to grow and disruption of the aggregates to provide new aggregates for 
further conversion. The level of amplification can be increased by increasing the 
number of cycles and is only limited by the availability of PrP
C
 and other essential 
cofactors. Protein misfolding cyclic amplification (PMCA) and the quaking induced 
conversion (QuIC) assay work on the same principle as each other but use different 
sources of PrP
C
 substrate and different methods of disruption.  
 
PMCA uses uninfected brain homogenate as the source of the PrP
C
 substrate for 
conversion and PrP
Sc
 aggregates are broken into smaller aggregates by sonication. It is 
difficult to standardise the conditions in PMCA and the assay has varying success at the 
hands of different laboratories. The QuIC assay uses recombinant PrP at a known 
concentration as the substrate and rapid shaking to disrupt the aggregates.  
 
The PMCA product is tested for amplification by immunoblot. Initially the QuIC assay 
amplification was measured by immunoblotting products (Atarashi et al., 2008); 
however the technique was improved by the addition of thioflavin T (Orru et al., 2009). 
When PrP
res
 forms amyloid fibrils the thioflavin T binds and fluorescence is enhanced. 






1.4.6 Loss of function versus gain of function 
 




 in neurodegeneration are not understood. Toxicity could be 
due to a gain of function of PrP
Sc
 or loss of function of PrP
C




 may possess toxic properties that are not related to the normal function of PrP
C
, 
such as aggregates interfering with synaptic function or triggering apoptotic pathways. 
It has been proposed that prion neurotoxicity is linked to PrP
Sc
 oligomers, which 
translocate to the cytosol and inhibit the ubiquitin-proteosome system (Kristiansen et 
al., 2007). The PrP106-126 fragment has been shown to be neurotoxic to cells expressing 
PrP
C
 both in vitro and in vivo (Forloni et al., 1993, Ettaiche et al., 2000). The neurotoxic 
peptide has a propensity to aggregate and form amyloid like fibrils (Forloni et al., 
1993). Reactive gliosis is a feature of prion diseases but is also common in other protein 
mis-folding diseases, such as Alzheimer’s disease. The PrP106-126 peptide neurotoxicity 
is dependent upon the presence of microglia, which are stimulated by the peptide into 
overproducing oxygen radicals (Brown et al., 1996).  
 
Despite this evidence for PrP
Sc
 as the toxic species several studies have shown that there 
is no correlation between PrP
Sc
 deposition and neurodegeneration. Models exist with 
abundant deposits of PrP
Sc
 amyloid but lacking clinical signs (Chesebro et al., 2005). 
This does not discount PrP
Sc
 as the toxic species, but rather suggests that the toxic 
species may be a particular conformation of PrP
Sc





Figure 1.6 Gain or loss of function mechanisms for PrP neurotoxicity 
Gain of function mechanism (A) PrP
Sc
 possesses toxic properties independent of PrP
C
 function 
or (B) Conversion to PrP
Sc
 subverts the protective function of PrP
C
 to the toxic function of PrP
Sc
. 
Loss of function mechanism (C) PrP
Sc
 is inert but neuronal death is caused by the loss of 




The loss of biological activity of PrP
C
 could be responsible for neurotoxicity. PrP
C
 has 
been proposed to be involved with anti-apoptotic activity and neuroprotection (Roucou 
et al., 2004). Loss of this neuroprotection could lead to neurodegeneration thus 
understanding the function of PrP
C
 may be important in elucidating the neurotoxic 
mechanisms.  However the lack of phenotype in PrP null mice is strong evidence 
against the loss of function mechanism. 
 
As arguments exist for both loss and gain of function it may be that the 
neurodegeneration is a result of both. A build-up of PrP
Sc
 causes stress on the cell, 
which is unable to respond effectively due to loss of function of PrP
C
 leading to 
neuronal dysfunction and neurodegeneration. PrP
C
 has been implicated in several signal 




 could alter the binding ability and 
initiate a toxic signalling cascade. 
 
1.5 Glycosylation of PrP in TSE disease 
 
Glycosylation can influence conformation of a protein and interactions with other 







. Glycosylation is not essential for conversion however the glycosylation status of 
both host PrP
C
 and donor PrP
Sc
 influence TSE disease outcome (Taraboulos et al., 1990, 
Tuzi et al., 2008, Cancellotti et al., 2013).  
 
Glycosylation is used as a tool to distinguish between TSE strains. PrP glycotype 
analysis forms part of the molecular classification and looks at the ratio of the different 
glycoforms and the size of the PK digested cleavage fragment of unglycosylated PrP
Sc
. 
Glycosylation alone does not define a strain as some strains share the same glycotype, 
yet display unique clinical and pathological features. Therefore, strains are distinguished 
by a combination of molecular, pathological and clinical classifications (Bruce, 2003, 
Beck et al., 2012, Gavier-Widen et al., 2005).  
 
Strains may have different requirements of host glycosylation in order to cause disease. 
Subtle changes in the stoichiometry of host PrP
C
 glycoforms can significantly impact 
prion conversion during in vitro amplification in a species- and strain-specific manner 
(Nishina et al., 2006). Unglycosylated PrP as a substrate for conversion by PMCA was 
essential for the formation of RML mouse PrP
Sc
, while diglycosylated PrP was required 
for hamster PrP
Sc
 formation. Disease incubation period varies with host glycosylation 
status in vivo (discussed in detail in 1.5.1) indicating that glycosylation assists in 
conversion (Tuzi et al., 2008, Cancellotti et al., 2013). 
 
Glycosylation may determine the targeting of different strains to different brain regions 
due to neuronal-specific differences in PrP glycosylation (Hecker et al., 1992, 
DeArmond et al., 1999). Glycosylation at the first site did not influence strain targeting, 
as vacuolation patterns seen in wild type mice and mice lacking glycans at this site were 
the same for three strains. However, vacuolation patterns were altered in 79A infected 
G1 mice indicating that the second site may contribute to strain targeting (Tuzi et al., 
2008).  
 
In TSE disease, strains show precise regional variation of PrP
Sc
 deposition, suggesting 
strain specific targeting of neuronal populations. When glycosylation is disrupted the 
pattern of PrP
Sc
 deposition can be changed therefore it has been proposed that 
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glycosylation can influence targeting (Cancellotti et al., 2010). The degree of 
glycosylation of PrP
Sc 
in TSE disease varies with brain region (Somerville et al., 2005), 
which may reflect the degree of glycosylation of PrP
C
. Regional differences in the PrP
C 
glycoforms have been observed (Beringue et al., 2003) and the stoichiometry of the 
PrP
C
 glycoforms has been shown to influence the efficiency of conversion in a strain 
dependent manner (Nishina et al., 2006) therefore the glycoforms available in different 
regions may determine the efficiency of conversion and deposition for the different 
strains.    
 
The glycosylation status of the host and glycosylation of PrP
Sc
 can allow selection of a 
strain (Cancellotti et al., 2013). When 79A from the PrP glycosylation deficient mice 
were tested in a strain typing panel of mice (C57, VM and the F1 cross) the vacuolation 
profile and incubation period order was different between mouse strains (Tuzi et al., 
2008, Cancellotti et al., 2013). G3 79A showed a similar profile to wild type 79A, but 
G2 79A appeared to be more similar to the 139A strain. The scrapie cell conversion 
assay (SSCA) also showed G2 to have a 139A phenotype. G1 79A showed a different 
phenotype from wild type mice both in the strain typing panel and the SSCA which may 
represent a novel strain (Cancellotti et al., 2013). There was no change in phenotype 
seen in G2 ME7 or G2 301C. 79A may be a less stable strain and is able to switch 
between 79A and 139A, depending upon host PrP. 
 
1.5.1 Susceptibility of GlycoD mice to TSE disease 
 
The GlycoD mice have been used to study the effect of glycosylation on the TSE 
disease process. Several different strains, both mouse adapted and non-adapted have 
been used in the GlycoD mice to assess the influence of host glycosylation status (Table 
1.7Table 1.7). PrP
Sc
 from the GlycoD mice was also used to assess the effect of 
glycosylation of the PrP
Sc
 on strain properties.  
 
All GlycoD mice were susceptible to at least one strain of TSE; however the 
susceptibilities varied according to glycosylation status of the host and the TSE agent 
(Figure 1.7). The susceptibility of G3 mice to at least one strain shows that 
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glycosylation is not essential to support TSE disease. G1 and G3 mice are resistant to 
most strains tested, with the exception of 79A where they are susceptible but with an 
increased incubation time. Both of these mouse lines lack glycans at the first 
glycosylation site suggesting that the presence of carbohydrates at the first site are 
important for determining susceptibility. G2 mice were susceptible to all strains tested, 
although they had increased incubation times for some strains. G2 mice were the only 




 is not required for infection as brain material from 
unglycosylated mice infected with 79A was able to cause disease in wild type mice. 
Moreover the infected GlycoD mice, which only have mono or unglycosylated PrP
Sc
; 
when used to inoculate wild type mice demonstrated the presence of diglycosylated 
PrP
Sc
 in the host (Tuzi et al., 2008) demonstrating that the host dictates the 
glycosylation of the PrP
Sc
 rather than the donor.  
 
Glycosylation appears to have a strain dependent influence on disease susceptibility. All 
GlycoD mice were susceptible to 79A but both G1 and G2 mice had an increased 
incubation period. G3 mice showed a dramatically reduced susceptibility, only 4 out of 
21 mice showed clinical disease and the incubation time was more than tripled 
compared to wild type mice. The prolonged incubation in the GlycoD mice suggests 
that both glycosylation sites facilitate infection by 79A.  
 
It is likely that the glycan at the first site is important for susceptibility to ME7 as mice 
lacking glycans at the first site were resistant to disease but mice with glycans present at 
the first site showed no difference in disease susceptibility and incubation time (Table 
1.7). The difference in localisation of PrP
C
 in the GlycoD mice is not responsible for the 
increased resistance to ME7 as G1 and G2 mice have comparable localisations yet 
different susceptibilities.  
 
The resistance of both G1 and G3 mice to five of the six TSE strains tested suggests that 
glycosylation at the first site is an important determinant for disease susceptibility. The 
G1 and G2 mice showed a similar decrease in cell surface PrP (Cancellotti et al., 2005) 
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therefore likely that the altered localisation of PrP
C
 is caused by the lack of 
glycosylation rather than altered localisation.  
 
 
Figure 1.7 Susceptibility of GlycoD mice to mouse adapted TSE strains 
The susceptibility of the GlycoD mice to 79A and ME7 is shown for primary and secondary 
passage. The number of mice susceptible (clinical and pathology positive) is shown with the 
total number of mice inoculated. Incubation period in days is shown in brackets. G1 and G3 
mice were resistant to ME7. Data from (Tuzi et al., 2008) and (Cancellotti et al., 2013). 
Table 1.7  Summary of susceptibilities and incubation periods for different TSE strains 
48 
 





















(148 +/- 2.6 days) 
 
5/5 
(194 +/- 2.1 days) 
12/12 
(167 +/- 9.3 days) 
4/21 




(163 +/- 2 days) 
 
0/16 
(600 < days) 
14/14 
(160 +/- 2.5 days) 
0/18 

































(600 < days) 
5/18 
(536 +/- 16 days) 
0/22 





(700 < days) 
 
0/14 
(600 < days) 
7/14 
(404 +/- 7.8 days) 
0/21 





0/17 11/19 0/21 
 
Susceptible Incubation ↑ 
Incubation ↑ by 







Subclinical disease was determined as no clinical disease but by the presence of both PrP
Sc
 
deposition and spongiform degeneration. 
 
Each box shows the number of animals which were clinically and pathologically positive for TSE 
disease and the total number of animals in the group. The incubation period is also shown in 
brackets for each strain and genotype. Boxes are colour coded to allow easier visualisation of 
the susceptibility patterns.  
 
The changes in disease susceptibility in the GlycoD mice may be due to the amino acid 
substitution rather than the absence of the glycans. However, there is a dramatic 
difference in TSE susceptibility between G3 mice and G1 or G2 mice. The G3 mice 
have the same amino acid substitution at position 180 as G1 mice yet G1-79A and G3-
79A show a difference in phenotype. The G3 mice also share the amino acid 
substitution at position 196 as G2 mice yet G2-79A and G3-79A show differences in 
disease phenotype (Cancellotti et al., 2013), suggesting that the difference is caused by 
the lack of glycosylation rather than the amino acid substitution. 
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Studies using different amino acid substitutions showed that Asn substitution did not 
prevent TSE infection or PrP
Sc
 replication suggesting that Ans residues can be replaced 
without directly affecting disease susceptibility (Ikeda et al., 2008, Neuendorf et al., 
2004). Studies using the GlycoD mice and other glycosylation deficient PrP mice with 
different amino acid substitutions produce similar results when inoculated with three 
different TSE strains (Tuzi et al., 2008, Neuendorf et al., 2004). Conversion of 
deglycosylated mouse PrP
C
 using serial PMCA showed no change in agent phenotype 
(Piro et al., 2009). This evidence suggests the effects are due to glycosylation deficiency 




1. PrPC possesses two glycosylation sites that can be variably glycosylated leading 
to 4 different glycoforms in vivo. Glycosylation of PrP
C
 plays an important role 
in TSE disease however the significance of the glycoforms is unknown for PrP
C
. 
This thesis will investigate the effect the glycosylation of the two different sites 
have on the cell biology of PrP
C
. It will also aim to determine whether the cell 
biology of the glycoforms can explain the differences in susceptibility in TSE 
disease in the GlycoD mice. 
 
2. Investigate the cell biology of the different glycoforms of PrPC using the 
different GlycoD mice to isolate glycoforms 
a. Establish whether glycosylation alters the steady state level of PrPC in 
the brain 
b. Establish the distribution of the glycoforms throughout the brain 
c. Establish whether glycosylation affects susceptibility to the natural 
proteolytic cleavage events 
d. Determine exact localisation and quantity of PrPC in the GlycoD mice 
 
3. Assess the effect of glycosylation on the interaction between the PrPC and PrPSc 
in an in vitro conversion assay (QuIC) 
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2 Materials and Methods 
 
All chemicals are from BDH unless otherwise stated. All experiments were carried out 
at room temperature unless otherwise stated. 
 
2.1 Animals used  
 
All animal breeding and experimental work was carried out under the regulations of the 
UK Animals (Scientific Procedures) Act 1986 and approved by the local ethics 
Committee. All transgenic animals have been approved by the Health and Safety 
Executive. 
 
3 different lines of PrP glycosylation deficient (GlycoD) mice were created using gene 
targeting methods and maintained on a 129/Ola background (Cancellotti et al., 2005). 
 
− G1 carries the N180T mutation in PrP to abolish the first glycosylation site 
− G2 carries the N196T mutation in PrP to abolish the second glycosylation site 
− G3 carries the N180T and N196T mutations in PrP to abolish both glycosylation 
sites 
 
All mice were 6 weeks or older and both sexes were used. No age or sex matching was 
carried out for the genotype groups.  
 
2.2 Quantification of PrnP mRNA in mouse brain 
 
2.2.1 Isolation of RNA 
 
Half brains were weighed and homogenised in RNA-bee (1ml/50mg tissue) [Amsbio] in 
a gentleMACS dissociator [Miltenyi]. For every 1ml RNA-bee 0.2ml chloroform were 
added and shaken vigorously. Samples were incubated on ice for 5 minutes before 
centrifugation at 12,000 x g for 15 minutes at 4°C. The aqueous phase containing the 
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RNA was transferred to a new tube and 500 µl isopropanol added for 10 minutes at 
room temperature to precipitate the RNA. Precipitate was centrifuged at 12,000 x g for 
5 minutes at 4 °C and the pellet washed twice with 75% ethanol and allowed to air dry. 
RNA was resuspended in RNase free water. Samples were treated with DNA-free 
[Ambion] to remove genomic DNA and RNA was stored at -80 °C long term.  
 
2.2.2 cDNA synthesis 
 
cDNA synthesis was carried out using a first strand cDNA synthesis kit [GE 
Healthcare] and a random hexamer primer (pd(N)6). The RNA was measured using a 
NanoDrop spectrometer and diluted to 1000ng/µl. 5 µl RNA in 3 µl RNase free water 
was heated to 65 °C for 10 minutes to denature and then chilled on ice. 5 µl bulk 
reaction mix, 1 µl Dithiothreitol (DTT) solution and 1 µl pd(N)6 primer was added and 
incubated at 37 °C for 1 hour. 
 
2.2.3 SYBR green Quantitative PCR (qPCR) 
 
Quantitative PCR was carried out using the Platinum SYBR green supermix-UDG 
[Invitrogen]. Each sample was carried out in quadruplet with a no reverse transcriptase 
control and non template control included. Each cDNA was diluted 100 fold with 
nuclease-free water and 4.75 µl added to 7.75 µl qPCR master mix (6.25 µl SYBR 
green master mix, 0.625 µl forward primer, 0.625 µl reverse primer, 0.25 µl Rox 
reference dye). Primers for Prnp and the housekeeping gene, β-actin had been 
previously optimised and analysed by S. Aungier, The Roslin Institute. Samples were 
mixed by gentle vortexing and then centrifuged briefly to collect the liquid at the 
bottom of the wells.  
 
Amplification was carried out on an Mx300 qPCR machine [Stratagene] using the 






50 °C 2 mins UDG incubation 
96 °C 2 mins Activated Taq polymerase 
40 cycles 
96 °C 15 secs Denaturing 
60 °C 30 secs Annealing and extension 
One cycle 
95 °C 1 min 
Melting curve analysis 
60 °C 30 secs 
95 °C 15 secs 
25 °C 30 secs 
 
The ΔΔCT values were calculated to assess fold change in Prnp expression against the 
housekeeping gene β-actin compared to Prnp in wild type mice. 
 
2.3 Preparation of protein from brain for biochemical analysis 
 
2.3.1 Total protein extraction 
 
Flash frozen whole brains or dissected regions of brain were weighed and appropriate 
volumes of ice cold lysis buffer [0.5% Nonidet NP-40 [Sigma], 0.5% sodium 
deoxycholate in PBS] added to give a 10% (v/w) homogenate. Protease inhibitors 
[phenylmethylsulfonyl fluoride (PMSF) final concentration 10 mM; N- ethylmaleimide 
(NEM) final concentration 10 mM] were added to prevent protein degradation by 
endogenous proteases. Brains were mechanically homogenised and centrifuged at 2000 
x g for 10 minutes to remove the nuclei and cellular debris. Supernatants were removed, 
aliquoted and frozen in liquid nitrogen (LN2). Homogenates were stored at -70 C. 
 
2.3.2 Protein extraction for lipid raft analysis 
 
At 37 C all membrane regions are soluble but at 4 C lipid raft regions are insoluble, 
whilst non-raft regions are soluble. This can be used to isolate the lipid raft regions from 
the non-raft regions of the membrane. All stages carried out at 4 C or on ice, using ice 
cold solutions and as quickly as possible. 
Flash frozen brains were mechanically homogenised in 10 ml homogenisation buffer 
[150 mM sodium chloride, 20 mM sodium dihydrogen orthophosphate, 2 mM disodium 
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hydrogen phosphate, 1 mM EDTA, 20% glycerol in dH2O] by 30 passes of a dounce 
homogeniser then passed through a 21 gauge needle 20 times. Homogenate was 
centrifuged at 5000 x g for 20 minutes to remove large debris. Supernatant was removed 
and centrifuged at 100,000 x g for 90 minutes to pellet the membranes. The resulting 
pellet was resuspended in 3 ml MES buffered saline (MBS) [25 mM MES and 0.15 M 
NaCl (pH 6.5 with HCl)] and further centrifuged at 100,000 x g for 90 minutes. The pellet 
was resuspended in 3 ml MBS with 2 mM EDTA and 2% (vol/vol) Triton X-100 and 
passed through a 21 gauge needle 15 times. It was then mixed at 4 C for 2 hours to 
fully solubilise all membranes. Solubilised membranes were diluted with an equal 
volume of 80% (w/v) sucrose in MBS to give a 40% sucrose solution. 0.8 ml membrane 
solution was injected under a discontinuous sucrose gradient [2.4 ml 30% (wt/vol) 
sucrose and 0.8 ml 5% (w/v) sucrose in MBS containing 2 mM EDTA and 0.5% (v/v) 
Triton X-100] and centrifuged at 100,000 x g for 18 hours. 10 x 400 l fractions were 
collected from the top of the gradient to the bottom. The pellet was resuspended in MBS 
with 2 mM EDTA and 2% (v/v) Triton X-100 with mild sonication. Fractions were 
stored at -70 C until being probed by western blot.  
 
Where necessary, individual fractions were concentrated in order to detect low-level 
proteins. Fractions were mixed with an equal volume of 40% (w/v) trichloroacetic acid 
and mixed at 4 C for 1 hour to precipitate the protein. The protein was then pelleted by 
centrifugation at 11,600 x g for 5 minutes and the pellet resuspended in 100 l 3M Tris-
HCl (pH 7). 
 
2.3.3 Micro dissection of mouse brain regions 
 
Microcentrifuge tubes were labelled with the brain number and area of the brain and 
then weighed. Snap frozen brains were removed from LN2 and allowed to partially thaw 
before dissection on a cold plate [Celltech]. The brain was sectioned coronally, starting 
from the brain stem, into 4 areas using a scalpel and forceps. Each section was then 
dissected into regions using the scalpel (Figure 2.1). The hippocampus was dissected 
using a punch method. A biopsy needle was used to punch out the hippocampus and a 
syringe used to blow the region out of the needle into a microcentrifuge tube. At least 4 
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punches were taken from each hippocampus. The brain regions were then flash frozen 
in LN2. Frozen samples were then re-weighed and empty tube weights subtracted to 
calculate the total brain weight. 3 blank tubes were weighed before and after freezing to 
use as a correction factor for the other samples. Brain regions were stored at -70 C. 
 
 
Figure 2.1. Dissected brain regions 
(A) Coronal sections cut through mouse brain as described in (Barr et al., 2004) (B) Seven 
different brain regions throughout the brain were selected. Blue areas were cut with a scalpel 
whilst the red areas were dissected using at least 4 punches of a canula needle for each 
hippocampus.  
 
2.3.4 Total protein estimation using the bicinchoninic acid assay 
 
Total protein estimation was carried out using the bicinchoninic acid assay (BCA) assay 
kit [Pierce]. Protein standards were made with bovine serum albumen (BSA)[Pierce] 
diluted in the same buffer as the samples to give a range of concentrations. 3 l 
homogenate was added to 57 l buffer to give a 1:10 dilution of the original 
homogenate (6 l homogenate added to 54 l buffer to give a 1:20 dilution). 20 l 
sample or standard was added in duplicate to a 96-well microtitre plate. Reagent A was 
mixed with reagent B [Peirce] 50:1 to create a working reagent. 180 l working reagent 
was added to each well. The plate was incubated at 37 C for 30 minutes then cooled to 
room temperature. The absorbance at 570 nm was read on a plate reader and analysed 
using Ascent software [Thermo Scientific]. Final absorbances were calculated by 
subtracting the blank reading (working reagent and sample buffer) and absorbances of 
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the BSA standards used to produce a standard curve. Concentrations of samples were 
derived using the standard curve.  
 
2.3.5 Deglycosylation of proteins using PNGase F 
 
20 μl 10% brain homogenate was denatured with 1 x glycoprotein denaturing buffer 
(0.5% sodium dodecylsulphate (SDS), 1% β-mercaptoethanol) [New England Biolabs] 
at 100 °C for 10 minutes before incubation with 1500 U of N-glycosidase F (PNGase F) 
[New England Biolabs] in 1 x G7 reaction buffer (50 mM NaPO4, pH 7.5) [New 
England Biolabs], 1% NP-40 [New England Biolabs] and 2.5 M urea at 37 C overnight 
with vigorous shaking. The reaction was stopped by freezing at -20 C. 200 μl 
methanol, 100 μl chloroform and 150 μl dH2O were added and centrifuged at 2,000 x g 
for 10 minutes to precipitate the proteins. The chloroform layer was removed and 200 μl 
methanol added to resuspend the precipitated proteins and stored at -20 °C. When 
samples were ready to be used for SDS gel electrophoresis they were centrifuged at 
13,000 x g and supernatant discarded. Pellets allowed to air dry before being suspended 
in 20 μl lysis buffer.  
 
2.3.6 Deglycosylation of proteins using Endoglycosidase H 
 
40 μl 10% brain homogenate was denatured with 1 x glycoprotein denaturing buffer 
(0.5% sodium dodecylsulphate (SDS), 1% β-mercaptoethanol) [New England Biolabs] 
at 100 °C for 10 minutes. Samples were left to cool to room temperature and 1 x G5 
reaction buffer (50 mM sodium citrate, pH 5.5) [New England Biolabs] added before 
splitting into two aliquots. 2500 U endoglycosidase H was added to one aliquot and 
dH2O added to the other and incubated at 37 C overnight with vigorous shaking. The 
reaction was stopped by freezing to -20 C. 
 
2.3.7 Proteinase K digestion 
 
10% brain homogenate was incubated with 100 µg/ml Proteinase K [Roche] at 37 C 
for 1 hour and 15 minutes with shaking. The reaction was stopped with 10 mM PMSF 
and 10 mM NEM. 
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2.3.8 Solubilisation in guanidine hydrochloride 
 
10% brain homogenate in lysis buffer was added to equal volumes of 2 M guanidine 
hydrochloride (Gnd HCl) and homogenised with a dounce homogeniser. Insoluble 
proteins were separated from soluble proteins by centrifugation at 16,200 x g for 10 
minutes. Supernatant contained proteins soluble in 1M Gnd HCl and stored at -20 C. 
The resultant pellet was resuspended in 6M Gnd HCl and stored at -20 C.  
 
2.3.9 Phosphatidylinositol-specific phospholipase C removal of GPI 
anchor  
 
A whole brain prepared as a 10% brain homogenate was centrifuged at 25,000 x g for 
10 minutes at 4 C to pellet membranes. Supernatant was retained and designated S1. 
The pellet was resuspended in 500 µl PBS and split into two 250 µl aliquots. One 
aliquot was treated with 0.5 U Phosphatidylinositol-specific phospholipase C (PI-PLC) 
[Invitrogen] and the other dH2O at 37 °C overnight. Samples were centrifuged at 16,000 
x g for 15 minutes and supernatant retained as S2. The pellet was resuspended in 500 µl. 
All fractions were frozen and stored short term at -20 C.   
 
2.4 Analysis of PrPC by Western blot 
 
2.4.1 Protein denaturation and separation by Sodium Dodecyl  Sulphate 
Polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Total protein samples were denatured in 1x NuPage
®
 LDS sample buffer [Invitrogen] 
and 1 x NuPage
®
 sample reducing agent [Invitrogen] at 70 °C for 15 minutes. Proteins 
were then separated based on weight by gel electrophoresis at 200V for 40 minutes 
using NuPage
®
 pre-cast 4-12% bis-tris gels [Invitrogen] in 1 x MES running buffer 
(MES 50 mM pH 7.2, Tris 50 mM, SDS 0.1%, EDTA 1 mM) [Invitrogen]. SeeBlue 
Plus2 prestained standard [Invitrogen] and MagicMark XP standard [Invitrogen] were 




For separation of monoglycosylated PrP in wt samples a tris-glycine system was used 
with a higher acrylamide percentage to increase separation. Total protein samples were 
denatured in 1x tris-glycine SDS sample buffer [Invitrogen] and 1 x NuPage
®
 sample 
reducing agent [Invitrogen] at 90 °C for 10 minutes. Proteins were then separated based 
on weight by gel electrophoresis at 120 V for 30 minutes followed by 150 V for 2.5 
hours using Novex
®
 pre-cast 18% tris-glycine gels [Invitrogen] in 1 x tris-glycine 
running buffer (Tris 24 mM, Glycine 192 mM, SDS 0.1%).  
 
2.4.2 Transfer of proteins to a membrane 
 
Separated proteins were transferred to a polyvinylidene fluoride (PVDF) membrane 
[Fisher]  at 25V for 1 hour using the NuPage
®
 tank transfer system in 1 x NuPage
®
 
Transfer buffer (25 mM bicine, 25 mM Bis-Tris (free base), 1 mM EDTA, 0.05mM 
chlorobutanol) [Invitrogen], 10% methanol and NuPage
®
 antioxidant [Invitrogen].  
 
2.4.3 Coomassie staining of polyacrylamide gel 
 
Coomassie brilliant blue stain was used to visualise proteins remaining on the gel after 
transfer to assess the efficiency of the transfer. Gels were incubated in coomassie 
brilliant blue stain (3 mM coomassie brilliant blue R-250, 50% methanol, 41% acetic 
acid) for 1 hour with agitation. The gel was then incubated for at least 2 hours or 
overnight if necessary with destain solution (23% ethanol, 7% acetic acid) with a 
minimum of 6 washes until the gel was clear. 
 
2.4.4 Ponceau S staining of membrane bound proteins 
 
The amount of protein bound to the membrane was visualised using Ponceau S solution 
to confirm that the transfer had been successful. The membrane was incubated in 
Ponceau S solution (0.1% Ponceau S, 5% acetic acid) [Sigma Aldrich] for 5 minutes so 
that protein bands were clearly visible. The membrane was then destained with Tris 
Buffered Saline with Tween (TBST) [50 mM Tris, 150 mM sodium chloride,1% tween 




2.4.5 Identification of membrane bound proteins by immunodetection 
 
Non-specific binding sites were blocked using 1% blocking solution [Roche 
Diagnostics] diluted in TBST for 1 hour at room temperature. Membranes were then 
incubated in primary antibody diluted (Table 2.1) in 0.5% blocking solution [Roche 
Diagnostics] for either an hour or overnight at room temperature with shaking. When 
two different antibodies of the same species were used then the primary antibodies were 
added together. Where two different antibodies of different species were used the 
membranes were cut at an appropriate marker and the separate pieces of membrane 
were processed separately. Excess primary antibody was washed off with 2 x 10 minute 
washes with TBST followed by 2 x 10 minute washes with 0.5% blocking solution. 
Membranes were incubated in species specific peroxidase conjugated AffiniPure 
antibodies [Stratech] at 0.05μg/ml diluted in 0.5% blocking solution for 30 minutes at 
room temperature. Membranes were washed 4 x 15 minutes in TBST to remove excess 
antibody. Bound secondary antibody was detected by light emission from SuperSignal 
West Dura Chemiluminescent Substrate [Fisher Scientific] using a Kodak 440 Image 
station with typical exposures of 1, 5 and 10 minutes. Membranes were also exposed to 
Lumi-Film Chemiluminescent Detection Film [Roche Diagnostics] and developed 





Table 2.1 Antibodies used in western blotting 
































aa. 140-145 0.1 
Gifts of S. 
McCutcheon 
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University  of 
Edinburgh 
 
BC6 aa. 146-156 0.05-0.025 
BH1 aa. 143-154 0.1 
DE3 aa. 146-153 0.1 
EA6 unknown 0.1 
FD12 unknown 0.1 
FH10 aa. 202-210 0.1 

















aa. 1-100 0.2 AbCam 
 
2.4.6 Stripping of PVDF membrane 
 
To allow re-probing of the membrane with a different antibody blots were stripped with 
Restore Western Blot stripping buffer [Thermo Scientific] for 2 x 15 minutes with 
shaking. Blots were then washed with TBS, TBST and 0.5% blocking solution before 
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Immunoblots were imaged using the Kodak Image station and Kodak MI software. 
Protein bands were selected manually by drawing around them and the sum intensity 
calculated. A blank region was also selected to measure the background intensity of the 
blot. 
 
2.5 Culturing primary cell lines 
 
All cell culture was carried out under aseptic conditions using a class 2 safety cabinet to 
prevent microbiological contamination. Cabinets were exposed to ultraviolet light when 
not in use and were cleaned with 70% ethanol before and after use. Cultures were 
incubated at 37 C with 5% CO2.  
 
2.5.1 Preparation of media 
 
Media was made up in 50ml batches and stored at 4 °C. One millitre of media was 
pipetted into a sterile culture flask and left in the incubator at 37 °C to check for 
microbiological contamination.  
 
Neuronal media (1 x B27 serum-free supplement [Invitrogen], 2 mM L-glutamine 
[Invitrogen], 100 units/ml penicillin [Sigma], 100 μg/ml streptomycin [Sigma], 0.25 
μg/ml amphotericin B [Sigma]; in Neurobasl media [Invitrogen]) was prepared for cells 
to be differentiated into neuronal cultures.  
 
Glial media (1 x G5 supplement [Invitrogen], 2 mM L-glutamine [Invitrogen], 100 
units/ml penicillin [Sigma], 100 μg/ml streptomycin [Sigma], 0.25 μg/ml amphotericin 
B [Sigma]; in Advanced D-MEM/F12 [Invitrogen] with 10% heat-inactivated foetal 
bovine serum [Invitrogen]) was prepared for cells to be differentiated into glial cultures. 
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2.5.2 Establishing cell suspensions to create primary cell cultures 
 
Embryos from mice culled at day 17 after plug formation were collected and heads put 
into sterile Hanks Balanced Salt Solution (HBSS) [Sigma]. Embryo heads were then 
transferred from the animal facility to the laboratory on ice. Heads were removed from 
HBSS individually and brains were dissected out using sterile forceps. Brain material 
was put into fresh HBSS on ice. One skull from each litter was frozen at -20 °C and 
stored to confirm the genotype, the remaining skulls were discarded. 4-5 Brains were 
transferred to 1.5 ml TrypLE Express [Invitrogen] and incubated at 37 °C for 15 
minutes to dissociate cells. TrypLE Express was removed and brains washed twice with 
HBSS. 10 ml media was added and cells dissociated into a single cell suspension by 
pipetting gently until the media was cloudy. Suspensions were left for 2 minutes to 
allow large debris to settle prior to cell counting. 
 
Cell suspensions were used initially to create direct primary cell cultures but the method 
proved to be unreliable for neuronal cultures and cells would often not differentiate into 
neurons. Neurospheres were generated to create neuronal precursor cells that were 
dividing, which could then be further differentiated into neuronal cultures.  
 
2.5.3 Establishing primary cell cultures directly 
 
10 μl cell suspension was diluted 1:10 with fresh media and then 1:2 with trypan blue 
[Sigma]. Cells were counted under a light microscope using a haemocytometer and the 
number of live cells present per ml was calculated.  
 
Sterile tissue culture plastics were pre-coated with poly-D-lysine hydrobromide [Sigma] 
and allowed to dry under a UV light overnight. Cell suspension was added so that there 
were 150,000 cells per well in 24 well plates or 6 million cells in a 10 cm culture dish. 
Media was added so that each well of a 24 well plate contains 500 μl in total and 10 ml 





2.5.4 Generation of Neurospheres 
 
2 or 4 ml cell suspension was transferred into 25 cm tissue culture flasks [Fisher] and 
neuronal media with 10 nM epidermal growth factor (EGF) [Invitrogen] and 10 nM 
fibroblast growth factor basic (FGFb) [Invitrogen] added to make total volume up to 10 
ml. Cultures were incubated for 3 days before media was transferred to a fresh flask to 
remove debris and adherent cells which had stuck to the plastic. Cultures were 
incubated for a further 2 days to allow neurospheres to form.  
 
Once neurospheres were formed media was changed every 3-4 days by centrifuging 
cells at 2000 x g for 2 minutes then removing supernatant and re-suspending pelleted 
cells in 10 ml fresh media with EGF and FGF. Once neurospheres were too big, usually 
after 7-10 days, they started to adhere to the flask and differentiate. When a lot of large 
neurospheres were present they were incubated at 37 C with TrypLe Express 
[Invitrogen] for 2 minutes then transferred to fresh media with EGF and FGF. 
Neurospheres were broken up into smaller neurospheres by gentle pipetting before 
being returned to flasks.  
 
2.5.5 Freezing and storing cells 
 
Neurospheres were broken up into small neurospheres before being frozen down to 
increase cell viability. Neurospheres were incubated at 37 C with TrypLe Express for 2 
minutes and transferred to freezing media (20% dimethyl sulphoxide (DMSO) in 
neurobasal media without growth factors). Cells were pipetted to dissociate large 
neurospheres and then frozen at -70 C for 24 hours. Cells were stored at -150 C long 
term.  
 
2.5.6 Differentiating cells from neurospheres 
 
One millitre culture containing neurospheres was removed from the flasks and 
incubated at 37 C with TrypLE Express for 5 minutes. Neurospheres were put in fresh 
neuronal media and broken up into a single cell suspension. The cell suspension was 
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split into 24 well plates that were pre-treated with either 1% gelatine or poly-ornithine 
to help the cells to adhere to the plastic.  
 
To differentiate the cells into neuronal cultures the EGF was removed from the media so 
that cells were cultured with neuronal media only containing FGF. Cultures were left 
for 5 days before they were checked for differentiation. Differentiation was monitored 
by looking at cell morphology.  
 
2.6 Immunocytochemistry (ICC) on cultured cells 
 
Media was removed from differentiated cells and cells were washed twice with 
Dulbeccos phosphate buffered saline (DPBS)[Invitrogen]. Cells were treated in fixative 
(4% paraformaldehyde and 0.25% gluteraldehyde in PBS) for 10 minutes at room 
temperature. Once cells were fixed they were removed from the safety cabinet and the 
rest of the protocol was carried out on the bench. The fixative was removed and excess 
washed off with 3 x 5 minute washes with PBS. Membranes were permeabilised with 
either 0.1% triton X-100 or 0.1% Saponin [Sigma] for 1 hour then rinsed 3 x 5 minutes 
with PBS. Non-specific binding sites were blocked with 3% BSA/PBS for 30 minutes. 
Cells were incubated in primary antibody (Table 2.2) in a humidified chamber for 1 
hour. Excess antibody was washed off with 3 x 5 minutes with PBS before cells were 
incubated in species specific Alexafluor conjugated antibody [Invitrogen] for 1 hour. 
Excess antibody was washed off with 3 x 5 minute washes with PBS. DAPI was used as 
a nuclear counter stain for cells to identify cell bodies. Cells were incubated in DAPI 
(diluted 1:50,000 in dH2O) for 5 minutes then washed twice with ultrapure water. 
Coverslips were allowed to air dry then were mounted onto glass slides using 
Vectashield hard-set mounting media for fluorescence [Vector labs]. Slides were stored 
at 4 C in the dark for up to 2 months. 
 
2.6.1 Confocal Imaging 
 
Slides were imaged using a LSM 5 confocal microscope [Zeiss] with lasers at 405, 488 
and 564nm. For PrP staining Null cells were used to set the laser strength in order to 
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reduce background fluorescence. The same microscope configuration was then used for 
all of the other genotypes to allow comparison between the genotypes. Images were 
captured using LSM imaging software [Zeiss]. A single image was captured by taking 
the mean values of 5 frame scans and a false colour was added. Images of the same 
section were overlayed using the LSM software to allow co-localisation of markers to 




Table 2.2 Antibodies used in ICC 
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2.7 Cryo-immunogold electron microscopy 
 
Electron microscopy was performed in collaboration with Sue Godsave and Peter Peters 
(Netherlands Cancer Institute, Amsterdam). Cells were grown and fixed in Edinburgh 





2.7.1 Preparation of cells for electron microscopy 
 
Primary neurons were grown on 10 cm tissue culture dishes at ~70% confluence, as 
described previously. Culture medium was replaced with 5 ml fresh media the day 
before fixation. Cultures were fixed in duplicate; one with just paraformaldehyde (PFA) 
and another with PFA and gluteraldehyde. 5 ml either PFA fixative (4 % PFA, 120 mM 
PIPES, 50 mM HEPES, 4 mM MgCl2, 20 mM EGTA) or PFA/gluteraldehyde fixative 
(4% PFA, 0.4% gluteraldehyde, 120 mM PIPES, 50 mM HEPES, 4 mM MgCl2, 20 mM 
EGTA) was added to each culture dish, without removing media. PFA fixative was left 
on the cultures for 24 hours while PFA/gluteraldehyde fixative was left on cultures for 2 
hours. Fixative was removed and cells were washed twice with PBS+ (0.15 M glycine 
in PBS). Cells were coated in 3 ml 0.1% gelatine in PBS to protect membranes and cells 
were scraped off gently using a rubber cell scraper. The cells were pelleted by 
centrifugation at 3,000 x g for 3 minutes and washed twice in PBS to remove the 
gelatin. Cells were resuspended in 1 ml storage solution (0.5% PFA, 60 mM PIPES, 25 
mM HEPES, 2 mM MgCl2, 10 mM EGTA) then the tube was filled to the top to prevent 
the cells from drying out during transport.  
 
Cells were mailed to Amsterdam in an airtight tube inside a polystyrene box at room 
temperature. Cells that have been frozen cannot be used for cryo electron microscopy so 





Blocks of cells were embedded in gelatin and frozen in LN2. Sections were then cut on a 
cryotome. Semi-thin sections (200 nm) for light microscopy were picked up from the 
diamond knife and mounted onto a slide with 2.3 M sucrose. Ultra-thin sections (60 nm) 
were picked up from the diamond knife with 1% methyl cellulose 25cP in a 1.15 M 
sucrose solution and transferred to formvar/carbon-coated copper grids (hexagonal grid 
bars, spaced 200 μm across). Slides were stored at -20 C until ready to be labelled. 
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2.7.3 Semi-thin fluorescent sections 
 
8 semi-thin sections of the same genotype were mounted on each slide. 100 μl liquid 
was dropped on each section without covering another section so that multiple antibody 
combinations could be used on a single slide. Non-specific binding sites were blocked 
with 1% BSA in PBS with 0.02% glycine (PBS-G) for 15 minutes. Sections were 
incubated in primary antibody (Table 2.2) for 30 minutes. Excess antibody was washed 
off with 3 x 5 minute washes with PBS-G before being incubated with species specific 
secondary antibody conjugated to a fluorochrome dye. Excess antibody was washed off 
with 3 x 5 minute washes with PBS. DAPI was used as a nuclear counter stain for cells 
to identify cell bodies. Coverslips were mounted over sections using Vectashield 
mounting media for fluorescence [Vector Labs]. 
 
Sections were examined using a Zeiss Axiovert 100 TV inverted microscope. 
Micrographs were taken using a Photometrics Series 200 Black and White CCD camera 
with SmartCapture2 software, which adds false colours to the images. 
 
2.7.4 Ultra-thin sections 
 
Gelatin was removed from the grids by heating to 37 C for 30 minutes on 2% gelatin 
plates. Grids were washed 5 x 2 minutes in PBS-G to remove any remaining gelatin. 
Grids were incubated with 1% BSA in PBS-G for 3 minutes to block any non-specific 
binding sites. Sections were then incubated with primary antibody (F4-31; diluted 1:100 
in 1% BSA in PBS) for 1 hour. Excess antibody was washed off 3 x 5 minutes with 
PBS-G. A rabbit anti mouse bridging antibody [Pierce] was used so that the protein A-
gold conjugate would be able to bind. Grids were incubated with the bridging antibody 
for 30 minutes then excess washed off 5 x 2 minutes with 0.1% BSA in PBS-G. Grids 
were blocked with 0.1% BSA in PBS-G before being incubated with Protein A 
conjugated to 10 nm gold particles [Utrecht Meedical Centre] in 1% BSA in PBS for 20 
minutes. Excess antibody was washed off with 6 x 3 minutes washes with PBS. 
Sections were then fixed onto the grids with 1% gluteraldehyde in PBS for 5 minutes. 
Grids were washed 10 x 2 minutes with distilled water. In order to visualise the cells 
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and their organelles the grids were negatively stained with uranylacetate/ 
methylcellulose (pH4) for 5 minutes. The uranylacetate/ methylcellulose was removed 
by picking up the grid with a 6 mm wire loop and dragging it across thick filter paper 
until only a 1/3 was left as a fine coating. Grids were left to dry in the loops before 
being removed and viewed under the electron microscope. Labeled grids were examined 
using a Tecnai 12 G2 electron microscope [FEI] at 80 kV. 
 
2.7.5 Quantification of gold labelling 
 
Quantification of labelling was performed on areas selected by systematic random 
sampling. Starting close to a grid bar micrographs were taken at regular intervals from 
each block. PrP null cells were included as a control to look for non-specific labelling. 
Micrographs with a final magnification of 11,000 were taken from two cell blocks per 
genotype, and both were found to give similar results.  
 
Gold particles labelling different structures were counted on micrographs. A structure 
was considered to be labelled if a gold particle was located within 20 nm. 
Ultrastructural features were used to distinguish between nuclei, mitochondria, Golgi 
apparatus (cisternae and vesicles) plasma membranes and internal membranes. For 
some internal membranes it was not possible to identify the structure due to the plane of 
sectioning so these were assigned to ‘other internal’.  
 
The total lengths of each type of membrane (e.g. axonal plasma membrane or Golgi) 
were estimated by counting all intersections of each membrane type with grid lines 1.2 
cm apart placed over the micrograph. Labelling density was measured using the 
following formula.  
 





2.8 Quaking induced conversion assay (QuIC) 
 
2.8.1 PrPSc seed preparation 
 
10% brain homogenate was prepared in lysis buffer from TSE clinically and 
pathologically positive mice and treated with PK to remove PrP
C
. Samples from all 
genotypes were then run on an immunoblot and PrP
Sc
 measured by densitometry. 
Samples were diluted with lysis buffer to the same concentration as the lowest 
genotype. Serial dilutions (1:10) were prepared by diluting brain homogenate in N2 
media supplement.   
 
2.8.2 Real-time QuIC reaction 
 
All reagents were made fresh on the day of use and were filtered through a 0.2 µm filter 
prior to use. Frozen recombinant PrP was thawed on ice and filtered through a 0.2 µm 
filter and then concentration measured on a NanoDrop. 98 µl reaction mixture (0.1 
mg/ml recombinant PrP, 300 mM NaCl, 1 mM EDTA, 0.01 mM thioflavin T in PBS) 
was added to each well of a 96 well optical bottom plate. 2 µl seed was added to each 
well and mixed by pipetting. The reaction was carried out on a double orbital plate 
reader [Fluoroskan, Omega] preheated to 42 °C. The shaking program was alternating 
700 rpm double orbital for 1 minute with no shaking for 1 minute. Fluorescence was 
measured (excitation at 450 nm and emission 480 nm) every 15 minutes within a 
shaking kinetic cycle for 60 hours at 42 °C. 
 
Each seed was carried out in 4-10 replicates per plate. All controls were included in 
quadruplet for each plate; positive control of a known positive seed, negative controls of 
normal brain homogenate from an uninfected animal and a recombinant PrP only (N2 
supplement [Invitrogen] used as a seed).     
 
Results were analysed using Mars data analysis software [BMG Labtech] and exported 
to an excel spreadsheet.  
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3 Expression of PrP
C




This chapter aims to measure the levels of PrP
C
, in whole brain and different brain 
regions in order to identify whether disruption of one or both glycosylation site(s) alters 
PrP
C
 levels. Proteolytic processing may affect the overall levels of PrP therefore the 
level of alpha cleavage will be assessed. Individual glycoforms may possess separate 
functions therefore this chapter will also characterise the ratios of glycoforms to assess 
the influence of glycosylation at one site on the glycosylation of the other in order to 




Prnp mRNA is constitutively and highly expressed in the central nervous system 
(Manson et al., 1992). Studies using IHC have shown that PrP
C
 levels did not always 
correspond with mRNA levels (Manson et al., 1992, Ford et al., 2002a). An absence of 
protein was seen in some mRNA positive neurons whilst other neurons showed low 
levels of mRNA but substantial amounts of protein. This could represent a high degree 
of post-translational regulation of PrP
C
. Glycosylation is a post-translational 
modification which can influence the cell biology of a protein through several 
mechanisms. The addition or removal of carbohydrates to a protein can have 
consequences for the stability of that protein and interactions with other proteins, which 
in turn can affect the turnover, and the overall levels. This chapter will assess whether 
the different GlycoD mice have differing levels PrP
C
 within the brain in order to 
understand the influence of glycosylation on the post translational regulation of PrP.  
 
Previous characterisation of the expression of PrP
C
 in the GlycoD mice showed that 
there was a reduction of PrP by immunoblot, indicating that the glycosylation may 
assist in preventing degradation (Cancellotti et al., 2005). However, when quantified 
using the dissociation enhanced lanthanide fluoroimmunoassay (DELFIA) there was no 
significant difference in PrP
C
 levels between the GlycoD mice (Cancellotti et al., 2005). 
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This method showed that levels of PrP varied greatly depending upon the antibody pairs 
used [F. Wiseman; PhD thesis 2007]. A 10-fold reduction of PrP was observed with 
FH11, an N-terminal antibody that does not recognise cleaved isoforms in comparison 
to an antibody that recognises all cleavage products. FH11 was used as a capture 
antibody with two different detection antibodies; there was no significant difference 
between genotypes for one and a huge variability for the second, which also showed 
variability between wild type mice and the control line. This variability between the two 
pairs was likely caused by the low levels of PrP detected and may represent a limitation 
to DELFIA quantification. 
 
In order to determine the total levels of PrP
C
 in the GlycoD mice PrP
C
 will be detected 
on immunoblot and the amount of PrP for each mouse will be compared to the levels in 
wild type mice. Several different antibodies with different epitopes will be assessed to 
ensure that the most appropriate antibody is used to measure PrP levels and that all 




 naturally undergoes proteolytic cleavage in vivo and has been observed in several 
species. The glycans are some distance from the major cleavage site and are unlikely to 
shield the N-terminal but they may prevent proteolytic enzymes from interacting with 
PrP easily. A change in cleavage levels may influence the degradation and consequently 
the overall level of protein. It has recently been shown for ovine PrP
C
 that the level of 
alpha cleavage fragment in brain can vary with the amino acid present at 171 which is 
quite far from the cleavage site at 115 (Campbell et al., 2013). This supports the notion 
that the glycosylation sites could have an influence on cleavage. This chapter will 
investigate the level of alpha cleavage in the GlycoD mutants to establish whether the 
glycans can affect the proteolytic cleavage.  
 
Alpha cleavage will be assessed at the same time as total protein levels by measuring 
the levels of one of the truncated fragments produced during alpha cleavage, C1, in 
brain homogenates. The N1 fragment is a soluble secreted protein and difficult to detect, 
however the C1 is membrane bound and all glycoforms can be detected on an 
immunoblot. The diglycosylated C1 fragment has a similar molecular weight to 
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unglycosylated full length PrP therefore all homogenates will be treated will the 
endoglycosidase, PNGase F to remove the glycans and render the PrP into 
unglycosylated isoforms which can easily be distinguished on an immunoblot. 
 
It has been shown that there are differing levels of PrP
C
 protein in different brain 
regions in hamsters and mice (Benvegnu et al., 2010). The CNS consists of many 
neuronal subtypes which can be characterised by morphology or by the 
neurotransmitters expressed. Neurons in different brain regions are very diverse in order 
to carry out different functions and to interact with various other neurons. The 
difference in regional PrP may be due to the different cell types within the brain that 
express varying levels of PrP
C
 (Ford et al., 2002a).  Glial cells have little or no 
detectable PrP
C
 and neuronal subtypes express varying levels of PrP
C
. It has been 
proposed that different glycoforms are more abundant in different brain regions. 
Diglycosylated PrP was more predominant in the cortex, hippocampus, olfactory bulb 
and part of the cerebellum (Beringue et al., 2003, DeArmond et al., 1999). It is therefore 
possible that different neuronal cell sub-types may have different levels of total PrP
C
 or 
different ratios of glycoforms to satisfy the various functions of the cells.  
 
This chapter will address whether certain isoforms are preferentially expressed in 
different brain regions using the GlycoD mice. This study will isolate brain regions 
through microdissection and PrP
C
 will be detected by immunoblot. PrP
C
 detection by 
IHC would allow the expression in different cell types to be assessed, however 
detection of PrP
C
 is difficult and low levels of PrP can make comparison of brain areas 
challenging, causing artefactual differences.  
 





to date; ectodomain shedding, alpha and beta cleavage (reviewed in (Liang 
and Kong, 2012, Altmeppen et al., 2012)). Enhanced beta cleavage is associated with 
TSE disease and is rarely observed in healthy animals (Chen et al., 1995). Beta cleavage 
occurs at the cell surface in response to reactive oxygen species (ROS) (McMahon et 
al., 2001). PrP
C
 has been implicated in neuroprotection against oxidative stress therefore 
an increased level of beta cleavage in the GlycoD mutants could indicate that these mice 
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have a higher level of oxidative stress and that glycosylation is important for the role of 
PrP
C
 in neuroprotection. Deglycosylation removes all of the glycoforms to leave 
unglycosylated isoform allowing the different truncated fragments to be identified. The 
C2 fragment will be identified and assessed to investigate whether it increases in the 




 is anchored at the membrane and many of the proposed functions rely upon the 
membrane localisation, such as signal transduction. This chapter will confirm that PrP
C
 
from the GlycoD mice is GPI anchored and that the mutations introduced do not prevent 
GPI attachment. Soluble full length PrP has been identified both in vitro and in vivo 
(Zhao et al., 2006). The significance of soluble PrP is not known, full length secreted 
PrP may represent an alternative degradation mechanism or may possess a unique 
function. There are two mechanisms of shedding PrP
C
 from the cell surface; cleavage at 
the GPI anchor possibly by phospholipases and cleavage close to the GPI anchor by 
metalloproteinases from the ADAM family (Parkin et al., 2004). The reduced total PrP 
in the GlycoD mice from might be due to increased ectodomain shedding leading to 
more rapid degradation. This chapter will isolate soluble proteins from membrane 
bound proteins to determine the amount of naturally cleaved, full length PrP shed from 
the cell in order to determine whether the glycans influence cleavage at the GPI anchor.  
 
This chapter will identify the levels of both total and truncated PrP
C
 in the GlycoD 
mutants for whole brain and different brain regions in order to understand whether the 




3.3.1 Microdissection of brain regions 
 
Frozen brains from GlycoD mutants and wild type mice were dissected into 7 different 
regions; cerebellum, brain stem, dorsal raphe, hippocampus, cortex, thalamus and 
septum. These brain regions were selected as they represent different brain regions that 
can be targeted by different strains of TSE. Brain weights for the individual regions 
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were consistent between mice (Table 3.1) showing that microdissection is a reliable 
method for isolating brain regions (Barr et al., 2004).   
 









Cerebellum A 43.6 3.48 0.64 1.73 
Brain Stem B 23.9 2.45 0.05 1.62 
Dorsal Raphe C 10.6 2.95 0.65 0.61 
Hippocampus D 9.20 4.07 0.88 0.45 
Cortex E 22.3 3.85 0.63 0.92 
Thalamus F 13.6 3.98 0.46 0.97 
Septum G 10.5 3.88 0.88 0.65 
 
Total protein levels for 10% w/v homogenates of each brain region were measured 
using the bicinchoninic acid (BCA) assay. There was no significant difference in protein 




Densitometry of immunoblots was carried out according to section 2.4.7 in Chapter 2. 
To assess the reproducibility of manually selecting the regions, densitometry was 
carried out on the same blot on several non-consecutive days (Figure 3.1). The 
maximum variability was 5% on repeated measurements of the same sample. Very little 
blot to blot variation was identified, showing that immunoblotting and manual 








Figure 3.1 Variability of manually selecting bands for densitometry 
Densitometry of the di and unglycosylated PrP bands was carried out on 5 non-consecutive 
days on the same immunoblot. (A) Lanes 1-3: a single wild type PrP homogenate at 10%, 5% 
and 2.5% w/v respectively. Lanes 5-6: a different homogenate at 10%, 5% and 2.5% v/w 
respectively. (B) Densitometry was carried out on diglycosylated and unglycosylated bands and 
the % diglycosylated PrP was calculated for each lane. A maximum difference of 5% was seen 
for each repeated measurement.   
  
3.3.3 Monoclonal anti-PrP antibody screen 
 
Some monoclonal antibodies used to detect PrP can have striking differences in the 
specificity for the glycoforms and truncated isoforms (Beringue et al., 2003) therefore it 
is essential to ensure an antibody chosen recognises all known isoforms. A range of 
antibodies with different epitopes were tested on immunoblots to assess whether the 
antibodies bind equally to all known isoforms or preferentially bind to a particular 






Figure 3.2 Epitope map for the monoclonal antibodies used to detect PrP 
PrP showing the location of the epitopes for the antibodies used to assess binding efficiency to 
the different glycoforms. The antibodies with an unmapped epitope (7A12, EA6 and FD12) 
recognise C1 fragments so have an epitope on the C-terminal between residues 111-230. 
Antibodies AG4 and FH11 were not used on immunoblots but were used as capture antibodies 
for previous DELFIA quantification [F. Wiseman; PhD thesis 2007]. 
 
Immunoblots were carried out on at least three different mouse brains of each genotype 
in duplicate, to account for mouse to mouse and blot to blot variation. All of the 







Figure 3.3 Immunoblots with different PrP antibodies 
(A) Diagram showing the expected band pattern on an immunoblot produced by the different 
isoforms of PrP
C
 for each GlycoD mutant. The unglycosylated band in wild type mice, denoted 
by a star also contains the diglycosylated C1 fragment. (B-H) Immunoblots with 6 µg of 10% 
brain homogenate loaded per well and probed with different mAbs (B) 7A12 (C) DE3 (D) FH10 
(E) AE11 (F) BC6 (G) FD12 and (H) BH1. All primary antibodies were probed at concentrations 
noted in Table 2.1 (Chapter 2).  
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Densitometry of the immunoblots in Figure 3.3 was carried out to measure the total PrP 
levels of each GlycoD mouse and compare it to wild type mice. All glycoforms of full 
length (FL) and C1 were included for each genotype. There was no significant 
difference in total PrP between the antibodies used suggesting that glycosylation does 
not influence the epitope binding of the antibodies tested. The different antibodies bind 
to all of the glycoforms with a similar affinity, suggesting that none of the antibodies 




Figure 3.4.  Assessment of anti PrP antibodies at detecting the glycoforms 
Densitometry from western blots was used to measure the levels of PrP
C
 in the PrP 
glycosylation deficient mice in relation to the level of wild type PrP
C
. A range of anti-PrP 
antibodies with different epitopes were used to assess whether any had a higher binding 
preference for a particular isoform or whether they bound all glycoforms equally. Each antibody 
was tested in duplicate on 3 different brains from a genotype. Monoclonal antibody EA6 was 
only carried out on a single immunoblot. There was no significant difference between the 
antibodies used for any of the glycoforms (ANOVA), suggesting that the carbohydrates are not 




The consistency in expression levels with different antibodies allowed a single antibody 
to be used to analyse the PrP levels for the rest of the brain regions. The antibody BC6 
was chosen to detect PrP
C
 for further experiments due to its high sensitivity as 
determined by antibody titrations carried out during optimisation.   
 
3.3.4 Degradation of PrPC 
 
To allow C1 to be measured at the same time as total PrP all genotypes were treated 
with PNGase F to remove the glycans. C1 is not always observed or detected without 
deglycosylation treatment and may represent a degradation product or an artefact 
produced by PNGase treatment. Conditions used to deglycosylate PrP may increase 
natural degradation of the protein, increasing C1 levels.  
 
A single homogenate was aliquoted and incubated with PNGase for different lengths of 
time to assess whether there was a steady state of C1 or whether it increased with time, 
indicating degradation. G3 mice were used as they do not have any glycans to remove 
and C1 levels can be compared with and without PNGase at the same time.  
 
C1 calculated in PNGase treated samples accounted for around 60% of total PrP and did 
not increase with the length of incubation period at 37 C, suggesting that C1 is not a 
degradation product (Figure 3.5). There was no difference between PNGase treated and 






Figure 3.5 C1 levels do not increase with prolonged PNGase F treatment 




 in wild type 10% brain 
homogenate (20 μl sample and 1500 U of PNGase F) treated for different lengths of time. (B) 
Percentages of full length and C1 isoforms were calculated by densitometry for each time point.  
 
3.3.5 Total PrPC levels in PrP GlycoD mice 
 
To identify whether the change in glycosylation alters the overall expression of PrP
C
, 
protein levels were measured in whole brain of the PrP glycosylation deficient mutants 
and wild type mice. PrP
C
 from brains were analysed by immunoblot and densitometry 
was carried out to quantify the amount of PrP relative to the wild type mice. Although 
densitometry on immunoblots is only semi-quantitative this method was chosen due to 
the ability to separate all of the isoforms so that they can be visually distinguished and 
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individually measured. An α tubulin loading control was used to determine the variation 





Figure 3.6 PrP from wild type and GlycoD mice detected on an immunoblot  
10% brain homogenates were treated with PNGase F at 37°C overnight. PNGase F was used 
to de-glycosylate PrP
C
 to obtain two distinct bands of full length and C1 isoforms that could be 
measured easily. Treated and untreated homogenates were run on an immunoblot and PrP 
detected with anti-PrP mAB BC6 at 0.01 mg/ml. A protein loading control, α-tubulin (50 kDa) 
was included. PNGase treated homogenates show just the unglycosylated full length and C1 
PrP. There is visibly less PrP in the GlycoD mutants. 
 
The immunoblots showed the expected banding patterns for each of the mutants (Figure 
3.6). As had been previously observed the two monoglycosylated PrP isoforms run at 
slightly different mobilities depending upon the glycosylation site occupied [F. 
Wiseman; PhD thesis 2007]. A doublet at the monoglycosylated band was also observed 
in TSE infected animals (Somerville, 1999) and has been postulated to correspond to 
glycosylation site occupancy. The major glycans attached to PrP
C
 are present at both 
sites however some larger tetra-antennary structures were only present at the second site 
(Stimson et al., 1999), therefore the monoglycosylated PrP in G1 mice with only the 
second site occupied had a slightly heavier molecular weight than the monoglycosylated 
G2.  
 
Truncated PrP, designated C1 was seen for all of the mutants; both full length and C1 





Figure 3.7 Total brain PrP levels as a % of total wild type PrP 
5-7 brains per genotype were used to create 10% homogenates which were run on 
immunoblots in duplicate. Densitometry was carried out for PrP and normalised with an -
tubulin loading control. PrP from the GlycoD mutants were measured as a % wild type PrP
C
. All 
GlycoD mutants had significantly less protein than the wild type mice (ANOVA, p < 0.001). 
There was no difference between G1 and G2 expression. G3 mutants had the lowest levels of 
PrP with significantly less than both G1 and G2 (p < 0.01).  
   
All mutants had significantly less PrP
C
 than wild type controls (ANOVA, p<0.001); G1 
and G2 mice have around 50% and G3 mice only have 32% PrP
C
 (Figure 3.7). This 
decrease in the PrP glycosylation deficient mice correlates with the decrease seen during 
the antibody screen. Although G1 mice have slightly less PrP than G2 mice this was not 
a significant difference. G3 mice had significantly less PrP
C





3.3.6 PrP mRNA levels in GlycoD mice 
 
To determine whether the reduction of PrP
C
 was due to post-translational control of 
PrP
C
 or simply reflecting a reduction in mRNA levels, real time qPCR was used to 





 mRNA levels measured by RT-PCR   
mRNA was isolated from half brains, treated with DNAse I to remove genomic DNA and then 
converted into cDNA. Prnp from two different animals per genotype was amplified in multiples 
by qPCR (8 per brain). The housekeeping gene beta actin was also measured to normalise 
cDNA amounts for each sample. A sample of pure water and a sample of the RNA without 
cDNA conversion were included as a control and confirmed lack of contamination.  
 
There was no significant difference in mRNA expression between any of the GlycoD or 
wild type mice (ANOVA), showing that they all expressed the same amount of Prnp 
mRNA (Figure 3.8). This result was expected due to the gene targeting method of 
creating these mice. However this is the first proof that there are no regulatory feedback 
loops that signal the decrease of PrP
C
 concentration.  
 
3.3.7 Misfolded PrP in GlycoD mice 
 
Expression of mutant PrP in vivo has led to development of spontaneous misfolding and 
disease (Chiesa et al., 1998, Hsiao et al., 1990). The reduction of PrP
C
 observed in the 
mutants could be due to the presence of misfolded PrP that spontaneously forms and has 
PrP
Sc
-like properties. The different conformation adopted by misfolded PrP can cause 
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antigens to be lost or changed therefore misfolded PrP may not be detected during the 
standard protein preparation for immunoblot.  
 
To establish whether there was any misfolded PrP with PrP
Sc
 properties present in the 
GlycoD mutants the solubility and PK resistance of PrP was assessed. Normal PrP
C
 is 
soluble in a weak guanidine hydrochloride solution (Gnd HCl; 1M) whilst misfolded 
PrP is insoluble. Brain homogenate was treated with 1M Gnd HCl to solubilise normal 
cellular PrP
C
. The insoluble proteins, including misfolded PrP were solubilised in 6M 
Gnd HCl. (Figure 3.9).  
 
 
Figure 3.9 Soluble and insoluble PrP
C
 in murine brain 
PrP was solubilised in 1M and 6M Gnd HCl to detect misfolded PrP
C
. (A) 10% brain 
homogenates were treated with 1M Gnd HCl to solubilise normal PrP
C
 and insoluble proteins, 
including misfolded PrP then solubilised in 6M Gnd HCl. PrP was detected by immunoblot using 
anti PrP mAb BC6 at 0.01 µl/ml (B) Densitometry data shows that the predominant form of PrP
C
 
is soluble in 1M but small amounts are seen at 6M for all genotypes.  
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Densitometry was carried out to quantify the ratios of soluble and insoluble protein. The 
majority of the PrP
C
 was soluble and detected in the 1M Gnd HCl fraction for all 
genotypes with a minority found in the insoluble fraction. There was no significant 
difference in the levels of PrP detected at 1M or 6M for any of the genotypes. Small 
amounts of PrP were detected for all genotypes, including the wild type control, in 6M 
Gnd HCl. A faint band was seen in the G3-2 sample at 1M Gnd HCl at the same 
molecular weight as G2 monoglycosylated full length PrP (shown by red asterisk in 
Figure 3.9). This is not seen in G3-1 and the sample does not show the expected pattern 
of a G2 homogenate. The monoglycosylated band was not included in calculation of 
soluble PrP
C
.     
 
 
Figure 3.10 PK resistance in PrP glycosylation deficient mouse brain  
(A) Expected molecular weights of PrP
C
 and the PK resistant core of PrP
Sc
. C1 fragments are 
not seen with PK treated PrP
Sc
 (B) Total brain protein was treated with 10µg/ml or 100µg/ml of 
PK to remove PK sensitive PrP
C
. Homogenate from a terminal mouse infected with 79A was 
used as a positive control to see the expected band shift of the PK resistant PrP core (asterisk). 
PrP
C
 was fully digested at 100µg/ml and incompletely digested at 10µg/ml, as was tubulin. 
Partial digestion showed all of the bands at the expected levels of PrP
C




In addition to its insolubility PrP
Sc
 is resistant to PK digestion and results in a PK 
resistant core. After PK digestion a shift in molecular weight from ~36 kDa to ~30 kDa 
is seen for diglycosylated PrP (Figure 3.10). Proteinase K digestion was used to see 
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whether there was any PK resistant PrP in normal brain homogenate. No PrP
Sc
 bands 
are seen in any of the GlycoD mice with 100 µg/ml PK thus all PrP
C
 present was PK 
sensitive. Incomplete digestion of PrP
C
 was seen with low levels of PK (10 µg/ml) as 
seen by a decrease in PrP
C
 and tubulin without a band shift indicating PrP
Sc
.   
 
There was no difference seen between the GlycoD and wild type mice in the solubility 
or PK sensitivity, suggesting that a lack of glycans do not cause PrP
C
 to spontaneously 
adopt any PrP
Sc
 properties.  
 
3.3.8 Total levels of alpha cleavage in whole brain  
 
The decrease in total PrP
C
 may be due to an increase in susceptibility to proteolytic 
degradation in PrP
C
 lacking glycans. The predominant cleavage event, alpha cleavage, 
produces truncated fragments which may have different half lives thus reducing protein 
levels. For each of the GlycoD mice densitometry was carried out to measure the ratio 
of full length PrP to C1 in PNGase treated homogenates (Figure 3.11). 
 
Figure 3.11. Cleavage levels in whole brain 
Densitometry was used to measure full length and C1 bands. C1 was calculated as a 
percentage of total PrP
C 
for each genotype (n=7). In immunoblots where PrP
C
 was not fully 
deglycosylated partially deglycosylated bands were included in the appropriate fraction, either 
full length or C1. 
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25% of wild type PrP
C
 undergoes alpha cleavage whilst G1 and G2 mice showed 34% 
cleavage and G3 mice showed 52% cleavage. All glycosylation mutants have a 
significantly higher proportion of C1 than wild type mice (ANOVA; F(3,24) = 180.4, p 
< 0.001). G1 and G2 have similar levels of C1 and G3 mice have a significantly higher 
proportion of C1 than both G1 and G2 mice (Student’s T-test, p < 0.001). As far as 
steady state levels are concerned over 50% of G3 brain PrP
C
 is present as C1 fragment. 
 
The proportion of C1 PrP was increased in all GlycoD mice however they expressed 
less total PrP. The increased C1 could be due to increased propensity of the enzyme to 
cleave the protein in the absence of glycans. Conversely the relative levels of alpha 
cleavage and C1 could be the same for all genotypes and the full length PrP decreased.   
 
The levels of C1 and FL were adjusted using the expression data collected in 3.3.5 to 
reflect the decreased overall expression to give a more accurate idea of the absolute 
levels of full length and C1 PrP in each GlycoD mutant. All values for C1 and full 
length PrP ware adjusted (Table 3.2) using the mean value of total brain expression for 
each genotype (G1, 46.1%; G2, 49.9%; G3, 32.1%).   
 
Table 3.2 Adjusted PrP values to reflect expression levels of each isoform relative to total 
wild type PrP 
PrP 
isoform 
wt G1 G2 G3 
FL 74.4 (± 0.0) 30.2 (± 2.0) 33.0 (± 1.0) 15.4 (± 2.0) 
C1  25.6 (± 0.0) 15.9 (± 0.3.0) 16.9 (± 0.3.0) 16.7 (± 0.5) 
Total 100.0 46.1 49.9 32.1 
 
The amount of C1 found in the GlycoD mutants was significantly less (7% decrease) 
than the wild type mice (ANOVA; F(3,24) = 151.3, P = 0.001,) when the data were 
adjusted to reflect the amount of PrP relative to wt PrP (Figure 3.12). There was no 




The reduction in full length PrP is much more pronounced (40-60%) and significantly 
less for all of the GlycoD mice than wild type mice (ANOVA; F(3,24) = 4307, 
P<0.001,). There is less than half the amount of full length PrP for G1 and G2 mice and 
only one fifth of the amount of full length wild type PrP in G3 mice (Figure 3.12). 
 
 
Figure 3.12 C1 levels corrected for overall PrP expression 
The ratios of C1 and full length PrP were adjusted using the total expression data for each 
genotype (n=7) to reflect the relative amount of C1 and full length PrP for each genotype. (B) 
Relative amounts of full length PrP and C1 for each genotype.   
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3.3.9 PrPC distribution throughout the mouse brain 
 
The lower levels of PrP protein in the mutants could be due to an overall reduction of 
PrP protein in all cell types or due to reduction of PrP in a specific neuronal population 
or brain region. To determine whether PrP is expressed equally throughout the brain, 
PrP levels were examined in seven different regions. An -tubulin marker was used as a 
loading control so that PrP could be normalised to the amount of protein loaded onto the 
immunoblot. Densitometry was calculated as a percentage of the total PrP
C
 for that 
brain to measure the distribution of PrP.   
 
Very small amounts of homogenate were produced for some brain regions due to the 
size of the mouse brain. Immunoblots were therefore only carried out in duplicate for 
each brain region of an animal. Samples were treated with PNGase to reduce the 
number of isoforms to two strong bands for improved quantification.  
 
Full de-glycosylation was not achieved with wild type, G1 and G2 mouse tissue 
therefore partial PNGase digestion showed bands of monoglycosylated PrP. These 
bands were included when calculating total PrP. G3 mice do not have glycosylated PrP 
therefore only unglycosylated PrP
C
 is expected however for consistency between the 






Figure 3.13. Immunoblots of PrP levels in different brain regions 
10% Brain homogenates were treated with 1500 Units PNGase F to deglycosylate PrP. 6µl 
homogenate was run on an immunoblot and probed with mAb BC6 (0.01µg/ml). (A) Diagram 
showing the expected PrP bands. (B) Each immunoblot shows PrP
C
 from 7 different regions of 
the same brain represents a different mouse. Brain regions A Cerebellum, B Brain stem, C 
Dorsal Raphe, D Hippocampus, E Cortex, F Thalamus, G Septum. Unexpected bands were 
seen in some G3 blots (shown by a red asterisk) which could possibly represent C2 fragments. 
A faint band was also seen in a single G1 mouse, which may represent the C2 fragment (shown 
by a black asterisk). 
 
Some of the brain regions with a high intensity of PrP show an extra band between the 
full length and C1 fragment (Figure 3.13, labelled with a red asterisk). This band could 
be the C2 fragment produced by beta-cleavage of PrP (Mange et al., 2004) or could be a 
91 
 
random degradation product of PrP
C
. An antibody with an N-terminal epitope would 
need to be used to confirm that this fragment lacks the N-terminal and is not a 
degradation product with the same molecular weight as C2. A double band is also seen 
in one G1 mouse where a single band of monoglycosylated C1 is expected (Figure 3.13, 
labelled with a black asterisk). This is possibly a degradation product of PrP
C
 and was 
only observed in a single mouse. All bands detected with the PrP specific antibody BC6 
were included in the densitometry.  
 
Densitometry was used to calculate the total intensity of PrP for each brain. The 
intensities of PrP in each region were then used to calculate how much PrP was found in 
each region, showing the distribution of PrP throughout the brain (Table 3.3).  
 
Table 3.3. Percentage of total PrP
C
 found in each brain region (n=5-7) 
Brain region  
% total brain PrP (sem) 
wt G1 G2 G3 
Cerebellum A 12.9 (0.6) 15.0 (2.5) 13.4 (0.4) 10.5 (1.7) 
Brain stem B 12.7 (0.8) 10.4 (1.2) 12.2 (0.9) 10.2 (2.6) 
Dorsal Raphe C 14.4 (0.3) 12.6 (1.6) 13.0 (1.2) 12.8 (1.6) 
Hippocampus D 13.8 (0.4) 16.5 (3.0) 13.4 (0.7) 17.3 (2.8) 
Cortex E 15.6 (0.8) 16.9 (3.0) 14.5 (0.6) 13.8 (2.2) 
Thalamus F 14.7 (0.8) 12.7 (2.4) 17.9 (2.1) 16.3 (3.6) 
Septum G 15.9 (0.5) 15.9 (3.1) 15.6 (2.2) 19.1 (6.8) 
 
The distribution of PrP
C
 was uniform throughout the brain, with each of the seven 
regions assessed having similar amounts of PrP
C
. There was no statistical difference 
between the brain regions within any of the GlycoD or wild type mice (Figure 3.14). A 
high level of animal to animal variation was seen with the GlycoD mice, especially in 
G3 mice. Although not significant there was a trend for increased PrP levels towards the 
front of the brain, with the brain stem and cerebellum having the lowest levels and the 
cortex, thalamus and septum having the highest. The brain stem had the lowest amount 
of PrP
C






Figure 3.14. Distribution of PrP in different brain regions 
Densitometry was carried out on immunoblots of different regions (4-8 brains per genotype 
carried out in duplicate) and protein loading normalised using an -tubulin marker. The intensity 
of PrP was calculated for the whole brain and then intensities for each region used to calculate 
the percentage of PrP found in each region. There was no significant difference in expression of 
PrP between brain regions selected or between PrP glycosylation deficient mice (ANOVA). All 
areas have similar levels of PrP
C
, regardless of the types of cells present in that area. There 
was a high level of mouse to mouse variation seen with the distribution of PrP throughout the 
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brain regions, especially in G3 mice. A Cerebellum, B Brain stem, C Dorsal Raphe, D 
Hippocampus, E Cortex, F Thalamus, G Septum 
Alpha cleavage is probably caused by the action of a number of proteases and several 
metalloproteases have been put forward as candidate enzymes. Cleavage may vary from 
brain region to brain region depending upon the availability of cleavage enzymes. The 
proportion of C1 was measured from the same immunoblots used to measure total 
protein (Figure 3.13). Each brain region of each genotype was assessed to determine 
whether there were regional differences of cleavage (Table 3.4).  
  
Table 3.4 C1 (as a percentage of total PrP) found in each brain region (n=5-7) 
Brain region  
% C1 (sem) 
wt G1 G2 G3 
Cerebellum A 24.7 (0.8) 33.7 (2.2) 31.8 (1.9) 53.5 (5.2) 
Brain stem B 24.5 (1.6) 36.1 (2.0) 35.3 (1.6) 54.6 (4.6) 
Dorsal Raphe C 26.2 (1.2) 36.5 (5.2) 33.5 (1.5) 46.3 (2.9) 
Hippocampus D 27.9 (1.2) 34.5 (3.7) 33.5 (2.0) 46.9 (5.6) 
Cortex E 24.7 (1.1) 32.8 (5.0) 33.3 (2.1) 53.4 (5.8) 
Thalamus F 25.6 (0.8) 32.8 (5.5) 33.6 (2.0) 55.8 (4.8) 
Septum G 25.9 (1.0) 34.8 (6.0) 36.0 (1.6) 53.1 (5.5) 
Average 25.6 34.5  33.8 51.9 
 
 
All brain regions within the same genotype showed similar cleavage levels (Figure 
3.15). There was no significant difference in the cleavage levels throughout the brain for 
G1 (ANOVA; F(6,28) = 0.11, p = 0.99), G2 (ANOVA; F(6,49) = 0.56, p = 0.78), G3 






Figure 3.15. C1 levels in different brain regions 
Densitometry was carried out on immunoblots of different brain regions. C1 levels for each brain 
region for each genotype were measured as a percentage of total PrP (4-8 brains per genotype 
carried out in duplicate). Brain regions A Cerebellum, B Brain stem, C Dorsal Raphe, D 
Hippocampus, E Cortex, F Thalamus, G Septum. There was no significant difference in C1 
levels between brain regions selected (ANOVA).  
 
3.3.10 GPI anchoring of PrP to the cell surface 
   
The decrease in total PrP may also be due to susceptibility to other proteases and 
cleavage events. Membrane associated PrP was separated from non-membrane 
associated PrP to establish that the GlycoD mutants are GPI anchored. All glycoforms 
were found predominantly in the membrane associated pellet (Figure 3.16). A small 
amount of PrP was detected in non-membrane associated fractions; however this did not 






Figure 3.16 Separation of membrane associated and non-associated PrP
C
 
10% brain homogenate was centrifuged to separate into a membrane associated pellet fraction 
and a non-membrane supernatant fraction (n=5 per genotype). Fractions were run on an 
immunoblot and probed with anti-PrP mAb BC6 (0.01µg/ml). Brain homogenates show that 
PrP
C
 from all genotypes were predominantly found in the membrane associated pellet.  
 
In order to see whether a PrP glycoform is more prone to C-terminal shedding a 
phosphatidylinositol-specific phospholipase C (PI-PLC) was used to cleave PrP
C
 from 






Figure 3.17 PI-PLC cleavage of GPI anchored PrP
C
  
(A) Diagram showing membrane bound PrP
C
 and shed PrP
C
 after PI-PLC cleavage (B) The 
expected immunoblot patterns of wild type PrP
C
 after PI-PLC treatment. PI-PLC untreated 
sample contains membrane bound PrP
C
 found in the pellet fraction, P. PI-PLC treated sample is 
comprised of shed PrP
C
 which is found in the supernatant fraction. Shed PrP
C
 is ~3kDa heavier 
than GPI anchored PrP
C
 due to the hydrophilic inositol phosphate stub (Stahl et al., 1987). (C) 
Diagram showing the collected fractions. Pellet fractions contain membrane associated PrP
C
, 
which is not necessarily GPI anchored. Supernatant fractions contain cleaved PrP
C
, untreated 
supernatant shows naturally shed PrP
C




Temperature, incubation period and enzyme concentration were altered in order to 
optimise the technique. The different conditions tested did not fully cleave all of the 
GPI anchors from PrP
C
 as it was still detected in pellet fractions, which is GPI 







Figure 3.18 Determining PI-PLC incubation conditions 
(A) A single 10% wild type homogenate was treated with different conditions in order to find the 
best conditions for shedding PrP
C
. Temperature, incubation period and enzyme concentration 
were altered. P = pellet, PrP
C
 in this fraction is membrane associated; S1 & S2 = supernatant 
containing naturally secreted proteins; PrP
C
 in this fraction is not membrane associated. (B) 
10% brain homogenates from GlycoD mice were treated with 0.5 U PI-PLC overnight at 37°C to 
cleave the GPI anchor (n=2). In untreated homogenate the PrP
C
 was predominantly found 
associated with the membrane in the pellet fraction. PrP
C
 was not detected in PI-PLC treated 
homogenates. Asterisks show IgG light chain detected in the absence of primary antibody.   
 
All conditions showed a much stronger PrP signal in the pellet fraction than the 
supernatant fraction (Figure 3.18; A). PI-PLC treated samples showed a reduction in 
amount of membrane associated PrP in the pellet fraction, indicating that PrP
C
 had been 
cleaved from the membrane. However, only small amounts of shed PrP
C
 were detected 
in the supernatant fractions. With extended incubation at 37 °C all membrane associated 







Figure 3.19 PI-PLC treatment of GlycoD mutants 
10% brain homogenates from GlycoD mice were treated with 0.5 U PI-PLC for 2 hours at 37 °C 
to cleave the GPI anchor. Samples were also left untreated to see whether naturally cleaved 
PrP
C
 could be detected in the supernatant fraction. P = pellet, membrane associated fraction; S 
= supernatant, membrane released fraction. 
 
PI-PLC treated samples showed that a large amount of PrP
C
 was still membrane bound 
and found in the pellet fraction. PrP
C
 was detected in the supernatant fraction and had a 
small shift in molecular weight indicating the loss of the GPI anchor.   
 
Untreated homogenates (Figure 3.19, left hand panel) showed the majority of PrP
C
 was 
GPI anchored and found in the membranes. Small amounts of PrP
C
 were detected in the 
supernatant, although there was not an apparent shift in molecular weight. This most 
likely represented inefficient membrane separation.  
 
3.3.11 Ratios of PrPC glycoforms 
 
It is not known whether wild type PrP
C
 favours glycosylation of one site over the other. 
The prevention of glycosylation at one site may have consequences for the 
glycosylation of the other site therefore one monoglycosylated glycoform may be 
favoured over the other.  
 
Under the PAGE conditions used previously in this chapter unglycosylated PrP cannot 
be easily distinguished from the diglycosylated C1 fragment. Electrophoresis on wild 
type mice was carried out for longer on an 18% polyacrylamide gel to allow the two 
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isoforms to separate so that they could be measured accurately. Densitometry was then 
carried out on all glycoforms for both full length and C1 fragments. 
 
 
Figure 3.20. Glycoform composition of wild type PrP
C
 
An Immunoblot showing the separation of full length unglycosylated PrP and diglycosylated C1 
PrP from a wild type brain. (A) All genotypes were compared side by side so that each band 
could be identified. Diglycosylated C1 is indicated by an asterisk (B) Immunoblots showing 
separation of three different wild type brains.  
 
In order to identify the different bands of the wild type PrP after full separation of all 
isoforms all the bands were compared with the GlycoD mice on an immunoblot. The 
diglycosylated C1 band (marked with an asterisk) was only present in the wild type 
homogenate and was lower than the unglycosylated bands from the other genotypes 
(Figure 3.20, A). Densitometry was carried out to calculate the ratios of glycoforms in 
wild type, G1 and G2 mice. Three different mouse brains were used to assess the 





Figure 3.21 Consistent wild type glycoform ratios from mouse to mouse 
Three different wild type mouse brains were homogenised and the glycoform ratios measured 
by densitometry. Ratios were calculated by combining values for full length and C1 bands for 
each glycoform. Each brain sample was run on 4-6 immunoblots.  
 
Ratios were similar for each wild type animal tested; the predominant glycoform was 
diglycosylated PrP and the mono and unglycosylated were minor glycoforms (Figure 
3.21).  
 
To investigate how the glycoform ratios are changed in the GlycoD mice the ratios of 
the glycoforms were measured and compared with the wild type ratio data above. The 
ratios were calculated for each individual genotype and the values adjusted using the 







Figure 3.22 Ratios of glycoforms for GlycoD mice  
Densitometry data was carried out on 3 brains for each genotype and used to calculate the 
amount of each glycoform present in wild type and in each mutant. (A) The ratio of each 
glycoform was measured by combining full length and C1 values for each glycoform in each 
genotype. (B) G1, G2 and G3 values were then adjusted to reflect the lower overall expression 
levels of PrP to give comparable levels of each of the glycoforms 
 
There was no difference in the ratios of monoglycosylated to unglycosylated PrP 
between the G1 and G2 mice (Figure 3.22, A). 70% PrP
C
 was glycosylated for both G1 
and G2 mutants. 30% PrP
C
 remained unglycosylated. There was significantly more 
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unglycosylated PrP in both G1 (T-test, P<0.001) and G2 (T-test, P<0.001) than the wild 
type mice. Very little animal to animal variation was observed. 
 
G1 and G2 values were adjusted using the values obtained for total brain expression to 
reflect the overall lower expression levels of PrP in these mice so that they could be 
directly compared with wild type PrP (Figure 3.22). Although there is a much lower 
overall PrP level in the G1 and G2 mice there is a significant increase in unglycosylated 
PrP in the G1 (T-test, p<0.001) and G2 mice (T-test, p<0.05) compared to wild type.  
 
3.3.12 Glycosylation site occupancy in wild type mice  
 
It has been shown that in the GlycoD mice the monoglycosylated bands have different 
electrophoretic mobilities when separated by electrophoresis, depending upon the site 
glycosylated (Figure 3.3). Wild type monoglycosylated PrP can be seen as a doublet on 
an immunoblot under certain conditions. It is assumed that these represent the two 
different monoglycosylated isoforms as they have the same electrophoretic mobility as 




 was run on an 18% acrylamide gel to separate out the monoglycosylated 
PrP into a doublet to see whether each band contributes equally or whether there is a 
predominant monoglycosylated form. The two different monoglycosylated isoforms in 




Figure 3.23 Separation of monoglycoforms in wild type PrP 
(A) Immunoblot showing 2 different brain homogenates at different dilutions, showing the 
separation of the monoglycosylated PrP. (B) Higher contrast immunoblot showing the 2 
monoglycosylated bands present in wild type PrP and with bands highlighted for densitometry. 
(C) Densitometry data shows that both monoglycosylated isoforms and the unglycosylated 
isoform are present at equal levels in wild type mice. 
 
The level of site occupancy can be calculated for each site by combining the levels of 
diglycosylated PrP, at which both sites are occupied, and the specific monoglycosylated 
PrP. Both sites have 78% glycan occupancy suggesting that glycosylation happens 
equally at both sites (Figure 3.24).  
 
The carbohydrates attached to PrP are large and heterogeneous and have not been fully 
elucidated. It was not possible to analyse the glycans to the level required to confirm 
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that the same range of glycans found on wild type PrP are also found on the GlycoD 
mutants and that the wild type bands correspond to the two different monoglycoforms.    
 
 
Figure 3.24 Glycan site occupancy of wild type PrP
C
 
The levels of each of the glycotypes in wild type mice can be used to calculate the level of site 
occupancy for each glycosylation site. The higher MW monoglycosylated band represents PrP 
with an occupied Asn 196, the lower MW represents PrP with an occupied Asn 180. 
Diglycosylated PrP has both sites occupied therefore each site can be calculate by the amount 
of diglycosylated and the relevant monoglycosylated PrP. Site occupancy was calculated for 3 








 detected by immunoblot showed a reduction of total protein in all of the 
glycosylation deficient mutants. Removal of a single glycosylation site, either the first 
or the second reduced the PrP protein level by 50% whilst removing both glycosylation 
sites reduced levels by 70%.  
 
During characterisation of the GlycoD mice it was reported that there was no difference 
in protein levels between the genotypes; however there were conflicting results with the 
different methods used to quantify PrP
C
 (Cancellotti et al., 2005).  A quantitative 
method, DELFIA was used to assess expression levels using three different capture-
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detection antibody pairs. This method showed that levels of PrP varied greatly 
depending upon the antibody pairs used and was in contradiction to the apparent 
reduction in protein determined by immunoblot.  
 
This contradiction in expression levels is most likely due to the choice of monoclonal 
antibody pairs used for DELFIA and the epitopes they recognise. There is strong 
antibody dependant detection of PrP
C
 using monoclonal antibodies, which by their 
nature may only be detecting a subset of isoforms. One antibody chosen had an N-
terminal epitope and only recognised the full length protein. This thesis showed that all 
of the antibodies within the C-terminal and central region of PrP
C
 were able to detect all 
isoforms and that the glycans did not hinder recognition.  
 
In order to overcome the variability caused by antibody pairs this study used 
immunoblotting with a single antibody to measure expression levels. To ensure that all 
isoforms were being detected a range of monoclonal antibodies were tested. The 
consistent levels of PrP
C
 for all of the glycoforms with the different antibodies tested 
suggest that neither carbohydrates nor the mutations are influencing epitope availability 
for the antibodies selected. 
 
It is possible that lack of glycans or the point mutation could cause the PrP
C
 to 
spontaneously adopt a different conformation or PrP
Sc
-like properties that could not be 
detected by the monoclonal antibody selected. Single amino acid changes have been 
demonstrated to cause spontaneous misfolding of PrP
C
 in vivo and in vitro (Imran and 
Mahmood, 2011). The experiments conducted here make this unlikely to be the case 
here. PrP
C
 from the GlycoD mice showed the same solubility as wild type mice in low 
levels of guanidine hydrochloride and was PK sensitive. The monoclonal antibody 
selected (BC6) is able to detect the misfolded PrP
Sc
 in mice infected with different TSE 
agents so it is unlikely that any isoforms are missed. The GlycoD mice do not show any 
signs of spontaneous disease associated with abnormal protein folding when aged 
(Cancellotti et al., 2005), further adding strength to the argument that the reduction is 
not due to abnormally folded PrP.  
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Despite the Glyco D mutants showing decreased total PrP there was a negative 
correlation between the percentage of C1 and the total PrP expression level; wild type 
had the highest total protein level and the lowest level of alpha cleavage whilst G3 have 
the lowest expression but the highest level of alpha cleavage. The increased proportion 
of truncated PrP lends strength to the argument that the glycans provide protection 
against proteolysis. However; when the reduced levels of total PrP are taken into 
consideration the absolute levels of C1 are significantly lower in the GlycoD mutants 
than wild type mice, arguing against increased proteolysis. Alpha cleavage may be 
indirectly affected by glycosylation, which can influence the trafficking and turnover of 
PrP
C
. The reduced PrP
C
 levels suggest that there is an increase in turnover in the 
GlycoD mutants, which could affect the exposure of PrP
C
 for proteolytic processing. 
 
This study shows that the glycosylation regulates the levels of PrP
C
 post-translationally, 
either through increased stability and/or through altered trafficking. Removal of both 
glycosylation sites reduced PrP
C
 levels significantly more than removal of a single site. 
There was no difference between the two monoglycosylated PrPs for either total or 
truncated PrP, suggesting that both glycans exert the same effect.  
 
3.4.2 Trafficking versus degradation 
 
As expected for a gene targeted model the levels of Prnp mRNA in the GlycoD mutants 
are the same as in wild type mice indicating that the reduction of PrP
C
 is due to post-
translational control. The reduction in the mutants may be due to increased turnover of 
the protein. Glycosylation is known to increase the half-life of many proteins through 
increasing stability, altering trafficking or through shielding from proteolytic 
degradation (Kundra and Kornfeld, 1999, Sola and Griebenow, 2009).  
 
The glycoforms may have altered degradation susceptibilities due to the shielding 
properties of the glycans, which provide protection from degradation leading to overall 
reduced PrP levels in their absence. G3 mice lacking glycosylated PrP had the lowest 
PrP levels and wild type PrP with two glycans had the highest levels. The G3 mice also 
had the highest proportion of cleavage, suggesting that glycans offer some protection 
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against cleavage. The levels of G1 and G2 PrP
C
 are indistinguishable from each other, 
suggesting that the presence of just one glycan is sufficient to offer a degree of 
protection from proteolysis.  
 
In addition to increased susceptibility to proteolysis a change in trafficking could also 
account for the reduced PrP levels and can act in two different ways, either through 
retention in the secretory pathway or through increased endocytosis. A lack of 
glycosylation may lead to retention in the secretory pathway and degradation as is seen 
with acetylcholinesterase in erythrocytes; unglycosylated protein is retained in the ER 
and not trafficked to the Golgi (Luk et al., 2012). Previous experiments have shown that 
unglycosylated PrP has a predominantly intracellular localisation (Salamat et al., 2011, 
Cancellotti et al., 2005), which may be due to retention in the ER or Golgi. However, 
monoglycosylated PrP showed no difference in localisation from wild type PrP and no 
difference depending upon the glycosylation site occupied (Cancellotti et al., 2005) 




 has been shown to bind to many different lectins and receptors, potentially via the 
glycans. The trafficking is heavily influenced by receptor binding. PrP
C
 relies on 
binding partners to be internalised from the cell surface (Parkyn et al., 2008, 
Gauczynski et al., 2001, Zanata et al., 2002). A change or lack of glycosylation could 
increase the interactions with some of the receptors, changing the rate of internalisation 
of the protein. If PrP
C
 is on the cell surface for longer it is more likely to have a longer 
half-life (Nunziante et al., 2003).  
 
Trafficking will need to be explored further to determine whether the reduction is due to 
an increased turnover or whether the protein is prevented from maturation and is 
degraded quickly. Half-life of PrP
C
 could be measured in primary cells from the 
different GlycoD mice. A decreased half-life would indicate more rapid degradation of 
the protein. Investigating the precise localisation of the PrP
C
 glycoforms will indicate 
whether the protein is retained in the secretory pathway or whether a large amount is 




3.4.3 PrPC in different brain regions 
 
In this study there were no regional differences in total PrP
C
 levels or truncated PrP 
levels observed within wild type mice or any of the GlycoD mutants. All seven regions 
assessed had the same amount of PrP showing equal distribution of PrP
C
 throughout the 
brain. The glycoform ratios were not measured in the brain regions of wild type mice; 
however, the equal distribution throughout the brain in the GlycoD mutants indicates 
that none of the regions preferentially produced a particular glycoform.  
 
There was a trend for lower PrP
C
 expression levels in the brain stem and to a lesser 
extent the cerebellum. This reduction could be due to fewer cells or few synapses in 
these regions. Both are predominantly white matter regions, containing highly 
myelinated axons, which have been shown to be almost completely unlabelled for PrP
C
 
(Ford et al., 2002a). The brain stem had less total protein than other brain regions 
measured. This may reflect the high levels of myelinated axons and fewer synapses in 
the white matter tracts.  
 
It was reasonable to speculate that the different brain regions would express different 
levels of PrP
C
 due to the different neuronal subtypes present in each region and the 
preference for glycoforms. PrP
C
 protein in the brain is predominantly neuronal and 
protein levels vary depending on the neuronal subtype despite the high levels of Prnp 
mRNA in all neurons (Ford et al., 2002a). This study indicated that there were no 
regional differences in any of the genotypes but may be limited by the technique used. 
Microdissection of the mouse brain takes relatively large areas of the brain, 
encompassing many different cell types. The cells may express different levels of PrP 
but for a heterogeneous mixture of cells the differences may be too subtle to detect. 
 
Studies have used IHC to look at distribution throughout the mouse brain. In one study 
regional differences were observed; the hippocampus and cortex had particularly high 
levels of protein, whilst the cerebellum and brain stem had low levels (Liu et al., 2001). 
In another study histoblots of wild type mice showed very weak staining and no 
differences in regional PrP
C
 expression levels and differences in expression levels were 
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only observed in transgenic mice overexpressing PrP
C
 (Herms et al., 1999).  Regional 
variations in mouse brain were described using immunoblotting (Liu et al., 2001) 
however quantification was not carried out and no assessment was made for variability 
of protein loaded, therefore the variations seen in brain regions may be more subtle once 
total protein levels were controlled for.  
 
There is a lack of consensus on PrP
C
 distribution in the mouse brain, possibly hindered 
by the techniques used and the difficulty in detecting PrP
C
. Regional differences in PrP
C
 
were mostly detected by histology, where tissue processing has a huge impact upon 
antibody detection. The use of monoclonal antibodies in IHC can reduce the amount of 
PrP
C
 detected due to antigen availability. Epitopes may be buried or difficult to access 
in certain tissues, especially as the protein is in its native state. Antigens may be lost 
during fixation and tissue processing, such as harsh antigen retrieval treatments. There 
are contradictions in the literature about PrP
C
 distribution in brain using the same 
antibody, mAb 8H4. PrP
C
 was detected in Purkinje cells in one study (Laine et al., 
2001) but not in another (Liu et al., 2001). During an immunoblot tissue is disrupted 
and PrP is denatured, potentially allowing equal epitope availability of all PrP 
molecules; however PrP
C
 cannot be assigned to individual cell types.  
 
There was no difference in cleavage levels between different brain regions in any of the 
GlycoD mutants. The enzyme(s) responsible for alpha cleavage has/have not been 
elucidated and data from this thesis support that the enzyme(s) is/are ubiquitously 
expressed throughout the brain. Several enzymes have been proposed as candidate 
enzymes for alpha cleavage but it seems likely that there are several enzymes with the 
ability to perform alpha cleavage (Liang and Kong, 2012). Different neuronal cell types 
may use different enzymes for alpha cleavage however the overall cleavage levels may 
be similar for each cell type or brain region because of the multitude of enzymes 
available. Additionally there may be very subtle differences in brain regions that are not 





3.4.4 The role of truncated PrP 
 
The significance of the truncated PrP is not understood therefore the implication of 
enhanced cleavage in the GlycoD mutants is difficult to elucidate. A high variability of 
alpha cleavage levels can be seen depending upon species, PrP sequence and age of 
animal (Laffont-Proust et al., 2006). Healthy humans displayed 30-50% C1 in brain and 
cleavage increased with age. In some humans and non-human primates C1 is the major 
PrP
C
 isoform (Laffont-Proust et al., 2005). It is not known whether full length PrP 
undergoes cleavage to create fragments with distinct functions or whether the C1/N1 
fragments serve to regulate the functions of full length PrP, or even a combination of 
the two.  
 
The N-terminal of PrP
C
 mediates some of the proposed functions such as copper 
binding at the synapse (Brown, 2003) and signal transduction (Vassallo et al., 2005) 
thus cleavage may be a regulatory mechanism of PrP
C
. Signal transduction is increased 
by copper binding and membrane perturbation (Haigh et al., 2009). Copper binds to the 
octarepeat region of the N-terminal and many ligands bind to the N-terminal to assist in 
movement of PrP out of the lipid rafts or movement of ligands into lipid rafts (Parkyn et 
al., 2008). Alpha cleavage removes the N-terminal and reduces the amount of 
functionally active full length PrP. 
 
Both C1 and N1 have been shown to be biologically active fragments. Cells 
overexpressing C1 had an increased cytotoxic response to staurosporine leading to the 
conclusion that C1 possesses pro-apoptotic functions (Sunyach et al., 2007), however 
mice expressing C1 alone showed no neurotoxicity (Westergard et al., 2011). This 
discrepancy could be due to treatment with pro-apoptotic agents; C1 enhances 
susceptibility to pro-apoptotic stimuli but is not neurotoxic under normal conditions. 
This susceptibility change could be due to down regulation of neuroprotective signal 
transduction caused by high levels of C1. Increased N1, which is believed to have 
neuroprotective properties, preventing cell death were not detected in the C1 
overexpressing cells (Guillot-Sestier et al., 2009). N1 is produced at the same time as 
C1 but is secreted so is difficult to detect and may be more rapidly degraded.  
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It is difficult to judge the likely effects of reduced C1 levels or increased C1 proportions 
without understanding the role C1 is playing. If truncated PrP fragments are acting as 
regulators for full length PrP then it is likely that the proportions of full length and C1 
are critical. If C1 and N1 have specific functions then the overall C1 level is likely to 
become more important.   
 
The increased proportion of C1 in the GlycoD mutants may influence PrP localisation in 
some cell types. The N-terminal has been shown to be important for several different 
binding partners, such as LRP1 which is involved in internalisation (Parkyn et al., 
2008). Truncated PrP
C
 lacking the N-terminal should not be able to be internalised as 
readily as full length PrP
C
 and should accumulate on the cell surface.  
 
3.4.5 C-terminal Shedding of PrPC 
 
The point mutations introduced in the GlycoD mutants do not influence GPI anchoring 
as all PrP
C
 glycoforms were detected in the membrane associated pellet. All glycoforms 
possess a GPI signal sequence and the GPI anchor is attached at translation into the ER, 
hence it is a reasonable assumption that the membrane associated PrP
C
 is attached by a 




 was not detected in PI-PLC untreated homogenate. PrP
C
 was 
detected in the non-membrane fraction but a lack of molecular weight change indicated 
that this is more likely to be due to inefficient separation. A study using Syrian hamster 
brain showed that ~10% PrP
C
 is lacking the lipid moiety of the GPI anchor (Borchelt et 
al., 1993) thus a small amount of naturally shed PrP would be expected in the GlycoD 
mice. Naturally shed PrP
C
 may be lower in mouse than hamster or levels may have been 
too low to detect by immunoblot.  
 
Treatment with PI-PLC reduced GPI anchored PrP
C
 but cleaved PrP
C
 was not always 
detected. Only a small amount of shed PrP
C
 could be detected and sometimes none at 
all. Low levels of cleaved PrP
C
 could be detected for some samples when the proteins 
were concentrated and PrP
C
 was also strongly detected in the membrane associated 
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pellet fraction. It has been reported that PI-PLC treatment significantly reduces 
detection on immunoblot, probably due to the negatively charged GPI stub preventing 
efficient binding to non-specific membranes, such as PVDF (Nishina and Supattapone, 
2007). Inefficient binding to the transfer membrane may lead to bound protein levels 
below the detection limit of an immunoblot. Immunoprecipitation would allow 
concentration specifically of PrP
C
 and allow higher concentrations of PrP to be 
immunoblotted, increasing detection.  
 
3.4.6 Occupancy of glycosylation sites 
 
Wild type PrP shows glycan site occupancy of 78% for each glycosylation site, 
indicating that neither site influenced glycosylation of the other site. Wild type PrP is 
usually analysed as three glycoforms, without distinguishing between the two mono-
glycoforms so it was not known whether glycosylation was favoured at a particular site. 
The equal site glycosylation showed that wild type PrP does not favour one 
monoglycosylated glycoform over the other. 
 
The occupancy of the glycosylation sites and the ratios of glycoforms may have 
implications on the function of the different isoforms. Many functions have been 
proposed for PrP
C
, from a role in cell signalling to cell survival and neuronal 
excitability. The importance of the existence of the different glycoforms of PrP
C
 for 
function or cell biology is unknown but the diverse functions proposed for PrP
C
 and the 
multiple isoforms may indicate separate functions for different isoforms.  
 
In general glycosylation at one site does not determine the glycosylation of another 
(Opdenakker et al., 1993). Glycosylation of the rabies virus glycoprotein Asn-37 is 
highly inefficient, possibly due to inaccessibility to glycosylation enzymes but is not 
significantly increased when other glycosylation sites are deleted (Shakin-Eshleman et 
al., 1992). Although not common there are examples of different glycosylation sites on 
the same protein with the ability to influence other glycosylation sites. Human protein C 
has four potential glycosylation sites which each impart different features. 
Glycosylation at Asn97 influences the level of core glycosylation at Asn329 (Grinnell et 
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al., 1991). Glycosylation can slow down folding of the protein allowing a longer 
exposure of other glycosylation consensus sites to the glycosylation enzymes. 
Glycosylation is not required for correct folding of PrP; however the glycosylation sites 
of PrP are close together and the presence of a glycan may hinder accessibility to the 
other glycosylation site. 
 
Glycosylation is predominantly used as a mechanism to alter the properties of the 
protein such as improving the activity or stability rather than completely changing the 
function. Enzymes lacking glycosylation are usually more active, presumably due to 
steric hindrance of the active site by large glycans, whereas the same glycosylated 
enzyme is more stable and has a longer half-life (Stevenson et al., 1993). A cell may 
possess a mixture of the unglycosylated and glycosylated forms of an enzyme to 
modulate the activity under different cellular conditions. Under stress a cell may rapidly 
turn over highly active enzyme and maintain less active enzyme (Stevenson et al., 
1993). PrP
C
 has been shown to protect neurons against oxidative stress potentially 
through beta cleavage (Watt and Hooper, 2005) therefore the multiple glycoforms may 
be necessary to initiate a correct response. A glycoform may be preferentially selected 
under stress conditions to increase cleavage and facilitate a more rapid response. 
 
The glycoforms may represent inefficient glycosylation rather than possess individual 
functions. G1 and G2 mice showed an increase in the amount of unglycosylated PrP 
compared to the wild type mice. Even when adjusted to reflect the lower overall 
expression levels the monoglycosylated mutants still expressed significantly higher 
levels of unglycosylated PrP than wild type mice. PrP null mice only show very subtle 
adverse phenotypes such as an altered circadian rhythm, increased susceptibility to 
seizures and neurons are more prone to stress (Tobler et al., 1996, Roucou et al., 2004, 
Walz et al., 1999). The GlycoD mice have not been subjected to phenotype testing so it 
may be that a change in glycoform ratios would lead to phenotypes under rigorous 
testing which may indicate functions of the glycoforms.  
 
In conclusion prevention of glycosylation at one or both sites significantly reduces PrP
C
 
levels. The reduction is due to post-translational processing and may be a result of 
114 
 
increased susceptibility to degradation or altered trafficking and turnover of 
unglycosylated and monoglycosylated PrP
C
. There is no difference in regional levels of 
PrP
C
 throughout the wild type brain and the disruption of glycosylation in the GlycoD 













Disruption of glycosylation decreases the total protein levels of PrP
C
 and increases the 
proportion of truncated protein. This chapter aims to assess the overall distribution of 
PrP
C
 within the cell and identify whether the glycoforms have an altered ultra-structural 
localisation of PrP
C
 on the cell surface. Altered PrP localisation in the GlycoD mutants 







 is a membrane bound protein localised predominantly on the cell surface with a 
dynamic and complex lifecycle. It is processed through the secretory pathway and 
delivered to the cell surface where it is continuously recycled into endosomes and back 
to the cell surface. Several functions have been proposed which are dependent upon cell 
surface PrP
C
, such as copper buffering at the pre-synapse (Vassallo and Herms, 2003), 
promotion of neurite outgrowth (Santuccione et al., 2005) and signal transduction 
(Roffe et al., 2010). PrP
C
 lacks a transmembrane domain to interact with cytoplasmic 
proteins therefore interactions with binding partners are important in carrying out some 




 relies on binding partners for endocytosis. Interactions with binding 
partners are therefore important determinants of cellular localisation (Taylor and 
Hooper, 2007). Glycosylation can affect the localisation in two different ways, either 
through trafficking to the cell surface or through interactions with binding partners. 
Glycosylation is important for membrane trafficking for several glycoproteins, such as 
the rat luteinizing hormone receptor (Clouser and Menon, 2005) and 
acetylcholinesterase in erythrocytes (Luk et al., 2012). Previous studies with the 
GlycoD mice have shown that G1 and G2 mice have predominantly cell surface PrP
C
, 
similar to wild type mice, but an increased proportion of intracellular PrP
C





 was mainly intracellular indicating that the glycans of PrP
C
 may have a role in 
determining the localisation (Cancellotti et al., 2005).  
 
In addition to glycan interactions the unstructured N-terminal also plays a role in 
internalisation. The N-terminal domain has been proposed as the ligand binding domain 
for many partners such as LRP1 (Parkyn et al., 2008) and NCAM (Schmitt-Ulms et al., 
2001). Deletion of the N-terminal portion of PrP
C
 reduces internalisation and turnover, 
suggesting an important role of the highly conserved N-terminal in trafficking and 
localisation of the protein (Nunziante et al., 2003). The GlycoD mutants have an 
increased proportion of truncated PrP lacking the N terminal [Chapter 3] so it may be 
expected that the G1 and G2 mutants have a higher proportion of cell surface PrP
C
 than 
wild type mice.  
 
The localisation of the different glycoforms may help to explain the reduced PrP
C
 levels 
and the increased proportion of truncated protein demonstrated in previous chapters. 
The previous study in the GlycoD mutants used immunofluorescence and was not 
sensitive enough to determine exact localisation so it was not known which intracellular 
compartments contain PrP
C
 and the quantities in each organelle type (Cancellotti et al., 
2005). It was also not known whether any unglycosylated PrP
C
 reached the cell surface 
in the G3 mice. This study will employ electron microscopy to determine the 
localisation of PrP
C
. Electron microscopy allows a greater magnification than confocal 
microscopy and cell structures can be identified by their morphology. Individual PrP 
molecules can be identified and their location can be determined by identification of the 
cell structures. This will allow PrP to be quantified for each organelle, allowing more 




 is difficult to detect at physiological levels using IHC, even in the CNS. 
Trafficking and localisation has previously been studied in overexpressing models in 
order to be able to detect PrP
C
 easily.However, overexpression is not an ideal system for 
studying PrP cell biology. Saturation of the intracellular transport mechanisms can lead 
to abnormal intracellular localisation. Overexpression can also lead to toxicity through 
misfolding and oligomerisation. The localisation will be investigated in vitro using 
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primary cells derived from stem cells of GlycoD mutant embryos to allow PrP to be 
studied at physiological levels. Previous studies investigated PrP in vivo (Cancellotti et 
al., 2005) however cells will be used in this study in order to confirm that localisation is 
the same as in vivo and in order to establish a system to investigate the trafficking of 
PrP
C
. Primary cells were chosen over immortalised cells as PrP
C
 has been shown to be 
involved in neuroprotection against oxidative stress and signal transduction, which may 
be altered during immortalisation.  
 
The brain consists of both neuronal and glial cells, such as microglia, astrocytes and 
oligodendrocytes. Glial cells account for a large number of cells in the brain and interact 
with neurons to provide a support system (Montgomery, 1994). While many studies 
have concentrated exclusively on neuronal PrP Prnp mRNA can also be detected in 
astrocytes in vivo and in isolated microglia cultured in vitro (Brown et al., 1990). 
Astrocytes express much lower levels of PrP
C
 than neurons and it is not clear whether 
the function and location of PrP in astrocytes differs from that in neurones (Witusik et 
al., 2007, Brown, 2004). Trafficking and turnover of PrP
C
 is likely to be cell specific 
(Fivaz et al., 2002), therefore establishing individual cultures will allow the localisation 
of PrP
C
 in glia and neurons to be analysed.  
 
The glycosylation may not only change the localisation of PrP within the cell but also 
within the membrane. The GPI anchor causes PrP
C
 to associate with small, organised 
microdomains of the membrane known as lipid rafts (Sarnataro et al., 2004) however, 
PrP
C
 must bind ligands in order to move out of lipid raft regions and initiate 
internalisation via clathrin coated pits (Sunyach et al., 2003). The presence or absence 
of glycans at a particular site may assist ligand binding and increase the amount of PrPC 
found in non-raft regions. There may be a different ultra-structural localisation of the 
glycoforms which may affect the rate of internalisation and therefore the turnover of the 
protein. 
 
This chapter will investigate the localisation of PrP
C
 in the GlycoD mice in order to 






4.3.1 Primary cell cultures 
 
In order to identify the localisation of PrP
C
 primary neuronal and glial cell cultures were 
derived from the GlycoD mice. Cultures were differentiated from pluripotent stem cells 
taken from E17 day embryos. Neuronal cultures were established using the neuronal 
growth factor B-27, which promotes neuronal growth and discourages glial 
differentiation (Brewer et al., 1993). Glial cultures were established using foetal bovine 
serum and the glial growth factor, G5 (Vermeiren et al., 2005). Differentiation occurred 
after 24 hours for glial cells and after 3 days for neuronal cells. Neuronal cultures were 
cultured for at least 7 days to allow dendritic growth and maturity.  
 
Cells were identified initially by morphology then by ICC to establish that pure cultures 
were obtained. A neuron specific cytoskeletal marker, microtubule associated binding 
protein 2 (MAP-2), was used to confirm neurons (Figure 5.1). An astrocyte specific cell 
marker, Glial fibrillary acidic protein (GFAP) was used to confirm glial cultures (Figure 
5.1). Neurons expressed high levels of MAP-2 but no detectable GFAP, showing that 







Figure 4.1. Primary cell cultures 
(A) Brightfield images of 7 day old haematoxylin stained neurons, showing the characteristic 
morphology of neurons with dendrites and axons. Cells are initially identified by this 
morphology. (B) Immunofluorescence of primary neurons showing cytoskeleton (MAP2, green) 
(C) Immunofluorescence of primary glia stained with GFAP (green). Cells are much larger and 




Characterisation of primary neuronal cultures was carried out to establish whether 
neurons were mature. Immunofluoresence was used to look at expression of VAMP2, a 
protein involved in the docking and/or fusion of synaptic vesicles with the presynaptic 
membrane and GABA, a neurotransmitter involved in the elongation of neurites and the 
formation of synapses.  
 
 
Figure 4.2. Characterisation of primary neuronal cultures 
Immunofluorescence of wild type neurons at 10 days showing expression of synaptic vesicles. 
MAP-2 showed that cells are neuronal and makes the individual dendrites and cell bodies 
visible to allow localisation of VAMP2 and GABA. VAMP2 is a synaptic vesicle marker showing 
pre-synaptic vesicles along the dendrites. The GABA neurotransmitter showed variable staining 
for different neurons and was mainly cytoskeletal.  
 
Cells expressed both VAMP2 and GABA, suggesting that the neurons are mature and 
expressing synaptic vesicles (Figure 4.2). VAMP2 appeared to be on the cell surface 
along dendrites, as expected of a vesicle protein. GABA showed weaker staining and 
variable levels were seen for different neurons. 
 
Cultures showed a low level of differentiated cells and a high level of undifferentiated 
cells and cellular debris, creating an unfavourable culture environment and reducing the 
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amount of time the differentiated cells could be kept alive. In addition to the toxicity 
created by debris and dying cells the low cell density of differentiated cells also 
hindered culture survival. Neurons that were isolated from other neurons in the culture 
dish were unable to form connections with other neurons and did not survive for longer 
than four days. Neurons in clusters that had formed connections between cells could 
survive for up to 14 days. Neuronal cultures were used for immunofluorescence and 
electron microscopy at 7-14 days.  
 
A second approach was taken for generating neuronal cultures. The cells isolated from 
embryos were cultured into neurospheres in order to create stocks of neuronal 
precursors, which could then be differentiated into neurons. Neurospheres were 
disrupted to create a single cell suspension and then cultured into differentiated neurons. 
Less debris and more neuronal differentiation were observed; however success rates in 
creating neuronal cultures were still less than 50%. Most cultures did not differentiate 
and once differentiated many cultures did not survive 14 days.  
 
Neuronal cultures were difficult to establish and only 10% cultures were successfully 
differentiated. Cells did not always differentiate after three weeks of incubation in 
culture conditions. Undifferentiated cells were adherent and were shown to be viable by 
trypan blue exclusion. These cells showed no neuronal morphology and remained small 





4.3.2 PrPC detection in primary cells by immunocytochemistry  
 
Immunofluorescence has been previously used to detect localisation in whole brain 
slices and showed an altered localisation, particularly in G3 mice (Cancellotti et al., 
2005). To establish whether the primary neurons were reflecting the differences in PrP
C
 
localisation seen in vivo the same method was used to detect PrP
C
 in neuronal cultures. 
Due to the reported low levels of PrP
C
 in astrocytes three different anti-PrP antibodies 
were tested to determine whether PrP
C




Figure 4.3. Immunofluorescence of astrocytes using different anti-PrP antibodies 
Astrocytes were labelled with three different anti-PrP mAbs; 6H4, 8H4 and BH1 at 
concentrations described (Table 2.2). 6 cultures per genotype were tested with each antibody. 
No difference in staining was seen between the three different antibodies for specificity of 
sensitivity. There was no difference between PrP null and PrP expressing cells in PrP 
fluorescence. The reduced staining in cells that were not treated with anti-PrP antibodies 
suggests non-specific binding of the primary antibodies. Scale bar shows 20 µm. 
 
Astrocyte cells showed very little difference in staining intensity between the PrP 
expressing cells and null cells (Figure 4.3), suggesting that there is a level of non-
specific binding with all three different antibodies. There were low levels of background 
staining and possible autofluorescence in cells when primary antibody was omitted. 
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When antibody concentration was reduced to try to reduce non-specific binding the 
signal was too weak to differentiate from background.  
 
 
Figure 4.4 Immunofluorescence of PrP
C
 on primary neurons  
Primary neurons were labelled with the anti-PrP mAb 6H4 at concentrations described in 
Chapter 2. Neurons showed low levels of staining that was difficult to differentiate from 
background staining and autofluorescence. Null neurons did not show any PrP specific labelling 
of neurons however there was staining and autofluorescence seen from debris and 
undifferentiated cells in all cultures (shown by white arrows).  
 
Neurons showed weak immunofluorescence with PrP antibodies. In all genotypes there 
was considerable autofluorescence and non-specific binding, especially of 
undifferentiated cells and cellular debris found in the cultures (Figure 4.4). 
Immunofluorescence was carried out on two different cultures of G1, G2 and null 
neurons. To reduce the non-specific signal semi-thin sections were used rather than 
whole cells. Cells were fixed and scraped from the culture dish to form a cell pellet and 
debris and small undifferentiated cells were removed by centrifugation.  
 
Semi-thin sections were performed on a single culture of each genotype and showed 
specific PrP fluorescence on wild type and GlycoD neurons that was not observed in 
null neurons (Figure 4.5). The semi-thin sections reflected the expression levels 
observed previously by biochemical methods; wild type neurons showed the strongest 





Figure 4.5. PrP staining of semi-thin sections of primary neuronal cultures 
Immunofluorescence of primary neurons to visualise PrP
C
 using anti-PrP mAb F4-31. Staining is 
much stronger in wild type PrP than in the mutants but is present in all genotypes except for 
null. Very little background fluorescence was observed in null cells.  
 
Immunofluorescence was not sensitive enough to investigate PrP localisation in cell 
cultures. PrP
C
 was difficult to detect by ICC in all cell cultures. PrP
C
 could be detected 
on neuronal cultures however fluorescence was weak due to the low expression level. In 
glial cells it was not possible to detect PrP
C
 in astrocytes. Electron microscopy was 
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therefore undertaken in favour of immunofluorescence as individual PrP molecules 
could be identified and quantified to determine localisation.  
    
4.3.3 Localisation of PrPC on neurons by cryo-electron microscopy 
 
Cryo-electron microscopy was carried out in collaboration with Sue Godsave at the 
Netherlands Cancer Institute, Amsterdam.  
 
Due to the low detection of PrP
C
 during immunofluorescence, two antibodies which 
have demonstrated high sensitivity, mAbs BC6 and F4-31 were used for electron 
microscopy to determine the optimal detection. Gold was detected on all membranes in 
all genotypes, allowing electron microscopy to be used to identify PrP
C
 localisation. 
There was heterogeneous labelling of PrP in neurons; some expressed high levels and 




Ten micrographs were taken for each genotype from two different neuronal cultures 
with both antibodies selecting cells that had high levels of PrP
C
 labelling. The 
micrographs were grouped by genotypes and blinded. The total gold particles were 
counted and gold associated with membranes (within 20 nm) were assigned to plasma 
membrane, Golgi, ER or to vesicles (Figure 4.6). If the structure was not identifiable 




 null neurons were used as a control for non-specific binding of the primary 
antibodies, as non-specificity was a problem with immunofluorescence. Neurons 
showed low levels of gold labelling of the nucleus and occasionally mitochondria 
(Figure 4.6, C). Gold particles associated with these structures were discounted as non-
specific labelling as this was also observed in the null neurons in the absence of gold 
labelling on other membranes. Null neurons did not show labelling of other membranes 







 associated with different cellular structures    
Cryo-electron micrographs showing PrP
C
 labelling on primary neurons using mAb F4-31 (A) 
Gold labelling of plasma membrane localised PrP
C
 (arrows) (B) Labelling of PrP
C
 on internal 
membranes. Arrows show PrP
C
 in the Golgi apparatus. Red asterisk shows ER associated gold 
particle. (C) Non-specific labelling of nucleus seen on a null neuron. G Golgi, ER Endoplasmic 




Figure 4.7 Micrographs of wild type neurons 
Wild type neurons labelled with anti PrP antibody F4-31 and 10nm gold particles. (A) 
Micrograph showing predominantly cell body and large dendrites (B) Micrograph showing small 





Figure 4.8 Micrographs of G1 neurons 
G1 neurons labelled with anti PrP antibody F4-31 and 10nm gold particles. (A) Micrograph 
sowing predominantly cell body and large dendrites (B) Micrograph showing small dendrites. 
PrP bound gold particles circled; Red = cell surface, green = Golgi, purple = internal 




Figure 4.9 Micrographs of G2 neurons 
G2 neurons labelled with anti PrP antibody F4-31 and 10nm gold particles. (A) Micrograph 
showing predominantly cell body and large dendrites (B) Micrograph showing small dendrites. 
PrP bound gold particles circled; Red = cell surface, green = Golgi, purple = internal 




Figure 4.10 Micrographs of G3 neurons 
G3 neurons labelled with anti PrP antibody F4-31 and 10nm gold particles. (A) Micrograph 
showing predominantly cell body (B) Micrograph showing small dendrites. PrP bound gold 





Figure 4.11 Background labelling in null neurons and low level labelling in G3 neurons 
Neurons labelled with anti PrP antibody F4-31 and 10nm gold particles. (A) Null neurons with 
non-specific binding of the nucleus (blue) and a plasma membrane (red) (B) Labelling in G3 
neurons was just above background labelling seen in null neurons. Intracellular labelling = 




Observations about the PrP
C
 labelling were made using the micrographs before 
quantification to gain an impression of the distribution. Gold labelling showed reduced 
PrP
C
 in all GlycoD neurons, particularly the G3 neurons, reflecting the reduced 
expression described in Chapter 3.  
 
As expected, wild type neurons showed labelling predominantly on the cell surface with 
less PrP on the Golgi and ER membranes (Figure 4.7). G1 and G2 neurons also showed 
substantial plasma membrane labelling but a higher amount of Golgi labelling than wild 
type neurons, especially in the G2 cells (Figure 4.8 and Figure 4.9). PrP
C
 was found on 
all cell membranes in G3 cells. Gold labelling on the plasma membrane was very low 
and most PrP
C
 tended to be associated with internal membranes. There appeared to be a 
high level of Golgi associated PrP
C




 localisation in neuronal cultures reflected the localisation observed in murine 
brains suggesting that primary cell cultures are a good model for studying the 
ultrastructural localisation of PrP
C
 in the GlycoD mutants. Using electron microscopy to 
detect PrP
C
 it was observed that there was a high variability in labelling of neurons for 
PrP
C
 within the same genotype. Some neurons had high levels of PrP
C
 labelling whilst 
some showed little or no labelling. Different neuronal types express different levels of 
PrP in vivo (Ford et al., 2002a) therefore the variability from cell to cell could indicate 
that cultures comprise a mixed neuronal type population. Immunofluorescence to detect 
GABA in the neuronal cultures showed some strongly positive neurons and others with 
only weak positivity (Figure 4.2) which also indicated different neuronal types. Cultures 
were created from whole brains and given a pan-neuronal growth factor rather than 
establishing a single neuronal type as it was possible that PrP
C
 had a different 
localisation for different cells. 
 
4.3.4 Quantification of PrPC labelling by electron microscopy 
 
Preliminary impressions of the micrographs showed a difference in PrP
C
 labelling of the 
different GlycoD neurons.Therefore, the gold particles were counted and quantified to 
allow a more accurate description of the localisation. Monoclonal antibody F4-31 
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showed the highest level of labelling so was chosen for quantification. To eliminate the 
variability of size of organelles the labelling density was calculated to show gold per 
µm membrane. Membranes were measured using a 1.2cm square grid and counting the 
number of times a membrane bisected the grid lines. Labelling density was calculated 
using the formula 
 
Gold labelling density = gold/(grid intersections*distance between grid lines) 
 
Labelling was quantified for plasma membrane and intracellular organelles using a 
semi-random method. Whole cells are too large to be captured on a single micrograph; 
therefore certain structures may be biased. An individual micrograph may favour 
plasma membrane if axons and dendrites are captured, equally a micrograph with cell 
bodies would be expected to be predominantly Golgi and under-represent plasma 
membrane. To avoid bias five micrographs that had predominantly plasma membrane 
and five micrographs that had predominantly Golgi and internal membranes were taken 
so that all structures were represented during quantification. Due to low gold labelling 
for all genotypes the gold counts were combined for all micrographs of the same 
genotype.  
 
Gold labelling could not be accurately quantified for G3 neurons due to the overall low 







 labelling in different cell regions 
Labelling density was carried out to measure the amount of gold per µm membrane. GC=Golgi 
cisternae; GV= Golgi vesicles; P=plasma membrane, cell body &processes > 200 nm across; 
sP = plasma membrane of processes up to 200 nm across; ER = endoplasmic reticulum; ves = 
other vesicles, outer membrane. Both G1 and G2 have a 5-fold reduction of PrP
C
 on the cell 
surface. Wild type and G1 neurons have similar amounts of PrP on non-Golgi internal 




Wild type neurons had the highest labelling density for all membranes except the ER, 
which reflects the higher expression observed in Chapter 3 (Figure 4.13). G2 had a 
higher labelling density than G1 for all membranes except the ER. Wild type neurons 
showed almost three times more labelling on the cell surface in comparison to the 
GlycoD mutants and twice as much PrP
C
 in vesicles. All GlycoD mutants express less 
PrP therefore it is not unexpected that mutants showed reduced labelling along 
membranes. Due to the low levels of PrP and high variability between micrographs no 
significant difference after statistical analysis was seen for any membrane for any 
genotype. 
 
The differences in PrP
C
 levels made comparisons between genotypes difficult. The 
labelling densities were used to calculate the distribution of gold throughout the cell for 
each individual genotype. Labelling of each membrane was calculated as a percentage 




Labelling density was combined from ER and vesicle membranes and expressed as 
other internal membranes. ER membranes can be hard to identify from micrographs if 
the membrane is bisected at an unfavourable angle thus it is likely that some ER gold 
counts are included as vesicles rather than ER. Small and large dendrites were also 





Figure 4.13. Distribution of PrP
C
 in different cell regions  
Labelling density of PrP
C
 from 10 micrographs was used to calculate the percentage of PrP
C
 on 
each membrane. 50% wild type PrP is found on the cell surface, whilst only 20% is found on the 
cell surface of G1 or G2 neurons. G2 cells had larger amounts of Golgi labelling than both wild 
type and G1 cells, which had similar amounts. G1 cells had much higher labelling of PrP
C
 on 









 was reduced in GlycoD mutants. Almost half of the PrP
C
 in wild type 
neurons was localised to the cell surface, whereas G1 and G2 only had around 20% on 
the cell surface. G2 mutants have a larger proportion of Golgi associated PrP
C
 than both 
G1 and wild type neurons (Figure 4.13), although gold labelling of the Golgi was at 
similar levels in wild type and G2 neurons. G1 cells have a higher proportion of internal 
PrP
C
 that is not associated with the Golgi. This may represent PrP
C
 retained in the ER or 
may represent PrP
C






 localisation in neuronal cultures reflected the localisation observed in murine 
brains suggesting that primary cell cultures are a good model for looking at the 
ultrastructural localisation of PrP
C
 in the GlycoD mutants.  
 
4.3.5 Endo H sensitive PrPC in wild type, G1 and G2 mice 
 
Electron microscopy showed that G1 and G2 mice had higher labelling of the ER than 
wild type mice (Figure 4.12), however ER can be difficult to identify on micrographs. It 
is likely that some ER labelling from the micrographs was not identified as ER and 
labelling was included with other vesicles. In order to confirm this increase in the 
mutants PrP
C
 in the ER was detected biochemically using Endo H to remove mannose 
rich oligosaccharides. Endo H is only able to remove the immature glycans that are 
present in the ER and not the mature glycans that are modified in the Golgi. 
Localisation of the glycoforms appeared to be the same in brain and cells (Figure 4.13) 
(Cancellotti et al., 2005) therefore brains were used to look at the amount of immature 
PrP
C





Figure 4.14 Immunoblots of Endo H treated PrP
C
 
10% brain homogenates were treated with and without 2500 Units Endo H for 24 hours and 
then run on an immunoblot. Three different mice per genotype were assessed in triplicate. 
Densitometry was carried out to compare the ratios of the glycoforms before and after treatment 
with Endo H.  
 
Brain homogenate was divided into two and one aliquot treated with Endo H for 24 
hours. Densitometry was carried out on immunoblots for all glycoform bands (Figure 
4.14). Endo H sensitive PrP
C
 was detected as a decrease in diglycosylated PrP for wild 
type mice and a decrease in monoglycosylated PrP for G1 and G2 mutants when 
compared with untreated homogenates. 
 
Immunoblots showed a very subtle difference that was difficult to assess without 
quantification. After Endo H treatment the diglycosylated (wild type) and 
monoglycosylated (G1 and G2) bands were reduced and the unglycosylated bands were 
increased as immature glycans were removed. Wild type mice showed a slight increase 






Figure 4.15 Level of Endo H sensitive PrP
C
  
Densitometry was carried out on immunoblots to calculate the change in each glycoform after 
treatment with 20,000U Endo H for 24 hours. Changes were very subtle, between 3 and 5% and 
not significant for any genotype. G1 mice had a higher level of Endo H sensitive PrP
C
 than wild 
type or G2 mice. 
 
Although there was no significant difference between the genotypes the G1 mice tended 
to have more Endo H sensitive PrP than the wild type and G2 (Figure 4.15). There was 
no difference between G2 and wild type, suggesting that the level of PrP
C
 in the ER is 
the same for both genotypes. This result reflects the increase of PrP
C
 in the ER of G1 
mice determined by electron microscopy.  
 
4.3.6 Lipid raft isolation 
 
The GPI anchor localises PrP to the lipid rafts, however binding partners cause PrP to 
move out of the lipid rafts for internalisation, which may be affected by the 
glycosylation status of PrP. To investigate the ultra-structural localisation of PrP
C
 lipid 
rafts were isolated from non-lipid raft membrane regions based on the selective 
insolubility of rafts in the presence of detergent at 4 °C, then separated out on a sucrose 
gradient. Fractions were collected and probed on an immunoblot to detect PrP
C
 






Figure 4.16. Expected lipid raft isolation profile on an immunoblot 
Diagram showing expected western blot after lipid raft isolation on a sucrose gradient. Fraction 
1 is the bottom of the gradient and fraction 10 is the top. Insoluble proteins, such as the raft 
marker and PrP will float to the 5-30% gradient interface, which is seen in fractions 7 and 8. 
There are many more soluble proteins, such as the non-raft marker so these will float with the 
denser gradient in fractions 1 and 2.  
 
Lipid rafts are preferentially isolated from cell cultures rather than brains, due to the 
high myelin content in tissues which can contaminate lipid rafts and hinder separation 
on the gradient (Persaud-Sawin et al., 2009). Due to difficulties in culturing neurons in 
large quantities limited amounts of cell cultures were available and were prioritised for 
electron microscopy studies. Brain material was readily available in sufficient quantities 
hence lipid rafts were isolated using a method developed for brain material.  
 
A variety of factors influence the detergent insolubility and physical separation of 
membrane regions therefore several conditions were changed to optimise separation 
(described below).  
 
4.3.6.1 The effect of temperature on separation 
 
Membrane regions are separated based on the differential solubility at 4 °C. At 37 °C 
both lipid rafts and non-raft regions are soluble; however at 4 °C lipid rafts become 







Figure 4.17 Comparison of solubilisation at 4 °C or 37 °C 
Immunoblots of each genotype of gradients carried out at (A) 4 °C and (B) 37 °C. All 4 
genotypes were carried out at the same time for each temperature but different brains were 
used for the different temperatures. Transferrin receptor (huTfR), the non-raft marker is shown 
in the top panel; flotillin (Flot-1), the raft marker is shown in the centre panel and PrP
C
 is shown 
in the bottom panel. Fraction 1 is the bottom of the gradient and fraction 10 is the top of the 
gradient. 
 
Separation was carried out at 4 °C as described by (Parkin et al., 1997) (Figure 4.17, A). 
When solubilised at 4 °C PrP was found in most membrane fractions but there was no 
separation of raft and non-raft proteins. In an attempt to improve separation the method 
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was carried out at 37 °C using a more physiological buffer that is thought to stabilise the 
membranes better (Chen et al., 2009) (Figure 4.17, B).  
 
Isolation was carried out four times using two different brains at each temperature. 
Isolation at 37 °C appeared to show the genotypes to be more similar with each other 
than at 4 °C; however neither protocol showed separation of the raft and non-raft 
markers and PrP was predominantly localised with both markers. This suggests that 
temperature may play a role in gradient formation and the speed the sample floats up the 
gradient rather than solubilisation. At 4 °C the sample may take longer to float to the 
appropriate density, producing the variable results and proteins found in the lower 
fractions for some gradients.   
 
4.3.6.2 The effect of gradient on separation 
 
Soluble and insoluble proteins are separated by floatation on a discontinuous sucrose 
gradient, made up of 30% and 70% sucrose. The majority of the membranes and 
membrane bound proteins are soluble and have a low buoyancy therefore sink to the 
bottom of the sucrose gradients and are found in fractions 1-3. Insoluble proteins are 
found at the gradient interface. 
 
Three different brains were separated on a gradient in quadruplet and the number of 
fractions PrP
C
 was detected in was very variable within the same brain homogenate. 
PrP
C
 was detected in either a few discreet fractions or in all fractions along the gradient.  
 
The refractive index was measured for each fraction to establish that a gradient was 
being formed and maintained during centrifugation (Figure 4.18). A discontinuous 
gradient was present at 0 and 4 hours. After 18 hours at 100,000 x g the sucrose had 







Figure 4.18 The influence of centrifugation time on gradient type 
A sucrose gradient was set up as described in the methods but without adding homogenate and 
centrifuged for different lengths of time. The refractive index was measured for each fraction to 
assess the density gradient. All sucrose solutions formed a gradient. The initial sucrose 
solutions formed a discontinuous gradient and this was still present after 4 hours. After 18 hours 
of centrifugation the gradient had changed to a continuous gradient. (n=4 per centrifugation 
time)  
 
Initially a sucrose gradient was set up with equal volumes of 30% and 70% sucrose, 
however PrP was found in fractions 2 to 7 without a gap between raft and non-raft 
proteins (Figure 4.19, A). To improve separation the gradient was set up with three 
times the amount of 70% sucrose so that the gradient interface and lipid raft proteins 
were in fractions 7-8 (Figure 4.19, B). A 3:1 sucrose gradient showed a shift in the 
fractions that PrP
C
 was seen in which would improve the separation of the raft and non-






Figure 4.19 Different sucrose gradients change the interface fractions    
Immunoblots showing insoluble wild type PrP at the gradient interface with (A) an equal volume 
of 70% and 30% sucrose and (B) 3:1 ratio of 70% sucrose to 30% sucrose. A 1:1 gradient 
showed PrP predominantly in fractions 3-5 whilst a 3:1 gradient moved the interface to fractions 
7-9 allowing a clearer separation from soluble proteins found at the bottom of the gradient.  
 
4.3.6.3 The effect of detergent concentration 
 
The detergent concentration plays a role in the solubility of rafts; too little and non-raft 
membranes are not solubilised, too much and rafts become solubilised. Different 
dilutions of detergent were tested in duplicate on the same wild type homogenate to 





Figure 4.20 The effect of detergent level on the solubility of PrP
C 
Wild type brain homogenates were solubilised at 37 °C with different concentrations of Triton X-
100 and separated on a discontinuous gradient. 1% is the standard level of detergent described 
in the protocols used. Higher levels of detergent reduced the number of fractions PrP was found 
in, although PrP was found in the soluble fractions with all detergent concentrations used. The 
transferrin receptor was seen as a doublet with 4% detergent (labelled with asterisk). The lower 
band probably corresponds to a degradation product (Vidal et al., 1997) and was observed in 
some immunoblots but not others. 
 
Adjusting the protein:detergent ratio altered the fractions that PrP was found in; 
however it did not alter the differential solubilisation of membrane regions. It was not 
possible to isolate lipid rafts from non-raft regions of the membrane using whole brains. 




there was no difference in localisation of raft and non-raft markers during fractionation 
therefore it was not possible to assign PrP to a raft or non-raft fraction. 
 
Isolation of rafts using detergent has been controversial. It has been reported that 
detergents may create rafts as artefacts of the preparation (Lichtenberg et al., 2005), 
redistribute gangliosides and alter raft properties (Heffer-Lauc et al., 2005) or interfere 
with organelles and raft integrity (Suneja et al., 2006). Different detergents can yield 
different subsets of detergent resistant membranes with unique properties (Chen et al., 
2007). Another GPI anchored protein, Thy-1, was found in distinct lipid rafts from PrP
C
 
(Brugger et al., 2004). Different methods have been developed which bypass the use of 
detergents however there was still significant membrane contamination of raft fractions 








 has the ability to alter localisation of the protein within the 
neurons. Glycosylation is not essential for cell surface expression but the GlycoD 
mutants have demonstrated that it is important for efficient surface expression. All 
glycoforms can be trafficked to the cell surface as a small amount of G3 PrP
C
 was seen 
on the plasma membrane.    
 
Previous localisation work on the GlycoD mice has shown that unglycosylated PrP in 
the G3 mice was intracellular (Cancellotti et al., 2005). This study has shown that 
although G3 PrP is predominantly intracellular a small amount is localised to the cell 
surface. Many of the proposed functions of PrP require cell surface PrP therefore the 
presence of unglycosylated surface PrP
C
 suggest that unglycosylated PrP is able to carry 
out these functions.  
 
Previous studies using G1 and G2 mice showed PrP expressed on the cell surface but a 
higher proportion of intracellular PrP in comparison to wild type mice (Cancellotti et 
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al., 2005). Co-localisation with ER and Golgi markers indicated that PrP was most 
likely in the Golgi. Electron microscopy in this study showed that G1 and G2 mice had 
a reduction in cell surface PrP
C
. There was no difference in the amount of surface PrP
C
 
between G1 and G2 cells; however there appeared to be a difference in internal 
localisation suggesting that glycans at the different sites influence trafficking.  
 
G1 neurons showed a higher level of ER associated PrP
C
 by cryo-electron microscopy 
than G2 neurons. An increase in Endo H sensitive PrP
C
 was also seen, albeit subtle. 
This ER associated PrP in the G1 mutants likely represents protein that is retained in the 
secretory pathway prior to being trafficked to the cell surface as the glycans retained the 
sensitivity to Endo H and had not yet been matured in the Golgi. G2 mice showed a 
similar proportion of PrP
C
 in the ER as wild type neurons; however 40% PrP
C
 
associated with the Golgi. The high proportion of Golgi PrP could be a reflection of 
slower trafficking to the cell surface or a higher proportion of retrograde transport back 
into the Golgi from the cell surface.    
 
Localisation in vivo was determined using immunofluorescence and confocal 
microscopy (Cancellotti et al., 2005) thus the sensitivity was not enough to see the exact 
localisation or to quantify the amounts of PrP on the cell surface. This study employed 
electron microscopy to increase sensitivity and to allow quantification of PrP
C
 on the 
different membranes, allowing differences in G1 and G2 mice to be identified.  
 
The glycan at the first site, which is abolished in G1 mutants, may assist transition of 
PrP
C
 from the ER to the Golgi. A mutation in the human PrP gene, T183A, abolishes 
the first glycosylation site and causes familial CJD (Grasbon-Frodl et al., 2004, Nitrini 
et al., 1997). Similar to G1 neurons, murine PrP with a T182A mutation is 
predominantly localised in the ER, and has been shown to have a shorter half-life than 
wild type PrP (Campana et al., 2006). However, T182A PrP is partially protease 
resistant whereas G1 PrP remains PK sensitive. G2 neurons had a higher proportion of 
Golgi-associated PrP
C







 localised to the cell surface is distributed equally to small processes (<200 nm) and 
to cell bodies and larger processes (>200 nm) in wild type neurons. Surface labelling 
was also equally distributed between large and small processes for the G1 and G2 
mutants. PrP
C
 is reported to localise to synapses (Herms et al., 1999) therefore it would 
be expected that smaller processes would be heavily labelled and larger processes less 
so. PrP
C
 also localised along developing axons and dendrites in vivo (Moya et al., 
2000). Neuronal cultures showed limited viability and a lifespan of less than 14 days 
therefore were used at 7-10 days old and axons were potentially still growing.  
 
It was not possible in this study to identify the proportion of PrP
C
 associated with lipid 
rafts in the GlycoD mice. In hindsight, isolation of lipid rafts would only identify large 
differences in localisation due to the complex trafficking of PrP
C
. In wild type cells a 
proportion of PrP is found in lipid rafts and a proportion in non-lipid rafts due to the 




 is predominantly found in lipid raft regions but in 
neurons has the ability to move into non-raft regions to be internalised. Around 20% of 
PrP is always found in the insoluble pellet found at the bottom of the gradient, 
representing PrP attached to internal membranes, such as the Golgi and ER, which are 
difficult to disrupt [personal communication with R. Morris, Kings College London].   
 
It is not known whether the different glycoforms have different localisations in wild 
type cells. It is possible that the wild type glycoforms detected are an artefact of 
detecting the protein in various stages of its life cycle. Very few antibodies that 
differentially recognise the glycoforms are available and have not been used to 
investigate localisation of the different glycoforms therefore it is not known where the 
different glycoforms are localised in wild type cells. The GlycoD mice have shown that 
all glycoforms can be expressed on the cell surface therefore are all likely to be 
functioning proteins rather than intermediates.  
 
4.4.2 Retention in the ER versus rapid endocytosis 
 
The increase in internal PrP in the GlycoD mutants may be due either to retention in the 
secretory pathway or rapid endocytosis from the cell surface. PrP
C
 has a dynamic life-
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cycle; it is processed through the secretory pathway and delivered to the cell surface 
where it is rapidly endocytosed with a half-life of ~20 minutes before being trafficked 
back to the cell surface (Shyng et al., 1993). PrP
C
 interacts with many different proteins 
in order to traffic correctly and glycosylation and cleavage of PrP influences these 
interactions.  
 
A lack of glycans did not prevent cell surface PrP in G3 cells indicating that 
glycosylation is not essential for cell surface expression. Loss of glycosylation can slow 
down trafficking to the cell surface, as is seen with the vascular endothelial growth 
factor (VEGF) (Yeo et al., 1991) and the C3b/C4b receptor (Lublin et al., 1986). Site 
directed mutagenesis to remove N-linked glycosylation of the yeast protein MFα1 
precursor protein delays transit from the ER to the Golgi (Caplan et al., 1991). 
Intracellular MFα1 precursor protein was also exposed to some proteolytic degradation 
so overall protein level was reduced (Caplan et al., 1991).  
 
Increased proportion of PrP
C
 in the secretory pathway suggests that glycosylation may 
play a role in trafficking of PrP
C
 to the surface. PrP lacking a single glycosylation site 
had a higher proportion of PrP
C
 associated with ER and Golgi. G1 PrP showed a greater 
amount of immature Endo H sensitive glycans which indicates that PrP is retained in the 
secretory pathway rather than recycling back to the ER and Golgi. PrP
C
 from the 
GlycoD mutants did not show any properties associated with misfolded protein [Chapter 
3] and structural studies have shown that the glycans impart little or no structure 
(Hornemann et al., 2004) so it is doubtful that partially or unglycosylated PrP is retained 
in the ER due to misfolding and triggering of the unfolded protein response (UPR). The 
monoglycosylated PrP
C
 may be retained in the ER to increase exposure to the 
glycosylation enzymes and increase the probability of further glycosylation. 
 
Although the GlycoD mutants showed an increased proportion of protein in the 
secretory pathway they had less PrP labelling than wild type neurons. This may indicate 
that protein is being delivered to the cell surface at the same rate in all mice but that it is 
endocytosed and degraded much quicker in the mutants. It has also been shown that a 
substantial amount of PrP is found in non-raft membranes and internalised through 
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clathrin mediated endocytosis (Sunyach et al., 2003, Laine et al., 2001). In order to 
move out of raft regions PrP
C
 is dependent upon ligand binding to transmembrane 
proteins to ‘piggy back’ into clathrin coated pits. The glycans of PrP
C
 may influence the 
binding ability and therefore the rate of endocytosis of each of the glycoforms. The 
overall reduction of PrP
C
 protein but not mRNA [Chapter 3] suggests that the GlycoD 
mutants have an increased level of degradation. The GlycoD mutants show no 
spontaneously misfolded protein so degradation is likely to be after endocytosis rather 
than through ER mediated degradation.  
 
The recycling and trafficking of PrP
C
 means it is not possible to definitively conclude 
whether PrP
C
 in the Golgi is being retained or recycled using the electron microscopy 
localisation data on its own. PrP
C
 is endocytosed and can be trafficked back to the ER 
and Golgi through interactions with Rab proteins, small GTPases that regulate vesicular 
transport in endocytosis and exocytosis (Zerial and McBride, 2001). Different Rabs are 
associated with different trafficking, for example Rab5 is associated with clathrin-
coated vesicles and early endosomes (Bucci et al., 1992, Stenmark et al., 1995) whilst 
Rab6 is involved in retrograde transport from the Golgi to the ER (White et al., 1999). 
Co-localisation with the different Rabs would help to indicate whether a protein was 
transported. Labelling surface PrP
C
 and pulse-chasing the cells would also give an 
indication of the trafficking and whether the mutant protein is retained or rapidly 
endocytosed.  
 
The GlycoD mutants have an increased proportion of truncated PrP
C
 lacking the N- 
terminal [Chapter 4]. This region has been shown to assist in internalisation and alter 
the level of cell surface PrP (Shyng et al., 1995, Nunziante et al., 2003). It would be 
expected that GlycoD mutants would have a higher level of surface PrP due to truncated 
PrP that cannot be endocytosed, however the mutants have less surface PrP than wild 
type mice. It was not possible to differentiate between full length and truncated PrP so it 
is not known whether surface PrP is truncated in the mutants. C1 on the cell surface 
may be shed through C-terminal cleavage more efficiently in the mutants leading to 




This chapter has shown that glycosylation at either site influences the localisation of 
PrP
C
 to the cell surface. Glycosylation is not required for cell surface expression 
however removal of one or both glycosylation sites reduces the proportion of cell 
surface PrP. The glycans are likely to assist in correct trafficking to the cell surface as 
an increased proportion of PrP
C
 is localised intracellularly within the secretory pathway 












 during TSE disease is influenced by the exposure to PrP
Sc
 
and the physical interaction with the molecules. Previous chapters have investigated 
how glycosylation can alter the exposure of PrP
C
 by changing the localisation and levels 
of protein. This chapter aims to identify the effect of glycosylation on the physical 
interaction with PrP
Sc
 to initiate conversion. The efficiency of the different glycoforms 
to convert to PrP
Sc
 and the ability to act as a template for protein misfolding and 






 is essential for TSE disease and one of the central events is the conversion of host 
PrP
C
 to the disease associated PrP
Sc




 is thought to occur via 
a direct interaction between the two (Horiuchi and Caughey, 1999). All glycoforms are 
able to convert to PrP
Sc
 however the presence of the glycans alters the efficiency of 
conversion.  
 
Glycosylation may affect the conversion through altering the kinetics of conversion. 
Helix 2 and 3 are important regions for amyloid formation and are believed to be the 




 transition (Yamaguchi et al., 2008, Chen and Thirumalai, 
2013). The first glycosylation site lies within helix 2 and presence of the glycan has 
been shown to reduce the rate of fibril formation by stabilising the intra-molecular 
disulphide bond formation (Bosques and Imperiali, 2003). G1 and G3 mice lack glycans 
at this site therefore would be expected to form fibrils faster than wild type and G2 
mice.   
 




 has been shown to be important for 
conversion and may contribute to the interspecies barrier observed with some TSEs 
(Kocisko et al., 1995). Homogenous seeding is more effective than heterogeneous 
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seeding, thus seeding mouse PrP
C
 with mouse PrP
Sc
 gives more efficient conversion 
than seeding hamster PrP
C
 with mouse PrP
Sc
 (Kocisko et al., 1995). The effect of 
glycosylation homogeneity has also been shown to be significant but is secondary to 
PrP sequence in determining compatibility for conversion in vitro (Priola and Lawson, 
2001). The cell free conversion assay showed that unglycosylated mouse PrP
C
 was 
converted more efficiently than glycosylated mouse PrP
C
 with a hamster PrP
Sc
 seed 





but did not appear to influence the conversion efficiency (Priola and Lawson, 2001). 
 
Several in vitro conversion assays have been developed to try to understand the prion 




 and to aid in identifying the infectious 
agent. These assays use a small seed from infectious material as a template to induce 
refolding and fibrillisation of PrP
C
 under different biophysical conditions.  
 
In this thesis the quaking induced conversion (QuIC) assay will be used to investigate 
the effect of glycosylation on the efficiency of conversion. The assay uses small amount 
of PrP
Sc
 to seed conversion with recombinant PrP
C
 in excess as a substrate (Figure 5.1). 
Initially the QuIC assay was carried out and amplification measured by immunoblotting 
assay products (Atarashi et al., 2008); however the technique was improved by the 
addition of thioflavin T (Orru et al., 2009). The amyloid fibrils formed during 
conversion bind to thioflavin T and fluorescence is enhanced. Fluorescence is measured 
throughout the incubation, giving a real time measurement of amplification (Orru et al., 
2009). Real-time QuIC will be used in this thesis but will be referred to simply as QuIC. 
The in vitro conversion product will be described as PrP
res
 rather than PrP
Sc
 as the 
conversion product is not necessarily the same as PrP
Sc
 generated in disease. The assay 
produces PrP which is PK resistant but is not able to cause TSE disease when inoculated 







Figure 5.1 The real-time quaking induced conversion assay 
A small amount of PrP
Sc
 (seed) is added to an excess of recombinant PrP (substrate). A double 
orbital shaker shakes the samples for 1 minute and then rests for one minute at 42 °C. 
Recombinant PrP binds to the PrP
Sc
 seed and is converted to PrP
res
. Agitating the sample 
disrupts PrP
res
 aggregates, generating more PrP
res
 seeds for conversion. As recombinant PrP is 
converted to PrP
res
 it forms amyloid fibrils, which causes enhanced fluorescence of Thioflavin T. 
This fluorescence is measured every 15 minutes over a 60 hour period and can be plotted on a 





Previous studies using the GlycoD mice have shown that both host PrP
C
 and donor 
PrP
Sc
 glycosylation influence TSE disease (Tuzi et al., 2008, Cancellotti et al., 2013). 
The previous chapters of this thesis have demonstrated that the cell biology of PrP
C
 is 





 and influence the disease susceptibility observed in the in vivo TSE experiments 
using the GlycoD mice. The QuIC assay can be used as a model for the in vivo 
infections to investigate the conversion of PrP
C
 in the GlycoD mutants. The in vitro 
nature of the assay allows confounding factors from the in vivo experiments, such as the 
differences in localisation and protein levels to be removed. The amount of substrate for 
conversion is in excess in the QuIC assay and can be normalised between the genotypes 
so that reduced protein levels are not limiting conversion. 
 
This chapter will address the efficiency of converting the different glycoforms of PrP
C 
(representing wild type TSE inoculation into a GlycoD mouse) and the ability of the 
different glycoforms of PrP
Sc
 in initiating conversion (representing GlycoD TSE 
inoculation into a wild type mouse). 79A has been chosen as the TSE strain for the 
QuIC assay as it is a well characterised strain in the GlycoD mice and all genotypes are 
susceptible to disease. Incubation time and pathology were different in the genotypes, 
suggesting that glycosylation may influence the ability to convert to PrP
res 
(Tuzi et al., 
2008).  
 
Recombinant PrP is unglycosylated therefore the effect of glycosylation on conversion 
of the different PrP
C
 glycoforms cannot be studied using recombinant PrP. The QuIC 
assay will be adapted to use brain homogenate as a substrate and conditions tested to 
allow amplification of the glycoforms of PrP
C
. Recombinant hamster-sheep chimeric 
PrP will be used to assess the efficiency of the different glycoforms to initiate 
conversion. The first 114 amino acids (23-137) are Syrian hamster PrP sequence, the 
last 93 amino acids (141-234) are sheep PrP sequence from the R154 Q171 polymorph. 
The recombinant PrP construct was provided by B. Caughey (National Institute of 
Allergy and Infectious Diseases, NIH, USA) and the protein produced by R. Alejo-
Blanco, (The Roslin Institute, The University of Edinburgh) and J. Alibhai (The Roslin 





 from all but the G3 mice are a heterogeneous mixture of glycoforms therefore 
it is not possible to examine the interactions of the individual glycoforms. It is important 
to consider that the different glycoforms may interact with each other and therefore the 
ratio of glycoforms may affect the conversion. GlycoD mice heterozygous for the wild 
type allele were also used as a seed to assess how the ratios of the glycoforms can 
change conversion. The heterozygous mice have a wild type allele thus produce all of 
the glycoforms; however they do not produce as much diglycosylated PrP so have a 




5.3.1 Quaking induced conversion assay 
 
The aim of the QuIC assay in this thesis was to identify the ability of the glycans to 
affect fibrillisation of the prion protein. The ability of PrP
C
 to convert to PrP
res
 can be 
assessed by the lag time to fibrillisation, the rate of fibrillisation and the total amount of 
fibrillisation.  
 
The QuIC assay measures fluorescence produced by thioflavin T binding to amyloid. 
However, there is an upper limit to detection which is usually reached during the assay. 
The amount of fluorescence produced does not always correspond to the amount of 
PrP
res
 detected by immunoblotting of the QuIC product. Different strains are thought to 
arise from different conformations therefore the different conformations may have 
differing abilities to cause thioflavin fluorescence. The different glycoforms may also 
have different conformations as they show different strain characteristics after challenge 
with 79A (Cancellotti et al., 2013). This means that amount of fluorescence is not a 
suitable measurement for the efficiency of conversion.  
 
The lag time was used to assess the ability of the glycoforms of PrP
Sc
 to initiate 
conversion. Using the GlycoD PrP
Sc
 as a seed for recombinant PrP allows the 
glycoforms to be assessed in initiating conversion; however as recombinant PrP is 
converted to PrP
res
 it provides more seed for further conversion. Therefore glycosylation 
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is only influencing conversion at the beginning of the assay. The lag time measures the 
first conversion events, which will be influenced by the glycans.   
 
The fluorescence was measured every 15 minutes and values plotted on a graph. The 
time to seed was determined by comparing the graph of the fluorescence and the 
individual fluorescence readings and looking at when the readings started to steadily 
increase from the average baseline reading. The fluorescence decreased after the first 
time point and fluctuated until amplification occurred. The baseline was calculated by 
taking an average from the third to the sixth fluorescent reading.  
 




 seed was created from a wild type mouse and GlycoD mice that were 
challenged with the mouse adapted TSE strain 79A as all GlycoD mice were susceptible 
to this strain. Mice had been inoculated with 79A from C57 mice and 10% brain 
homogenates were prepared from mice culled in the terminal stage of clinical disease 
that were confirmed to be pathologically positive for disease.  
 
Due to limited numbers of animals from previous transmission studies only one 
terminal animal from each genotype was used as a seed so it is not known whether there 
is any animal to animal variability in seeding ability. Terminal animals have different 
amounts of deposition between and within genotypes. To overcome this PrP
Sc
 seed was 
measured and adjusted so that the same amount of PrP
Sc
 was used for each reaction. 
This should eliminate animal variation within a genotype. 
 
5.3.1.2 Normalising PrPSc seed 
 
Each mouse used to create the PrP
Sc
 seed had different levels of PrP
Sc
 deposition in the 
brain, therefore different concentrations of PrP
Sc
 seed. It would be expected that a 
higher concentration of seed would cause conversion to have a shorter lag time as there 
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is more material to initiate conversion. Serial dilutions of seed were prepared in order to 
validate that reducing the amount of seed increased the lag time.  
 
Seeding with both wild type and G1 PrP
Sc
 showed that reducing the amount of seed 
increased the length of time it took to seed the conversion (Figure 5.2). The highest 
dilution was the fastest to seed, however the lower the dilution the less difference there 





, showing that a higher dilution will give better sensitivity and is 





Figure 5.2 Effect of seed dilution on seeding times 
Two different 10% homogenate seeds from 79A terminally infected mice (A wt; B G1) were 




 and used in the QuIC assay. Fluorescence was measured every 
15 minutes and an average of 4 repeats calculated. The time to seeding was measured and is 
marked with an arrow for each dilution. Both seeds show that the more dilute the seed the 
longer the time to seeding. There was very little difference in time to seeding for lower dilutions 




The concentration of seed affects the time to seeding therefore the amount of PrP
Sc
 was 
normalised for each genotype of homogenate used as a seed. To measure PrP
Sc
 brain 
homogenates were treated with PK at 37 ˚C for 75 minutes to remove the PrP
C
 and then 
run on an immunoblot which was scanned using a near infrared imager and 
densitometry carried out on each sample. A recombinant PrP standard was included to 
allow the software to calculate the quantity of PrP
Sc
 in each of the samples.    
 
 
Figure 5.3 Quantification of PrP
Sc
 in 79A infected mice 
Homozygous GlycoD mice and GlycoD mice heterozygous for the wild type allele were used as 
seed. (A) Expected PrP
Sc
 banding pattern for each of the genotypes on an immunoblot.  The 
homozygous GlycoD did not have all of the glycoforms. The heterozygous mice had all of the 
glycoforms but in different ratios to the wild type mice. (B) 10% Brain homogenates from 
clinically positive mice infected with 79A were treated with 50 µg/ml Proteinase K for 75 minutes 
at 37 °C to remove PrP
C
. Samples were run on fluorescent immunoblots in quadruplet and 
scanned using a near-infra red scanner. A standard of known recombinant PrP was also run on 
the same immunoblot so that quantification by densitometry could be carried out. Each sample 
had the same area highlighted and fluorescence was measured. The top row shows the over-
exposed immnoblots so that all samples can be seen easily by eye. The bottom row shows the 
same immunoblots at a shorter exposure and the areas marked for quantification. The imager 
software was used to quantify each band. A wild type with very little PrP
Sc
; B G1 mouse; C 




 was quantified for each sample on at least two immunoblots. Loading controls, 
such as α-tubulin, were digested by PK so could not be used to control for differences in 
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sample loading. The replicates showed that there was little variation in loading the 
sample onto the gel. Once the concentration of PrP
Sc
 of each of the genotype was 
calculated they were diluted to the same quantity as the lowest sample.  
 
5.3.1.3 Controls and spontaneous fibrillisation 
 
Spontaneous fibrillisation is a concern of the QuIC assay and has been seen in 
uninfected controls. This questions whether there is true seeding of PrP
Sc
 or whether the 
samples can spontaneously misfold under QuIC conditions. For each QuIC run several 




) contamination in infected 
samples. A recombinant only control was used in quadruplet to ensure that the 
recombinant was not spontaneously forming PrP
res
 during the assay. A normal brain 
homogenate seed control of each homozygous genotype was included to ensure that no 




 was seen infrequently in some of the controls (less than 3 per 20 controls). 





 could be differentiated as infected samples were positive before 24 hours but 
PrP
spon
 was never seen before 24 hours (Figure 5.4). Recombinant C showed 
amplification at around 8 hours however PrP
spon
 was not observed until after 30 hours. 
 
Different batches of recombinant were tested to assess whether they formed PrP
spon
 at 
different efficiencies. Three different recombinants, all hamster-sheep chimeras, were 
initially at different concentrations but were diluted to 0.1mg/ml in the assay.   
Recombinant PrP strongly influences the QuIC reaction; all batches of recombinant PrP 
are produced using the same method and equipment by R. Alejo-Blanco and J Alibhai 
yet there was variation between the conversion times for PrP
res
 and in PrP
spon
 formation 





Figure 5.4 Recombinant PrP variation on PrP
spon
 formation  
Three different batches of hamster-sheep recombinant was used as substrate in the QuIC 
assay. Each box shows thioflavin T fluorescence over 60 hours and represents an individual 
well. Each sample was run in quadruplet using the same recombinant master mix and seed. 
Recombinants A and B showed no PrP
spon
 formation with NBH or recombinant PrP as a seed. 
Recombinant C showed PrP
spon
 5 out of 7 wells with uninfected seed.  
 
Recombinant A showed no spontaneous PrP
res
 in any of the uninfected samples and all 
infected repeats showed amplification. Recombinant B did not show spontaneous PrP
res
 
but did not amplify the infected sample within 60 hours, so would not be appropriate for 
amplifying infected PrP
Sc
 seed. Recombinant C showed formation of spontaneous PrP
res
 
in 5 out of 7 controls; however it was possible to distinguish between PrP
spon
 and 
amplification by the difference in lag time. One well showed an erratic fluorescence 
(marked with an asterisk) which was possibly caused by condensation on the plate 
preventing accurate fluorescence readings and was discounted  
 
5.3.2 The ability of the glycoforms to initiate conversion 
 
To establish whether the glycosylation affects the ability to initiate conversion the QuIC 
assay was carried out with normalised seed from brain homogenate of each of the 
GlycoD mice to identify whether any glycoforms were more efficient at seeding 






The QuIC was carried out using 6-10 repeats for each genotype of PrP
Sc
 seed per assay. 
The assay was carried out six times using recombinant PrP from three different batches, 
each one for two assays. The lag time was calculated for each repeat and combined for 
all assays to produce an average for each genotype (Table 5.1).  
 
Table 5.1 Time in minutes for different glycoforms to seed PrP
res
 conversion in 
recombinant PrP (n=26-45) 
 
Mean seeding time (minutes) 
wt G1/G1 G1/wt G2/G2 G2/wt G3/G3 G3/wt 
Mean 845 816 746 440 451 718 808 
sem 48 55 29 26 28 39 52 
 
There was a significant difference between the seeding times for the genotypes 
(ANOVA, p<0.001). G2/G2 and G2/wt had significantly shorter seeding times 
compared to the other genotypes (p<0.05). There is no significant difference between 





Figure 5.5 Seeding times of PrP
Sc
 from different GlycoD mice 
PrP
Sc
 from 79A terminal brains from GlycoD mice was quantified and diluted so that all seed 
homogenates contained the same amount of PrP
Sc
. The QuIC assay was carried out with 2µl 
normalised homogenate to seed conversion of 0.1 mg/ml recombinant PrP; shaking for 1 
minute, resting for 1 minute at 42 °C for 60 hours (n=26-45). The time to seed was measured as 
the first fluorescent reading above the baseline reading taken at 0 minutes. The mean was 
taken for the time to seed from all values from all recombinants. 
 
It was expected that unglycosylated PrP
Sc
 would seed fastest as it lacked glycans to 
hinder binding to the recombinant PrP, however there was no significant difference 
between diglycosylated and unglycosylated PrP. G2 PrP increased the seeding 
efficiency significantly (Figure 5.5), suggesting that the glycan at the first site may 
assist in seeding conversion. There was no difference in seeding time for mice 
homozygous or heterozygous for the G2 allele indicating that G2 PrP only needs to be 
slightly increased to allow efficient seeding. 
 
5.3.3 Recombinant PrP batch effect 
 
To assess whether variation in seeding times could be influenced by the batch of 
recombinant PrP the assays were analysed for each recombinant batch separately. Batch 
to batch variation was seen during optimisation of the QuIC assay and affected the time 
to seed with a 79A positive control and the generation of PrP
spon
 (Figure 5.4). It is not 
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known why different batches were more efficient at conversion however the lack of 
significance when all assays are combined may be due to variability in seeding times 
caused by the different recombinant batches.   
 
Table 5.2 Time (mins) for each genotype to seed PrP
res
 amplification for different batches 
of recombinant PrP  
Rec 
Mean seeding time (sem) 
wt G1/G1 G1/wt G2/G2 G2/wt G3/G3 G3/wt 
1 568 (68) 838 (93) 698 (49) 465 (48) 387 (68) 804 (68) 625 (77) 
2 935 (37) 743 (66) 862 (41) 322 (15) 487 (18) 810 (35) 742 (24) 
3 1194 (57) 1208 (115) 620 (22) 568 (34) 486 (47) 452 (15) 1254 (47) 
 
Reproducibility was good between replicates of the same recombinant PrP substrate 
however there was a significant variation in seeding times for different batches of 
recombinant PrP (ANOVA, p<0.001; Table 5.2). The different efficiencies of 
conversion with different recombinant batches (Figure 5.4) would be expected to affect 
each genotype equally so the overall seeding times would be quicker or slower but the 
patterns in seeding times for the different genotypes would remain constant. However 
the relationships in seeding times were different for the different batches of 




Figure 5.6 Seeding times of different glycoforms with different recombinant PrP 
PrP
Sc
 from 79A terminal brains from GlycoD mice was quantified and diluted so that all seed 
homogenates contained the same amount of PrP
Sc
. The QuIC assay was carried out with 2 µl 
normalised homogenate to seed conversion of 0.1 mg/ml recombinant PrP; shaking for 1 
minute, resting for 1 minute at 42 °C for 60 hours. The time to seed was measured as the first 
fluorescent reading above the baseline reading taken at 0 minutes. A mean was taken for all 
replicates for each recombinant to allow comparison between recombinant batches. 
 
Recombinant 1 showed that G2 mice had the quickest time to seed, followed closely by 
wild type mice and then G3 and G1. Mutants with a G2 allele were significantly faster 
than G1/G1, G1/wt and G3/G3 mutants to seed conversion (p<0.05). Heterozygous 
mice had quicker seeding times compared to their homozygous GlycoD mutant 
counterparts. Adding a wild type allele to the GlycoD mutants appeared to reduce the 
time of PrP
Sc
 to seed. This suggests that diglycosylated PrP
Sc
 is converting recombinant 
PrP more efficiently than the other glycoforms.     
 
Recombinant 2 showed that G2 PrP was the fastest to seed followed by G1, G3 and then 
wild type PrP. As seen with the recombinant 1 G2/G2 PrP
Sc
 seeded significantly faster 
(p<0.05) than all other genotypes and G2/wt seeded significantly faster (p<0.05) than all 
other genotypes, except G2/G2. Wild type PrP
Sc
 seeded significantly slower than 
G1/G1, G3/wt, G2/G2 and G2/wt seeds (p<0.05). Heterozygous G1 and G2 mice had 
slower seeding times compared to their homozygous GlycoD mutant counterparts. 
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Adding a wild type allele to these GlycoD mutants increased the time of PrP
Sc
 to seed. 
This suggests that diglycosylated PrP
Sc
 is converting recombinant PrP less efficiently 
than the other glycoforms. G3 and G3 heterozygous mice showed the same patterns as 
seen with recombinant 1 and adding deglycosylated PrP reduced seeding time.  
 
Recombinant 3 showed two different groups of seeding times; G1/wt, G2/G2, G2/wt 
and G3/G3 had faster seeding times and were significantly different to G3/wt, G1/G1 
and wild type PrP
Sc
 (ANOVA, p<0.001). There was no pattern between the 
heterozygous and homozygous counterparts for each genotype. There was a higher 
variation in seeding times for each genotype with recombinant 3. 
  
There is a difference in seeding efficiencies of the different GlycoD mice that can be 
reproducibly measured using the QuIC assay. G2 was consistently the fastest glycoform 
to seed conversion with all three of the recombinant PrPs tested.  
 
Table 5.3 Rankings for the seeding efficiencies of the genotypes with different 
recombinant PrP (1 is most efficient)   
Rec 
Ranking of seeding efficiency 
wt G1/G1 G1/wt G2/G2 G2/wt G3/G3 G3/wt 
1 2 4 3 1 1 4 3 
2 4 2 3 1 1 3 2 
3 2 2 1 1 1 1 2 
 
The order of the genotypes to convert was different for each batch of recombinant 
(Table 5.3). The rankings show that G2 PrP is consistently the fastest, however with one 





5.3.4 Brain homogenate as the substrate for the QuIC assay 
 
The QuIC assay was used to assess the ability of each of the glycoforms to convert into 
PrP
res
. The in vivo data has shown differences in susceptibility when the GlycoD mice 
were challenged with 79A, which may be due to the glycans altering the ability of PrP
C
 




The QuIC assay has been developed using unglycosylated recombinant protein as the 
conversion substrate therefore cannot be used to assess conversion of the glycoforms. 
Normal brain homogenate was tested as a substitute for recombinant PrP to allow the 
glycoforms to be converted. Initially wild type and null brain homogenate were used in 
order to optimise conditions. Serial dilutions were used for the substrate to assess the 





Figure 5.7 Normal brain homogenate as a substrate for the QuIC assay 
10% normal brain homogenate was used as a substrate for the QuIC assay using an ME7 seed 
that had previously been used in a QuIC assay. Uninfected brain was used as a seed to control 
for spontaneous PrP
res
. The positive control is an ME7 (10
-3
) seed in 0.1 mg/ml recombinant PrP 
substrate and the negative control is 0.1 mg/ml recombinant PrP substrate without any seed. 
Each condition was carried out in quadruplet and fluorescence was measured every 15 minutes 
over 60 hours. There was no PrP
res
 amplification in any of the dilutions using normal brain 
homogenate as a substrate.  
 
No seeding or amplification was seen with any of the wild type normal brain 
homogenates as a substrate for conversion (Figure 5.7). Amplification was seen in the 
positive controls (recombinant PrP as a substrate) showing that the ME7 seed was able 
to initiate conversion. Amplification of ME7 was not possible with crude brain 






Figure 5.8 Quic assay with PI-PLC treated substrate 
10% normal brain homogenate was treated for 36 hours with 0.5 U PI-PLC to release PrP
C
 from 
the membrane. Membrane depleted brain homogenate was used as a substrate for the QuIC 
assay using an ME7 seed. Uninfected brain was used as a seed to control for spontaneous 
PrP
res
. The positive control is an ME7 (10
-3
) seed in 0.1 mg/ml recombinant PrP substrate and 
the negative control is an uninfected brain (10
-3
) seed in 0.1 mg/ml recombinant PrP substrate. 
Two different recombinant substrates were used for both controls. Each condition was carried 
out in quadruplet and fluorescence was measured every 15 minutes over 60 hours. There was 
no PrP
res
 amplification in any of the dilutions using normal brain homogenate as a substrate.  
 
It has been suggested that lipids may inhibit conversion in the QuIC assay. PrP
C
 
prepared from homogenate is membrane associated and brains are lipid rich due to 
myelin. To address this normal brain homogenate was treated with PI-PLC to release 
the protein from the membrane in order to try to reduce the amount of lipids present in 
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the substrate. 10% homogenates were treated with PI-PLC for 36 hours to ensure full 
cleavage and released protein separated from the membranes by centrifugation. Protein 
was concentrated to provide as much substrate possible. Total protein was not measured 
initially as very little substrate was generated  
 
Even with reduced lipids there was no amplification seen with normal brain 
homogenate as a substrate for conversion (Figure 5.8). Crude brain homogenate was not 
a suitable substrate for the QuIC assay and further purification of PrP
C 
from brain 




This study is the first to investigate the effect of the glycoform acting as a template for 
conversion. Homology between seed and substrate has been shown to be important for 
conversion (Priola and Lawson, 2001) but only the effect of glycosylation of the 
substrate, which undergoes conformational change, has been studied. The results 
presented here suggest that the glycan at the first site may assist in initiating conversion 
as PrP
Sc
 from G2 mice were able to initiate conversion faster than other genotypes. The 
first glycan lies within helix 2 of PrP
C
 and has been shown to stabilise the intra-
molecular disulphide bond formation. The glycan may also stabilise PrP
Sc
 aggregates, 
allowing a more stable seed or providing a better template for PrP
C
. The delay in 
seeding for the other genotypes may indicate that the second site is inhibiting 
conversion.  
 
If the glycan at the first site is assisting in conversion then it would be expected that 
wild type PrP
Sc
, which also contains PrP with the first site glycosylated would be more 
efficient at converting PrP
Sc
 than the G1 and G3 which lack this glycan. However, with 
the exception of G3 the different genotypes are heterogeneous mixtures of the 
glycoforms therefore the ratios of the glycoforms in wild type PrP
Sc 
may prevent 




Differences were not observed in the ability to initiate conversion between wild type, 
G1 and G3 mice, which is in contradiction to the incubation periods seen with 79A in 





 may be more important than the physical interactions between the two 
molecules in determining disease susceptibility. The altered localisation and reduced 
expression levels described in previous chapters may contribute more to the increased 




The similarity in seeding times may indicate that the glycans do not impart any effect on 
conversion. The effect of glycosylation on conversion was secondary to PrP sequence 
(Priola and Lawson, 2001) therefore the differences observed in the G2 seeding times in 
this study may be due to the sequence differences between the recombinant PrP and 
PrP
Sc
 seed. The batch of recombinant PrP had a huge effect on the outcome of the assay 
and a single recombinant showed differences between the genotypes. It is not 
understood why a batch effect was seen with the different recombinant despite being 
produced using the same method. Further investigation is needed to determine whether 
there is a true difference in seeding times or whether it is an effect caused by the 
recombinant. Different species of recombinant need to be tested to eliminate the 
variation seen with recombinant PrP and to assess whether the differences in seeding are 
species specific and likely to account for differences between the GlycoD mutants seen 
in TSE disease. A recombinant mouse PrP would need to be used with these PrP
Sc
 seeds 
to identify whether the differences seen were due to glycosylation or PrP sequence.   
 
Conversion assays all have different limitations therefore other assays could be tested in 
conjunction with the QuIC assay to give a more rounded view of conversion. PMCA 
has been shown to produce infectious PrP
res
 and can use either crude homogenate or 
recombinant as a substrate for conversion (Shikiya and Bartz, 2011, Barria et al., 2009). 
However the conditions for PMCA are less standardised and the technique is more 
variable than the QuIC assay. Cells can be used to study conversion and amplification 
of PrP
res
 in more physiological conditions, however few cell lines exist which are can be 






5.4.1 Limitations of the QuIC assay 
 
There are several limitations of using an in vitro assay that must be considered when 
relating in vitro results to in vivo data. The PrP
res
 generated during QuIC has yet to be 
shown to be infectious, suggesting that the QuIC assay is not a true representation of the 
conversion process in vivo. The lack of infectivity may be due to a cofactor required for 
infectivity which is not supplied in the QuIC assay. 
 
The QuIC assay detects PrP
res
 that is in an amyloid conformation, however PrP
Sc
 exists 
in several different forms in vivo; from small oligomers to larger fibrils and amyloid 
(Silveira et al., 2005). The different aggregates are all associated with infectivity 
(Silveira et al., 2005) but it is not known which aggregate is the infectious species, or 
whether all PrP
Sc
 aggregates are equally involved in disease. Amyloid is not 
characteristic of every TSE strain therefore the QuIC assay may not be relevant to all 
strains.  
 
Due to the in vitro nature of the QuIC assay other factors which may influence 
conversion during disease are not accounted for. The glycans may influence the ability 
to bind and convert to PrP
Sc
 but the localisation of the protein will also influence 
whether PrP
C
 comes into contact with PrP
Sc
. It is thought that cell surface PrP is 
important for conversion (Goold et al., 2011) therefore the reduced cell surface PrP
C
 in 




 is a defining feature of TSEs the role of PrP
Sc
 in disease is poorly 
understood. There is a lack of correlation between PrP
Sc
 deposition and disease. Models 
exist that have large amounts of aggregated PrP but lack disease symptoms (Chesebro et 
al., 2005, Piccardo et al., 2007), equally there are models that exist with little or no 
detectable PrP
Sc
 but succumb to clinical disease and are highly infectious (Barron et al., 
2007). The amount of PrP
res





Despite the limitations mentioned above the QuIC assay provides a useful tool to study 
the interactions of the glycoforms during conversion and taken together with the cell 
biology of the different glycoforms can be potentially used to explain differences in 
TSE susceptibility and pathology. 
 
This chapter has demonstrated that the glycoforms have a different ability in initiating 
conversion with recombinant PrP. G2 PrP
Sc
 was more efficient at seeding amplification 
than the other genotypes. This is the first time that a difference between G1 and G2 
mice has been observed that could account for the difference in disease susceptibility in 




6 Discussion  
6.1 Glycosylation and cell biology of PrPC 
 
Glycosylation is an important post-translational modification. The addition of glycans 
can change the property of the protein without having to encode this change in the 
genome and the complex structures of glycans can provide extra diversity to the 
glycoprotein (Varki and Sharon, 2009). The glycosylation sites of PrP are highly 
conserved across species suggesting an important role in either the protein’s cell 
biology or function (Lee et al., 2003, Kim et al., 2004). This thesis demonstrates that 
although glycosylation is not essential for the health or survival of transgenic mice it 
influences the localisation and expression of PrP
C
, which in turn could influence normal 
function and TSE susceptibility.  
 
Gene targeted mutants were employed here to investigate the effect of glycosylation on 
the cell biology of PrP
C
. The GlycoD mice have PrP
C
 with selectively abolished 
glycosylation expressed under the same physiological conditions as wild type PrP. This 
unique system allows the complexity of the glycoforms and the effects of the individual 
glycosylation sites to be studied by isolating the individual glycoforms.  
 
The data presented here demonstrates that glycosylation has an effect on the localisation 
and protein levels of PrP
C
. Removal of either the first (G1) or the second (G2) 
glycosylation site produced changes in cell biology that were almost indistinguishable 
from each other. Disruption of both glycosylation sites (G3) produced a more extreme 
phenotype than removal of a single site.  
 
Interestingly there was very little difference in cell biology between the two 
monoglycosylated glycoforms. The lack of differences between G1 and G2 mice 
indicate that both glycosylation sites have a similar effect on determining the cell 
biology. The glycosylation sites of PrP
C
 are close together and are occupied by similar 
oligosaccharides (Stimson et al., 1999) therefore interactions that alter the localisation 
and trafficking may not be selective with the first or second site, just by the presence of 
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a single glycan. The glycosylation sites are likely to shield similar areas from 
proteolytic degradation, thus there is no difference in the degradation of the 
monoglycosylated glycoforms.    
 
The function of PrP
C
 remains elusive and it is not known whether the different 
glycoforms have unique functions or even if all glycoforms are functioning. The 
differences observed in the cell biology of the different glycoforms can indicate whether 
the glycoforms are likely to carry out specific functions.  
 
6.1.1 The effect of glycosylation on protein levels  
 
This is the first time that it has been demonstrated that removal of either one or both of 
the glycosylation sites of PrP
C
 reduces PrP protein levels [Chapter 3]. Removal of a 
single glycosylation site reduced protein by 50% and complete removal of glycosylation 
reduced protein levels to around 32% total protein of that in wild type mice. The 
decrease of PrP
C
 in the GlycoD mutants may limit the ability to perform its normal 
functions.  
 
Real-time PCR of the Prnp gene [Chapter 3] and previous northern blot analysis 
(Cancellotti et al., 2005) showed that PrP mRNA levels in the brain were the same for 
all GlycoD mutants as in wild type mice. This showed that the reduction of protein was 
due to post-translational regulation rather than transcriptional regulation. It also 
demonstrates that down regulation of PrP
C
 does not feed-back and regulate the level of 
transcription in the CNS.   
 
In addition to the different glycoforms, truncated isoforms are also present in vivo. 
There are several cleavage events possible for PrP but the predominant one under 
normal physiological conditions is alpha cleavage. The data shown here demonstrates 
an increased proportion of the alpha cleavage product, C1, when a glycosylation site is 
abolished [Chapter 3]. In the wild type mice 25% of PrP underwent alpha cleavage and 
was detected as a C1 fragment. G1 and G2 mice had ~35% as the C1 isoform and up to 




The proportion of C1 is increased in the GlycoD mice but the absolute levels of C1 are 
reduced slightly. The relative levels of C1 in the GlycoD mutants are also preserved 
whether a single glycosylation site or both are abolished. This increase in proportion of 
C1 but the preservation of the absolute levels of C1 suggests that truncation and the 




N1 has been shown to be neuroprotective both in vitro and in vivo by down regulating 
the p53 pathway (Guillot-Sestier et al., 2009) and protective against Aβ toxicity in cell 
culture (Guillot-Sestier et al., 2012). C1 enhances susceptibility to pro-apoptotic 
conditions but is not neurotoxic under normal conditions. The glycoforms may exist to 
balance the production of the neuroprotective N1 fragment and the full length PrP. 
Diglycosylated PrP had higher protein levels indicating that it was degraded less 
readily, either through trafficking or through protection against proteolytic enzymes; 
however it produced less N1. The unglycosylated and monoglycosylated glycoforms 
were able to contribute the same amount of C1/N1 but were degraded more readily 
hence they do not contribute so much towards full length PrP. The full length PrP may 
function more efficiently with both glycans present whereas the N1 does not possess 
glycans therefore the presence or absence of glycans on the full length has no bearing 
on the function of N1.  
 
6.1.2 The effect of glycosylation on localisation 
 
In order to define the localisation of the glycoforms electron microscopy was used to 
quantify the amount of PrP associated with different cell membranes. This study shows 
that glycosylation of PrP
C
 is not essential for cell surface expression however removal 
of either of the glycosylation sites significantly reduces the presence of PrP
C
 on the cell 
surface. Previous studies showed that abolition of both glycosylation sites caused 
retention of PrP
C
 inside the cell (Cancellotti et al., 2005)[F. Wiseman; PhD thesis 2007]. 
This study allowed localisation to be investigated at a higher resolution to identify 
whether unglycosylated PrP could be localised to the cell surface and showed small 
amounts of PrP
C




G1 and G2 mutants showed reduced surface PrP
C





ER and Golgi. Previous data using the GlycoD 
mice had shown that removal of a single glycosylation site appeared to increase the 
proportion of intracellular PrP but that the protein was still predominantly on the plasma 
membrane (Cancellotti et al., 2005) in contrast to other PrP glycosylation deficient 
mutants, which showed intracellular retention of PrP
C
 in cell models (Rogers et al., 
1990). The limited resolution of immunofluorescence may account for the differences 
between the studies. The method used here was able to quantify PrP on the different 
membranes and showed that cell surface PrP
C 
only accounted for 20% of total PrP in 
both G1 and G2 neurons. The intracellular distribution was also slightly different 
between G1 and G2 mice indicating that the different glycans assist with trafficking at 
different points through the secretory pathway.  
 
The altered localisation in the GlycoD mutants is likely due to the changes in the ability 
to interact with other proteins. PrP
C
 relies on ligands for trafficking, particularly for 
endocytosis. The ligands bound to PrP
C
 determine the method of internalisation, and 
have the potential to determine the destination.  
 
The location of PrP
C
 in the cell can influence the ability to carry out different functions. 
The glycosylation can change function through either modulating the interactions with 
other proteins or through changing the localisation, and therefore the availability of 
ligands. The glycosylation of PrP may influence the ability to bind with ligands through 
direct recognition of the glycans by lectins (Gabius, 1994) or through shielding of 
binding domains on the peptide. The multiple ligands demonstrated for PrP
C
 could 
induce different trafficking and signalling thus allowing the multiple functions 
proposed.   
 
Several functions have been proposed for PrP
C
 in neurons and many rely on the cell 
surface localisation in order to carry out these functions. PrP has been implicated in 
signal transduction however the reduced cell surface expression of PrP
C
 in the GlycoD 
mutants may have a limited ability to initiate signal transduction. Different signal 
178 
 
transduction pathways can be activated by the binding of different partners (Arsenault et 
al., 2012). PrP
C
 interacts with the intracellular Fyn kinase when associated with lipid 
rafts and caveolin-1 although the mechanism is undetermined (Mouillet-Richard et al., 
2000). PrP
C
 also binds to astrocyte-secreted stress-inducible protein 1 (Stip-1) in lipid 
rafts modulating the pool of cellular proteins needed for proper neuronal function 
through the PI3K–Akt–mTOR and ERK1/2 pathways (Roffe et al., 2010, Caetano et al., 
2008). PrP
C
 interacts with the neural cell adhesion molecule (NCAM) in cis and trans to 
recruit NCAM into lipid rafts and activate p59
fyn




 has also been implicated in copper homeostasis at the synaptic cleft. PrP
C
 binds 
copper at the cell surface which promotes endocytosis to allow maintenance of copper 
in the pre-synaptic cytosol and buffering against toxic levels of copper (Vassallo and 
Herms, 2003).  
 
The reduced cell surface PrP
C
 indicates that the glycoforms may be less efficient at 
carrying out the functions of PrP
C
. The functions of PrP
C
 are associated with cell 
survival and growth, therefore monitoring and responding to the cell environment is 
important to allow the correct response. The glycoforms may exist to allow a response 
to environmental changes and therefore the GlycoD mutants may be less able to adapt to 
change.  
 
6.1.3 Localisation and protein levels 
 
The altered localisation of the GlycoD mutants observed in Chapter 4 may result in the 
reduced expression levels observed in Chapter 3 through several mechanisms. The 
localisation of the PrP
C
 will influence the exposure to other cellular proteins, such as 
degradation enzymes, ligands and the alpha cleavage enzymes. Interactions with 
enzymes can reduce the protein levels directly through degradation whilst interactions 
with ligands can reduce proteins indirectly through altering trafficking and degradation. 
 
It is not known whether the increased proportion of intracellular PrP in the GlycoD 
mutants is due to retention in the secretory pathway or due to rapid endocytosis from the 
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cell surface. The GlycoD mutants had an increased proportion of intracellular PrP but 
the level of intracellular PrP was slightly less than in the wild type mice. The increased 
proportion of intracellular PrP is likely due to a decrease in cell surface PrP
C
 caused by 
more rapid endocytosis from the cell surface. PrP
C
 that has been endocytosed is exposed 
to degradation enzymes, reducing protein levels. 
 
PrP is continuously recycled between the cell surface and endocytic vesicles before 
degradation. Endocytosis is mediated by binding partners, which are influenced by the 
glycans attached to PrP
C
. The Glycans of diglycosylated PrP
C
 may bind to surface 
proteins, such as galectins which prevent endocytosis.  
 
The increased Endo H sensitive PrP in G1 mice [Chapter 4] suggests that this glycoform 
is retained in the ER rather than being retro-translocated back to the ER. The delay in 
trafficking to the cell surface may push PrP
C
 in the G1 mice to be targeted for 
degradation without being trafficked to the cell surface.  
 
The altered localisation of PrP
C
 in the GlycoD mice can affect the amount of protein 
through a change in alpha cleavage levels. Alpha cleavage has been proposed to occur 
in the late Golgi (Walmsley et al., 2009) or in the early endocytic compartments (Shyng 
et al., 1993). The almost normal levels of C1 detected in the GlycoD mutants despite the 
reduced level of total PrP
C
 suggests that the increased proportion of intracellular PrP 
allows the alpha cleavage to occur at the same rate in all genotypes. 
 




 is expressed selectively and at lower levels in tissues outside the CNS (Ford et al., 
2002b) however PrP
C
 has been shown to be important for peripheral myelin 
maintenance in the PNS (Bremer et al., 2010). PrP null mice showed a chronic 
demyelinating polyneuropathy in peripheral nerves as mice aged. Maintenance of 
myelin was dependent upon axonally expressed PrP
C
 with the ability to undergo alpha 
cleavage (Bremer et al., 2010). The lack of myelinopathy in the CNS suggests that PrP
C
 
has different functions in different tissues.  
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In a limited study G3 mice surprisingly showed no peripheral myelinopathy despite the 
reduce expression of CNS PrP
C
 and the alteration in cellular localisation no changes 
were seen in sciatic nerves (PNS) or optic nerves (CNS) of aged G3 mice, however null 
mice showed dysfunctional myelin in the sciatic nerves but not the optic nerves 
[Iremonger unpublished observation]. The expression of PrP
C
 in the periphery of the G3 
mice was not assessed although the lack of glycosylation showed a change in cell 
biology in the CNS that would be expected to be mirrored in the PNS. 
  
Alpha cleavage is important in the function of PrP
C
 in the PNS (Bremer et al., 2010) 
suggesting that either the N1 or C1 fragments were essential for peripheral myelin 
maintenance. Rescue was also dependent upon axonal PrP
C
 showing cross talk between 
neurons and myelin producing Schwann cells and an effect of PrP
C
 in trans (Bremer et 
al., 2010). This thesis has shown that surface PrP
C
 is vastly reduced in the GlycoD 
mutants therefore the ability of the C1 fragment to act in trans would be reduced in G3 
mutants. However there was no peripheral myelinopathy phenotype in the G3 mice 
showing the reduced surface C1 has no effect in the PNS. The overall amount of C1 and 
presumably N1 is only slightly reduced in the G3 mice therefore it is more likely that 
the secreted N1 is acting as the factor for myelin maintenance.  
 
6.2 Glycosylation and TSE disease susceptibility   
 
Glycosylation of PrP is thought to be important in TSE disease as it is believed that the 
glycans may encrypt strain characteristics through modulation of protein conformation. 
The GlycoD mice provided a tool to study the effect of glycosylation on TSE disease 
and allow a direct comparison of the effects on disease of the two different 





 can influence disease (Cancellotti et al., 2013). The glycosylation status of 
the host can change the susceptibility to disease with different TSE strains, altering 






 and its conversion into the disease associated isoform PrP
Sc
 is poorly understood 
but is central to TSE pathogenesis (Weissmann et al., 1994). PrP
Sc
 is generated by direct 




 therefore two factors can 
influence conversion; the physical interaction and ability of PrP
Sc
 to induce 







This thesis has investigated the effect of glycosylation on the normal isoform of PrP and 




 during an in vitro 
conversion process. The glycans can significantly alter the localisation and expression 
levels of the PrP
C
 isoforms. The data collected in this thesis can be used to elucidate the 
contributions of the cell biology and the interactions of the glycans during conversion in 
the changes seen in the altered susceptibilities of the GlycoD mice during TSE disease.   
 
6.2.1 The effect of glycosylation on incubation period and disease 
susceptibility 
 
The increased incubation period and resistance in the GlycoD mutants may be 
accounted for by the altered localisation shown in Chapter 4 and by the decrease in full 
length PrP demonstrated in Chapters 3. 
 
All GlycoD mice have significantly reduced levels of PrP
C
 which has been shown to 
influence TSE disease incubation time. There is an inverse correlation with the amount 
of PrP and the incubation period. Heterozygous mice which only carry a single Prnp 
gene (PrP
-/+
) have significantly longer incubation times than mice carrying two copies 
of the gene (Bueler et al., 1993, Manson et al., 1994b). The absence of PrP renders an 




 levels correlate to incubation period thus all GlycoD mice would be expected to 
have an increased incubation period. It would be expected that as G1 and G2 mice have 
the same PrP levels that they would also have the same incubation periods and G3 have 
an increased incubation period. Although there is an increase in incubation period the 
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PrP levels do not correlate completely suggesting that other factors are also influencing 
incubation period. It would be expected that reducing PrP
C
 levels by 50% would double 
the incubation time. Previous experiments with heterozygous mice showed that 
challenge with TSE strain 301C increased the incubation period by 150 days (Manson et 
al., 1994b), however G1 and G2 mice had the same amount of PrP
C
 as the heterozygous 
mice yet the incubation time is increased by 340 days in G2 mice and G1 mice are 
resistant. G3 mice were also resistant to 301C (Table 1.6).    
 
Challenge of the GlycoD mice with 79A produced disease in all genotypes but showed 
an increased incubation time. A reduction of PrP
C
 by two thirds in G3 mice increased 
the incubation period by 290 days. G1 and G2 mice had half the amount of PrP
C
 
however the incubation period was only increased by 50 and 20 days respectively 
(Table 1.6).  
 
Another factor influencing the incubation period is the localisation of PrP
C
 within the 
cell. All GlycoD mice showed a decrease in cell surface PrP
C
, which is believed to be 




 has yet to be clearly 
defined but it has been proposed that PrP
C
 must reach the cell surface in order to be 
converted (Goold et al., 2011, Arnold et al., 1995, Kenward et al., 1992). Tagged PrP
C
 
has been shown to convert rapidly upon exposure to external PrP
Sc 
on the cell surface 
before being endocytosed (Goold et al., 2011). Conversion has also been shown to take 
place in endocytic vesicles after endocytosis from the cell surface (Marijanovic et al., 
2009). The GlycoD mice had an increased proportion of PrP
C
 associate with the ER and 
Golgi, suggesting retention in the secretory pathway. This PrP
C
 will not be as readily 
converted because it will not come into contact with PrP
Sc
 until it has been expressed on 
the cell surface.  
 
6.2.2 Differences between G1 and G2 mice  
 
The cell biology investigated in this thesis has revealed very little difference between 
the G1 and G2 mice in the localisation of PrP
C
 [Chapter 4], the amount of total PrP and 
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the levels of proteolytic cleavage [Chapter 3]. However the disease susceptibility is very 
different for G1 and G2 mice (Table 1.6).  
 
G1 mice had half the amount of PrP
C
 than wild type mice yet were resistant to five of 
the six strains tested and showed a resistance similar to G3 mice. This is perhaps not 
surprising considering that in addition to reduced PrP
C
 it is also mislocalised and very 
little PrP is found on the cell surface. Interestingly G2 mice had an incubation period 
equal to wild type mice in ME7 despite expressing 50% less protein and a reduced level 
of cell surface PrP. G2 mice were also susceptible to sCJD when all other mice, 
including wild type mice, were resistant.  
 
The localisation study showed a subtle difference in localisation between the two 
monoglycosylated PrPs [Chapter 4] and may explain the differences between G1 and 
G2 mice. Both monoglycosylated PrPs had the same amount of intracellular PrP
C
 but 
different distributions. The differences between the intracellular localisation could be 
influencing the differences in susceptibility seen in between the G1 and G2 mice. PrP 
glycosylated at the second site (G1) showed a higher level of immature PrP
C
 in the ER 
whilst PrP glycosylated at the first site showed a higher proportion in the Golgi 
[Chapter 5]. The primary site of conversion to PrP
Sc
 is the plasma membrane (Goold et 
al., 2011) however intracellular compartments of the endocytic compartments have also 
been identified as potential conversion sites (Borchelt et al., 1992, Marijanovic et al., 
2009, Veith et al., 2009). PrP
C
 is recycled from the cell surface into different endocytic 
compartments and can undergo retrograde transport back to the Golgi [reviewed in 
(Linden et al., 2008)]. PrP in the Golgi is more likely to be exposed to PrP
Sc
 that has 
undergone retrograde translocation and subsequently be converted than PrP in the ER. 
G1 mice have more non-Golgi associated PrP, which could be due to ER retention, so 
less mature PrP
C




 is dependent on intact lipid rafts and in vitro conversion is enhanced 
by cofactors found in lipid rafts (Goold et al., 2011, Abid et al., 2010). While it was not 
possible here to isolate lipid rafts or identify the ultrastructural localisation of the 





 is predominantly found in lipid rafts but moves out of raft 
regions when bound to some ligands in order to be internalised. Glycans have the ability 
to interact with ligands therefore the absence of glycans at either site may hinder 
interactions. It is possible that G2 PrP is present in lipid rafts for longer period of time, 




G2 mice have more Golgi associated PrP
C
 than wild type mice, which could represent a 
faster synthesis and turnover of PrP, so that although there is less total PrP
C
, during TSE 
infection there is a faster supply of PrP
C
 which can be converted. This may explain why 
G2 mice have reduced incubation periods compared to wild type mice 
   
6.2.3 The effect of glycosylation on PrPSc deposition 
 
This thesis examined the expression levels and alpha cleavage levels in several brain 
regions in an attempt to determine whether these regions preferentially expressed PrP
C
 
in the GlycoD mutants and whether this corresponded to differences seen in PrP
Sc
 
deposition during TSE disease. This study showed that there was no difference in 
expression of PrP
C
 or levels of alpha cleavage in different brain regions for any of the 
GlycoD mice, indicating that the change in regional deposition of PrP
Sc
 was not due to 





 deposition was changed in the GlycoD mice with some TSE strains (Tuzi et al., 
2008). G3 mice showed deposits of amyloid plaques whereas wild type mice showed 
diffuse deposition of PrP
Sc
. It has been proposed that different TSE strains may be 
targeted to a particular subset of cells within the brain which leads to accumulation of 
the PrP
Sc
 glycoform that is most abundant in those cell types. The GlycoD mutants 
suggest that different brain regions do not preferentially express a particular glycoform 
and that the overall levels of each glycoform is maintained despite the different cell 
types for each region.  
 
The equal distribution of PrP
C
 throughout the brain suggests that the cell biology of 
PrP
C
 does not determine the targeting of PrP
Sc
 deposition. The strain targeting may be 
determined by another co-factor required for conversion which is found in different 
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brain regions, such as a ligand found in a particular cell type that allows PrP
C





The QuIC assay showed no difference in the ability of the glycoforms to fibrillise and 
form amyloid in vitro. Amyloid formation has been proposed as a protective mechanism 
during protein misfolding diseases (Silveira et al., 2005, Treusch et al., 2009) therefore 
it would be expected that glycoforms with a better ability to form amyloid would 
provide resistance to disease. G3 mice showed amyloid plaques in vivo however in vitro 
there was no difference in the efficiency of forming amyloid between G3 mice and mice 
that do not form amyloid in vivo. 
 
6.2.4 The role of alpha cleavage in TSE disease 
 
Cleavage plays an important role during TSE disease as well as the normal cell biology 
of PrP
C
. The increased alpha cleavage in the GlycoD mice [Chapter 3] is likely to have 
a two-fold effect on disease; reduced full length PrP available for conversion and a 
higher proportion of C1 to act as an inhibitor of conversion. G3 mice were the least 
susceptible to TSEs and had the highest proportion of C1.  
 
Alpha cleavage has been shown to be an important factor for TSE disease susceptibility. 
The proportion of PrP
C
 that underwent alpha cleavage correlated with the increased 
resistance in all GlycoD mutants. The same influence has been observed in other 
species. C1 levels have been linked to decreased susceptibility both in vitro and in vivo. 
Increased C1 levels have been correlated with decreased susceptibility to scrapie in 
sheep (Campbell et al., 2013).  
 
It is believed that C1 is unable to convert to the protease resistant disease isoform 
during TSE disease as the cleavage occurs in the cytotoxic PrP
106-126
 peptide (Chen et 
al., 1995) and C1 was not detected in PK treated immunoblots detecting PrP
Sc
. Mice 
only expressing C1 were resistant to disease and did not accumulate abnormal protein 
(Westergard et al., 2011). However, C1 can fibrillise in vitro (Campbell et al., 2013). 
Due to the increased proportion of C1 the G3 mice had the smallest amount of full 
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length PrP of all the genotypes. The reduction of full length PrP could account for the 
increased resistance to TSE as there is less PrP
C
 available for conversion to PrP
Sc
. The 
G1 and G2 mice also had reduced levels of full length PrP and decreased susceptibility 
to disease in comparison to wild type mice.  
 
C1 acts as a dominant negative inhibitor for conversion therefore the higher proportion 
of C1 in the GlycoD mice provided a higher level of inhibition (Westergard et al., 
2011). Studies using TgC1 mice showed that co-expression of a transgene for full 
length PrP delayed disease onset indicating that an increased proportion of C1 increases 
incubation period (Westergard et al., 2011). The proportion of C1 has been shown to 
affect disease in vitro and in vivo. Studies in overexpressing cell cultures have shown 
that the proportion of C1 was important in protecting against the M1000 strain (Lewis et 
al., 2009). 
 
This protective effect of the alpha cleavage and its catabolites could provide a 
therapeutic target for disease. Increasing the levels of alpha cleavage in vivo would 
reduce the amount of full length PrP
C
 available for conversion to PrP
Sc
. Introduction of 
the C1 fragment would also act as an inhibitor for conversion, decreasing conversion 
and potentially increasing incubation period. 
  
6.2.5 The role of glycosylation during conversion 
 
All glycoforms have the ability to convert to the disease associated isoform however 
this thesis demonstrates that there are different efficiencies of initiating conversion for 
the GlycoD mice [Chapter 5]. Glycosylation at the first site appeared to increase the 
efficiency of conversion over other glycoforms.  
 
The increased efficiency to seed PrP
Sc
 by G2 mice may help to explain the incubation 
periods in some TSE strains. The changes in cell biology demonstrated here for G2 
mice would predict that incubation times would be more similar to G1 mice, with 
increased incubation periods and resistance. However, G2 mice had much shorter 
incubation periods than expected for all TSE strains. G2 mice had the same incubation 
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period as wild type mice when challenged with ME7 even though they had half the 
amount of PrP
C
. This may be a reflection of the increased efficiency in conversion in 
reducing the incubation period. 
 
This study showed that unglycosylated PrP is no more efficient at seeding the 
conversion than diglycosylated PrP [Chapter 5]. There was no difference in the seeding 
ability of G1 and G3 mice, which display the greatest amount of resistance to most TSE 
strains and the wild type mice, which are the most susceptible. Glycosylation can 
increase stability therefore reducing a proteins ability to aggregate (Kayser et al., 2011, 
Banks, 2011) so it would be expected that unglycosylated PrP would be more efficient 
at conversion. In vitro conversion assays have shown that unglycosylated PrP converts 





. However, in one study the glycosylation had no influence when the 
sequence of PrP
C 
was the same as PrP
Sc
 (Priola and Lawson, 2001). This suggests that 
the differences in susceptibilities are more influenced by the changes in cell biology 
seen in the GlycoD mutants than the interactions of the glycoforms during conversion.  
 
However, this study only examined the ability to initiate conversion and not the ability 
to sustain conversion. The partially glycosylated glycoforms may have different 
efficiencies for conversion once a substantial amount of seed is present. It is also 
important to consider interactions between different glycoforms when interpreting 
seeding data from in vitro conversion using the GlycoD mice. Only G3 mice have a 
homogeneous protein all others are a heterogeneous mixture of different glycoforms. G1 
and G2 PrP is a mixture of mono and unglycosylated PrP and wild type mice have a 
mixture of all glycoforms. Different prion strains require different glycoforms to 
propagate PrP
Sc
 in the in vitro conversion assay, PMCA (Nishina et al., 2006). The 





 exists in several different aggregation states from small oligomers to large 
amyloid aggregates. G1 and G3 mice showed amyloid plaques with some TSE strains, 
suggesting that the absence of the first glycosylation site promotes amyloid formation. 
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Amyloid has been proposed to be a protective mechanism in protein misfolding diseases 
(Treusch et al., 2009) by sequestering the misfolded protein away from the toxic smaller 
oligomers. Although there was very little difference in seeding times between wild type, 
G1 and G3 PrP in in vitro conversion the increased resistance in the G1 and G3 mice 
could be due to the production of amyloid preferentially over smaller oligomers.  
 
6.3 Final conclusions 
 
This is the first time that the effect of PrP glycosylation has been studied in relation to 
the normal cell biology of the protein. This thesis has demonstrated that the 
glycosylation of PrP
C
 infuences the cell biology of the protein post-translationally. The 
study demonstrates that the glycans are likely to play a role in cell surface expression 
[Chapter 4] and are also responsible for shielding against proteolysis [Chapter 3]. 
Removal of a single glycan causes a reduction in PrP
C
 levels, an increased proportion of 
cleavage products and a more intracellular localisation. There are very subtle 
differences between a single glycan at either site, which perhaps reflects the spatial 
closeness of the two sites and the similarities of the glycans attached to either site. A 
complete lack of glycosylation causes a more extreme change than removal of a single 
glycan. 
This thesis has shown that in addition to influencing the normal cell biology the 
glycosylation of host PrP
C
 has a role in determining susceptibility to TSE disease and 
incubation period through several mechanisms. A reduction in susceptibility may be in 
part due to the reduced availability of full length PrP
C
 on the cell surface available for 
conversion. The increased proportion of the neuroprotective N1 peptide and the 
dominant negative inhibitor, C1, may also help to increase resistance when glycans are 
lacking.  
 
This study is the first to show that despite the similarities in protein levels and cell 
surface localisation between the two monoglycoforms there is a vast difference in 
susceptibility and disease outcome with different TSE strains. This indicates that 
although cell biology influences TSE disease it is not the sole determinant. A limited 
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study has shown that the presence of a glycan at the first site can increase the ability of 
PrP
Sc
 to initiate conversion.  
 
6.4 Future work  
 
There is a need to further understand the cell biology of the normal cellular prion 
protein and its isoforms. PrP is highly conserved through several species suggesting an 
important function yet PrP
C
 is not essential for development and survival. Several 
functions in neuronal development and survival have been proposed which could be 
carried out by different isoforms. The GlycoD mutants could be used to look at 
candidate binding partners, such as laminin receptor precursor 1 and NCAM (Parkyn et 
al., 2008, Santuccione et al., 2005) and the interactions with the different glycoforms. 




 has been implicated Alzheimer’s disease (AD), another protein misfolding disease 
thus understanding the biology and function of PrP
C
 may also identify therapeutic 
targets for AD as well as TSE diseases. PrP
C
 is thought to be a high affinity binding 
partner of amyloid-β (Aβ) oligomers and N1 has been shown to protect against toxic Aβ 





 has a dynamic trafficking and lifecycle and the differences between the GlycoD 
mice in total PrP expression and cell surface expression could be due to altered 
trafficking or turnover. This study looked at localisation as a snapshot therefore it is 
difficult to know whether PrP from the GlycoD mice is retained in the secretory 
pathway or whether it is endocytosed more efficiently from the cell surface. Primary 
cultures can be used to further investigate the rate of endocytosis from the plasma 
membrane. Cell cultures can also be used to investigate the half-life and degradation 




The GlycoD mice are a useful tool to study the glycoforms separately but it would be 
useful to be able to identify the different PrP
C
 glycoforms in wild type mice. The 
GlycoD mutants show a dramatic change in cell biology but it is not known whether this 
is reflected in wild type mice where the glycoforms can potentially interact with each 
other. 30% of PrP in wild type mice is incompletely glycosylated but it is not known 
whether this represents PrP in the secretory pathway which will go on to be fully 
glycosylated and delivered to the cell surface or whether this is PrP at the cell surface. 
Cell compartments of wild type mice could be separated to identify the ratios of 
glycoforms in each cell compartment and identify whether monoglycosylated and 
unglycosylated PrP localisation is reflected from the GlycoD mice.  
 
This study has demonstrated that the localisation and expression of PrP
C
 are not the 
only factors to influence conversion to PrP
Sc
. This study showed that the different 
glycoforms had differing abilities to initiate conversion with the QuIC assay. However, 
the PrP
C
 for conversion was from a different species and showed batch to batch 
differences. This assay could be carried out using mouse recombinant PrP to assess 
whether it is a more appropriate substrate. To further investigate the influence of the 
glycans on the proteins ability to undergo conversion the GlycoD PrP could be used as a 
substrate for other in vitro conversion assays, such as the PMCA.  
 
The work produced in this thesis has highlighted the complexity of the cell biology of 
the prion protein and the many aspects of PrP
C
 which influence TSE disease. The cell 
biology of PrP
C
 is a major contributor to susceptibility and could potentially be used to 
design therapeutic targets of TSEs. Insight into the cell biology of PrP
C
 may lead to 
understanding of the function, which could, in turn, help to identify whether the 
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